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ABSTRACT 
 
Economic evaluations are being used increasingly often in attempts to meet the challenges of optimally 
allocating scarce health care resources. The cost-effectiveness of cancer treatments has been assessed 
widely perhaps because there is a global interest about the economic issues related to cancer. Cancer is 
one of the leading causes of morbidity and mortality worldwide, and thus, is a major challenge to health 
care funding. The burden of cancer is likely to increase due to ageing of the population, intensive care 
with targeted drugs, and increasing treatment costs. Thus, cancer consumes a large and potentially 
increasing proportion of the total health care budget.  
The general aim of this thesis was to study pharmacoeconomic methods and to apply them to 
evaluate the cost-effectiveness and budget impact of cancer treatments in Finland. In most cases, new 
treatments are more effective but also more expensive compared to their predecessors. The thesis 
consists of studies into sunitinib in the treatment of metastatic renal cell carcinoma (mRCC), and 
trastuzumab in the treatment of HER2-positive early breast cancer. The studies include various elements 
of economic evaluations, including cost-effectiveness analyses, budget impact analyses, value of 
information analyses, and burden of illness estimates. The utilized methods were chosen individually in 
each of the studies. 
The results of this thesis revealed that renal cell carcinoma imposes a considerable economic burden 
on society, and leads to premature deaths and productivity losses. Sunitinib was found to be cost-
effective as a second line treatment compared to the current treatment practice at the time of the study 
(best supportive care), in Finland. The conducted literature review revealed that sunitinib could be 
considered as a cost-effective treatment option in the treatment of mRCC, globally. 
Analyses of short-course trastuzumab demonstrated a good cost-effectiveness profile compared to 
treatment without trastuzumab, in HER2-positive early breast cancer. The value of information analysis 
illustrated that most of the uncertainty in the results was related to effectiveness parameters. 
Furthermore, the budget impact analysis indicated that treatment length has a major effect on the budget 
impact of trastuzumab. 
Pharmacoeconomic methods represent a useful tool to support decision making related to the 
introduction of new cancer treatments. These studies revealed that the utilized cancer model was 
suitable for modeling the natural disease progression with respect to mRCC and breast cancer. Although 
the results, based on modeling, are surrounded by uncertainty, this may be quantified to reduce decision 
uncertainty. A probabilistic approach was applied to cost-effectiveness analyses and budget impact 
analysis. This approach can achieve a better recognition of uncertainty and it enhances the methodology 
currently used in budget impact analyses.  
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TIIVISTELMÄ 
 
Lääkehoitojen taloudellisia arviointeja hyödynnetään terveydenhuollon rajallisten resurssien kohdenta-
mispäätöksiä tehtäessä yhä useammin. Syöpäsairaudet ovat maailmanlaajuisesti yksi merkittävimmistä 
kuolleisuutta ja sairastavuutta aiheuttavista sairauksista. Väestön ikääntymisen, kehittyvien ja entistä 
kalliimpien hoitomuotojen myötä syöpä aiheuttaa huomattavan taakan yhteiskunnalle. Tulevaisuudessa 
syövän odotetaan vievän yhä suuremman osan terveydenhuoltoon kohdennetuista resursseista, minkä 
vuoksi mielenkiinto syövän hoidossa käytettävien hoitomenetelmien taloudelliseen arviointiin on li-
sääntynyt kustannusvaikuttavimpien hoitomenetelmien tunnistamiseksi.  
Tämän tutkimuksen tavoitteena oli kehittää lääkehoitojen taloudellisessa arvioinnissa käytettäviä 
menetelmiä sekä soveltaa niitä syöpälääkkeiden kustannusvaikuttavuuden ja budjettivaikutuksen arvi-
ointiin Suomen terveydenhuollon olosuhteissa. Tutkimus koostuu osatutkimuksista, joissa arvioidaan 
kahta lääkehoitoa (sunitinibia metastasoituneen munuaissyövän hoidossa ja trastutsumabia aikaisen 
vaiheen HER2-positiivisen rintasyövän hoidossa) lääketaloudellisesta näkökulmasta. Osatutkimuksissa 
on hyödynnetty useita erilaisia taloudellisen arvioinnin menetelmiä, kuten kustannusvaikuttavuus-
analyyseja, budjettivaikutusanalyyseja sekä taudin taakkaa ja lisätutkimusnäytön arvoa kuvaavia ana-
lyyseja. Menetelmät eri osatutkimuksissa on valittu kyseisen tutkimuksen näkökulman ja tavoitteen 
mukaisesti. 
Tutkimus osoitti, että munuaissyöpä aiheuttaa huomattavan taloudellisen taakan yhteiskunnalle, 
sekä johtaa ennenaikaisiin kuolemiin ja tuotannonmenetyksiin. Sunitinibi-hoidon osoitettiin olevan 
kustannusvaikuttava toisen linjan hoitovaihtoehto verrattuna vallitsevaan hoitokäytäntöön Suomessa. 
Lisäksi kansainvälisiin tutkimuksiin pohjautuvan kirjallisuuskatsauksen perusteella havaittiin, että 
sunitinibia voidaan pitää potentiaalisesti kustannusvaikuttavana hoitovaihtoehtona metastasoituneen 
munuaissyövän hoidossa myös maailmanlaajuisesti. Lyhytkestoisen trastutsumabi-hoidon kustannukset 
ovat toteutetun arvioinnin perusteella kohtuulliset verrattuna sillä saavutettuihin hyötyihin aikaisen 
vaiheen HER2-positiivisen rintasyövän hoidossa. Hoidon keston havaittiin olevan merkittävä 
trastutsumabin budjettivaikutukseen vaikuttava tekijä sairaanhoitopiiritasolla. Suurin 
kustannusvaikuttavuusanalyysin tuloksiin vaikuttava yksittäinen epävarmuuden lähde liittyi 
trastutsumabi-hoidon tehoa kuvaaviin parametreihin. 
Lääketaloustieteellisiä menetelmiä voidaan hyödyntää uusien syöpälääkkeiden käyttöönotto-
päätöksiä tehtäessä. Tutkimus osoitti, että käytetty päätösanalyyttinen mallinnus soveltuu metastasoi-
tuneen munuaissyövän ja rintasyövän etenemisen kuvaamiseen. Mallinnukset ovat yksinkertaistuksia 
todellisuudesta ja lisäksi käytettäviin parametreihin liittyy aina epävarmuutta. Päätöksentekoon liittyvää 
epävarmuutta voidaan kuitenkin vähentää kuvaamalla parametriepävarmuuden määrää esimerkiksi 
tutkimuksessa käytettyjen probabilististen herkkyysanalyysien avulla. Lääketaloustieteelliset menetel-
mät tarjoavat loogisen kehyksen päätöksenteon tukemiseen epävarmuuden alaisuudessa. 
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”How many pharmacoeconomists does it take to change a light bulb? The answer is four. One to 
estimate the cost of the new light bulb, one to estimate the life expectancy of this new light bulb, one 
to estimate the quality of life associated with the light from the new light bulb, and one to package 
the information so that it convinces the decision maker to take out the old light bulb and put in the 
new one.”J.Mauskopf 
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1 Introduction  
Health care systems around the developed world are struggling with the dilemma of 
limited resources and growing needs, arising from aging of the population, new treatment 
strategies, and increasing health awareness of the population. Economic evaluations are 
being used increasingly often in an attempt to meet the challenges of optimizing the 
allocation of scarce health care resources. These methods are utilized to promote efficient 
use of resources, as well as controlled introduction and sustainable use of health care 
interventions. 
The use of economic evaluations has been growing in recent years. The purpose of 
performing these evaluations is to ensure the best possible use of limited health care 
resources. (Drummond et al. 2005) Choices are inevitable, and economic evaluations 
provide a means to support the decision making process. One of the reasons for the 
increase in the costs of health care is the introduction of new medical treatments. In many 
cases, these new treatments have represented substantial clinical advances in disease 
management and prevention; unfortunately they often are more costly than their 
predecessors. Nevertheless, in order to fully understand the value of a new drug, one has to 
evaluate its impact on a broad range of outcomes. Whether or not the drug represents good 
value for money, is then determined by its cost with respect to alternative treatments. 
(Mauskopf 2001)  
Pharmacoeconomics, as a discipline, is concerned with the clinical and economic aspects 
of pharmaceuticals within health care and society. Pharmacoeconomics is a 
multidisciplinary science, which uses methods originating from health economics. Most 
pharmacoeconomic projects are performed by a team of people who have training in the 
relevant disciplines, such as pharmacy, statistics, medicine, economics, health economics 
and epidemiology. (Mauskopf 2001) Cost-effectiveness analysis, which is the most 
commonly used method in economic evaluation, aims to inform decision makers about 
how much improvement in health can be expected for a given expenditure of resources 
(Grosse 2008).  
This thesis utilizes methods from pharmacoeconomics to assess new cancer treatments. 
Since it is a leading cause of morbidity and death worldwide, cancer poses a challenge to 
health care funding both due to more expensive treatments, and the rising incidence rates. 
It presently consumes a large and a potentially increasing proportion of total health care 
spending. (Peppercorn et al. 2011) It has been estimated that there were 12 million new 
cancer patients worldwide in 2008. In Europe alone, 3.2 million new cancer cases are 
diagnosed each year. These numbers are rising, and by 2030, it is predicted that there will 
be 27 million new cancer patients each year throughout the world. (Ferlay et al. 2007, 
Meropol and Schulman 2007, Ferlay et al. 2010) Between 1993 and 2004, the total sales for 
cancer drugs increased from €840 million to €6.2 billion in Europe (Wilking and Jönsson 
2005). Medical costs are responsible for half of the economic burden of cancer (Meropol and 
Schulman 2007), which emphasizes the importance of conducting economic evaluations of 
these treatments.  
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2 Structure and aims of the thesis 
This thesis begins with an introduction to the cost and burden of cancer, and to the 
methods used in pharmacoeconomics. The following sections illustrate how the cost and 
burden of cancer have developed during recent years. This plases into context the research 
studies, and highlights the importance of economic issues in cancer treatment. This is then 
followed by chapter 4 guiding the reader through the general methods used in 
pharmacoeconomic evaluations, while the subsequent chapter concentrates on specific 
issues related to the pharmacoeconomics of cancer. This introductory chapter is followed 
by studies containing various elements of pharmacoeconomic evaluations, including cost-
effectiveness analyses, value of information analyses, budget impact analyses and the 
burden of illness estimates. The first study is a review of the global cost-effectiveness of 
sunitinib in metastatic renal cell carcinoma (mRCC) (I). This represents an overview of the 
methods currently used in cost-effectiveness analysis in the context of cancer. The review is 
accompanied by studies where pharmacoeconomic methods will be used to estimate the 
impact of the evaluated treatments (II-V). These original evaluations are performed from a 
Finnish perspective. 
The general aim of this thesis was to study pharmacoeconomic methods and to apply 
them to evaluate the cost-effectiveness and budget impact of cancer treatments in Finland. 
The studied diseases were metastatic renal cell carcinoma and early phase Human 
epidermal growth factor receptor 2 (HER2) -positive breast cancer. The specific aims of the 
studies were: 
 
 To present an overview of the published cost-effectiveness studies of sunitinib in 
metastatic renal cell carcinoma, together with the results and methodology utilized 
in obtaining the results. 
 To estimate the cost-effectiveness of sunitinib in the second-line treatment of 
metastatic renal cell carcinoma in Finland. 
 To assess the burden of illness due to renal cell carcinoma in Finland. 
 To assess the budget impact of trastuzumab from the perspective of a single hospital 
district, and to apply a probabilistic approach to budget impact estimations. 
 To estimate the cost-effectiveness of short-course trastuzumab in the adjuvant 
treatment of HER2-positive early phase breast cancer in Finland, and to estimate the 
value of further research. 
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3 Cost of cancer in Finland 
There are more than 224,500 persons who have been diagnosed with cancer in Finland. 
During the year 2010, a total of 31,532 new cancer cases were diagnosed (Figure 1), and 
11,686 cancer deaths occurred in Finland. By 2020, the corresponding annual numbers are 
predicted to be 33,800 and 12,540. The increases in both new cancer cases and cancer deaths 
are predominantly due to the aging of the population. While the absolute numbers of 
deaths and new cases are increasing, the age-adjusted incidence and mortality rates are 
actually predicted to decline. At the beginning of year 2010 there were approximately 
91,240 prevalent cancer patients whose diagnosis had been made during the previous 5-
year period, and this number is predicted to increase to 110,000 by 2020. (Finnish Cancer 
Registry 2009, Finnish Cancer Registry 2012) The demographic changes in the Finnish 
population will be one of the key drivers of cancer costs in the future. The increasing 
number of cancer patients, their enhanced survival times and the increasing cost of 
treatment, represent major challenges to society from different aspects. Nonetheless, the 
overall burden of cancer will inevitably increase from all economic, humanistic and clinical 
perspectives.  
 
Figure 1. Mean annual number of new cancer cases in 1964-2010, in Finland with 5-year mean 
values being presented for 1964-2008 (Finnish Cancer Registry 2012) 
 
The development of cancer medicines has advanced by leaps and bounds during recent 
years. A typical feature for this development has been the emphasis on biological rather 
than cytotoxic approaches. Thus, many of the newly developed cancer medicines are 
specific to particular patient groups or distinct tumour types. While this has achieved 
advances in survival and other clinical outcomes, it has also led to increasing costs 
associated with treatment. The rapid development of monthly treatment costs during the 
21st century is illustrated in Figure 2. 
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Figure 2. Monthly cost of cancer drugs in US at the time of approval by Food and Drug 
Administration (FDA) from 1965 to 2008. The prices are in USD 2007 value. The dotted line 
represents median costs during each 5-year period (Bach 2009). 
 
Treatment of cancer is generally carried out in specialized health care units. The 
treatments of cancer differ according to the place and type of tumour, and the stage and 
malignancy of the disease. The choice of treatment is also affected by the age and the 
general condition of the patient, as well as by the presence of co-morbidities. (Mäklin and 
Rissanen 2006) Going largely hand in hand with the different treatment strategies, also the 
cost of cancer care vary according to tumour site, phase of care, disease stage at diagnosis 
and patient survival (Purushotham et al. 2011). 
In 2009, total health care expenditures in Finland were €15.7 billion, which is 9.2% of the 
gross domestic product (Ministry of Social Affairs and Health 2011). Cancer accounts for 
5% of all health care costs in Finland, and this is expected to increase in the future. The total 
annual cancer-related costs in Finland were €528 million in 2004, with costs estimated to 
reach €1.5 billion by 2020. (Ministry of Social Affairs and Health 2010) The increase in costs 
is expected to be especially steep with respect to cancer medications, which are predicted to 
increase by more than fourfold by 2015 compared with the situation in 2004 (Mäklin and 
Rissanen 2006). Alternative estimates, based on statistics from the Organisation for 
Economic Co-operation and Development (OECD), found direct cancer costs of €587 
million, which is €113 per capita and 6.9% of total health care costs in 2002, in Finland. 
According to the same estimates, cancer drugs are responsible for 3.5% of total drug costs, 
i.e. €48 million in total or €9 per capita, in 2002. (Wilking and Jönsson 2005) In another 
report by Wilking and colleagues (2009), the estimated figures for Finland were smaller 
compared to those previously mentioned. In 2007, the direct cost of cancer was estimated to 
be €93.6 per capita, while the average per capita costs were €148 in Europe. The share of 
cancer treatment costs from the total health expenditures in Finland was reported to be one 
of the lowest in the European countries. During 2007, this proportion (4.3%) was well below 
the European average (6.3%). (Wilking et al. 2009)  
The cost of cancer treatment has risen rapidly during the 21st century. The unadjusted 
medication costs in cancer clinics of Finnish university hospitals have risen by 100-403% 
from year 2000 to 2008. The average cost per patient in these hospitals ranged from 886€ to 
1,348€ in 2008. Cost of medication accounted for 14% to 38% of the total expenses of the 
oncology clinics. Nevertheless, these proportions are not fully comparable due to 
organizational differences. (Ministry of Social Affairs and Health 2010) The cost of inpatient 
care is expected to grow more slowly than the cost of outpatient care. The increasing costs 
of outpatient care are due to several factors, i.e. the increased number of patients, active 
patient follow-up, new adjuvant and combination treatments, radiation therapy, and the 
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use of targeted treatments (Mäklin and Rissanen 2006). A trend towards more ambulatory 
cancer treatment may reduce cancer-related hospital treatment days even though more 
patients are being treated. The cost of administration of expensive targeted treatments, 
especially those given by the intra-venous (i.v.) route, is likely to increase the costs of both 
inpatient and outpatient care in specialized health care units. 
Most of the costs of cancer to society are attributable to cancer therapy. In 2004, inpatient 
care accounted for 45%, and reimbursed cancer drugs for 11% of all cancer related costs. 
However, in 2015 the reimbursed medications are expected to be responsible for an 
increased amount, between 17–31% of the total cancer costs. (Mäklin and Rissanen 2006) In 
2010, the total wholesale for antineoplastic and immunomodulating agents in Finland was 
€345 million (Table 1). This accounts for 18.5% of the total medicine sales to pharmacies and 
hospitals at wholesale prices. Drug sales to pharmacies were 58.1% out of this total with the 
rest (41.9%) being sales to hospitals. The sales of antineoplastic agents increased from the 
previous year by 5%, being €142 million. Antineoplastic agents (ATC L01) and Endocrine 
therapy (ATC L02) include mostly agents used for cancer treatment. Antineoplastic agents 
and endocrine therapy, used in outpatient care, were reimbursed to 15,300 and 33,600 
individuals, respectively. (Finnish Medicines Agency and Social Insurance Institution 2011) 
Special refunds (in Euros), based on cancer diagnosis, have increased by nearly 25% each 
year, during the beginning of 21st century (Mäklin and Rissanen 2006).  
During the years 1996–2005, 19 new chemical entities were introduced into outpatient 
treatment of cancer (ATC L01, L02) in Finland. The total sales of these new cancer 
medicines in 2005 was €23.6 million, accounting for 40% of the total costs of the ATC 
groups L01 and L02 (Martikainen and Enlund 2009). Many of the targeted anticancer 
treatments that have entered the market recently, or are likely to enter market in the next 
few years, are unlikely to be curative treatments. Instead, these agents are becoming 
available for late stage disease, with limited life-expectancy gains. In addition, treatment 
protocols in the future are expected to be more complex, and include diagnostics, which 
increases their costs. (Sullivan et al. 2011)  
 
Table 1. Wholesale and reimbursement of antineoplastic and immunomodulating agents. 
Presented with the major subgroups (Finnish Medicines Agency and Social Insurance Institution 
2011). 
 
ATC 
code Name of ATC group 
Whole 
sales 
Reimbursements by  
Social Insurance Institution  
    
  
(x1000€) 
 
Patients 
receiving 
(n) 
Average 
€/patient 
Total € 
(x1000€) 
L 
 
ANTINEOPLASTIC AND 
IMMUNOMODULATING AGENTS 
345,095 
 
 
104,809 
 
2,501 
 
262,117 
 
L01 Antineoplastic agents 142,018 
 
15,268 3,225 49,241 
 L01A   Alkylating agents 3,488 
 
1,329 2,774 3,023 
 L01B   Antimetabolites 17,091 
 
8,727 9,63 8,408 
 L01C   Plant alkaloids and other natural products 19,630 
 
1,649 1,666 2,747 
 L01X   Other antineoplastic agents 97,096 
 
N/A N/A N/A 
  L01XC      Monoclonal antibodies 57,133 
 
N/A N/A N/A 
  L01XE      Protein kinase inhibitors N/A 
 
1,581 20,411 32,269 
L02 Endocrine therapy 25,600 
 
33,596 991 33,293 
 L02A   Hormones and related agents 13,740 
 
12,733 1,366 17,389 
 L02B   Hormone antagonists and related agents 11,860 
 
23,841 667 15,904 
L03 Immunostimulants 57,357 
 
8,283 7,524 62,322 
L04 Immunosuppressants 120,120 
 
54,110 2,167 117,260 
N/A=Not available, ATC=Anatomical Therapeutic Chemical 
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The studies in this thesis concentrate on sunitinib and trastuzumab, which both belong 
to the newer class of cancer drugs. Trastuzumab is a monoclonal antibody (L01XC), and 
sunitinib belongs to the protein kinase inhibitors (L01XE). Trastuzumab is used and 
administered in specialized health care units, and thus not reimbursed by the Social 
Insurance Institute (SII). In this thesis, it represents an example of a hospital product. 
Sunitinib, instead, is an oral product that is used in outpatient care. In 2010, 
reimbursements due to sunitinib (restricted basic refunds (42%) or special refunds (100%) 
were paid to 370 patients with total costs amounting to €6.73 million. (Finnish Medicines 
Agency and Social Insurance Institution 2011). “Other antineoplastic agents” (L01X) 
presents highest total wholesales (€), among all ATC-groups in Finland. The wholesale 
value of this group has grown rapidly from €15.8M in 2002 to €105,7M in 2011. (IMS health 
2012) The value of the total wholesales of trastuzumab and sunitinib is presented in Figure 
3. 
 
 
 
Figure 3. Total wholesale of sunitinib and trastuzumab in Finland during 2002-2011. Wholesale 
prices in Euros without value added tax (IMS Health 2011). 
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4 Methods used in pharmacoeconomic evaluation 
There is an established need for assessing which treatments would produce the best value 
for the invested resources. This may be performed via different methods commonly used in 
health economics: cost-minimization analysis (CMA), cost-benefit analysis (CBA), cost-
effectiveness analysis (CEA), and cost-utility analysis (CUA). (Drummond et al. 2005) The 
characteristics of these analytical methods are presented in Table 2. Today, the most widely 
used evaluation methods are CEA and CUA, which are also the methods utilized in the 
current thesis. In this thesis, cost-effectiveness analysis refers to both CEA and CUA. The 
difference in CUA and CEA is in the health outcome unit they are using. While CEA uses 
natural units, such as life-years, CUA uses a metric called quality-adjusted life-year 
(QALY). QALY incorporates health-related quality of life to life expectancy, and thus 
combines mortality and morbidity. One QALY is equal to one year lived in perfect health 
(quality weight 1) and, for example, it is equivalent to two life years lived with quality 
weight 0.5.  
 
Table 2. Characteristics of the methods for economic evaluations (Drummond et al. 2005) 
 
Type of analysis Treament outcome Treatment cost 
Cost-minimization Assumed equal Monetary unit 
Cost-benefit Monetary unit Monetary unit 
Cost-effectiveness Natural unit (e.g. LYG) Monetary unit 
Cost-utility QALY Monetary unit 
LYG=life-year gained; QALY=quality-adjusted life-year 
 
The increasing interest towards economic evaluations, during the previous decades, has 
arisen both from the need for rational allocation of health care resources, and the increases 
in the regulatory requirements (Tannock et al. 2011). However, the fundamental goal is 
similar from both viewpoints. This trend is illustrated in Figure 4 showing the increasing 
number of cost-effectiveness analyses published during the last decades. 
 
 
Figure 4. Number of published cost-effectiveness analyses in the years 1976–2010 (Center for 
the Evaluation of Value and Risk in Health 2011) 
 
Cancer accounts for a large and constantly growing proportion of health care costs. 
Therefore, there has been an increasing interest specifically in examining the economic 
issues concerning cancer treatments. Similarly to the overall number of studies, the number 
of cost-effectiveness analyses published related to cancer medications has increased rapidly 
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in first decade of the 21st century (Figure 5). In general, the most commonly evaluated 
treatments have been those indicated for the most common types of cancer. In addition, the 
rapid development of disease management in certain cancer types is related to the increase 
in the number of evaluations. Half (53%) of all cost-utility analyses published prior to 2008 
concerned pharmaceuticals, with 14% being related to cancer; breast cancer was the most 
frequently studied type of cancer (36%) (Greenberg et al. 2010). 
 
 
Figure 5. Number of published cost-effectiveness studies concerning cancer medications during 
2000–2009 sorted by geographical location (A), and disease type (B) (Data from Pihkola 2011) 
 
Cost-effectiveness analysis determines if a new treatment provides value for the 
additional investments. However, it does not consider the affordability of a treatment. For 
this reason, it is recommended that a comprehensive pharmacoeconomic evaluation should 
include budget impact estimations that consider the additional costs among the entire 
target population (Annemans 2010). 
4.1 INCREMENTAL COST-EFFECTIVENESS RATIO AND WILLINGNESS TO 
PAY THRESHOLD IN A COST-EFFECTIVENESS ANALYSIS 
In a cost-effectiveness analysis, the cost-effectiveness of a new treatment is assessed 
through an incremental cost-effectiveness ratio (ICER) (Drummond et al. 2005). The ICER 
informs how much would have to be paid for an additional health unit (e.g. QALY, LYG). 
Cost-effectiveness is always a relative measure, and thus the new treatment is compared 
against an existing treatment or treatments. The comparator should be the current standard 
of care or the most relevant alternative treatment. The equation for ICER is, 
 
 
where CN and CO are the expected costs for new and old treatment, and EN and EO are the 
expected effectiveness of new and old treatment, respectively (Briggs 2001). Lambda (λ) 
denotes maximum willingness to pay threshold. The resulting ICER is usually illustrated in 
a cost-effectiveness plane (Figure 6), where the point estimate may be situated in any of the 
four quadrants. In north-east (NE) corner, the new treatment is more costly and more 
effective, in south-east (SE) corner the new treatment is less costly and more effective, in 
south-west (SW) corner the new treatment is less costly and less effective, and in the north-
west (NW) corner the new treatment is more costly and less effective. In NW quadrant, the 
old treatment dominates over its new rival, while in SE quadrant the new treatment 
dominates the old therapy. Estimation of cost-effectiveness is especially relevant when the 
new treatment is neither dominant nor dominated by the compared treatment (Dasbach et 
al. 2010). In NE and SW quadrants, a decision must be made based on the relative costs and 
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effectiveness. Commonly, the new treatment will be more effective but more costly 
compared to the old treatment, and thus the point estimate for ICER often lies in the NE 
corner. Consequently, the decision about the cost-effectiveness will depend on society’s 
willingness to pay (WTP) threshold level (Briggs 2001). 
 
 
 
Figure 6. Cost-effectiveness plane (Drummond et al. 2005). The incremental cost-effectiveness 
ratio (ICER) may be placed in any of the four quadrants in the cost-effectiveness plane. The 
arrows depict the direction of incremental costs and effects. Willingness to pay threshold depicts 
the maximum acceptable ICER. Alternative commonly used notations are presented in brackets. 
NE=north-east, NW=north-west, SE=south-east, SW=south-west.  
 
Willingness to pay (WTP) threshold refers to the value that society is willing to invest in 
an additional health unit. Whether or not a product is considered as cost-effective depends 
ultimately on the WTP threshold, which determines the maximum acceptable ICER. (Briggs 
2001) Nevertheless, while there is inevitably uncertainty related to the ICER estimate, the 
probability of a treatment being cost-effective at a certain WTP threshold may affect the 
decisions related to cost-effectiveness. Even though explicit WTP thresholds produce 
transparency in decision making, they are difficult to justify in all situations (Gyrd-Hansen 
2007). Figure 7 illustrates how reimbursement decision would apply in the case ȱȱan 
explicit WTP cut-off point, or if WTP was considered as a range. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Willingness to pay threshold as an explicit point (A), and as a range (B), assuming 
that reimbursement decision depends only on cost-effectiveness (Devlin and Parkin 2004) 
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Nevertheless, fixed threshold values are widely used globally, even though these are 
considered controversial and arbitrary (Grosse 2008). A maximum threshold established by 
NICE has been £30,000/QALY, although higher threshold values have been proposed for 
end-of-life drugs (Drummond and Mason 2007). WHO recommendations for cost-
effectiveness thresholds are also sometimes utilized. According to these recommendations, 
a treatment is highly cost-effective if the cost-effectiveness ratio (CER) is below the per 
capita gross domestic product (GDP) in the region, and cost-effective if the CER is 1-3 times 
the GDP per capita. (WHO 2003) However, these thresholds may not comparable to those 
suggested for ICER, and thus should be judged with caution if used in this context.  
Grosse (2008) has performed a review in an attempt to clarify the foundations of a 
commonly cited QALY threshold of USD50,000. This came into use in the 1990s, though a 
longer history for this threshold has been claimed. This USD50,000 threshold is often stated 
to refer to a dialysis standard, even though the studies originally proposing this value did 
not mention dialysis as its basis (Grosse 2008). Interestingly, based on the findings from the 
literature review, Grosse (2008) concluded that the USD50,000 threshold has been chosen 
for the convenience of a round number and that it has no actual scientific basis. Moreover, 
according to Grosse (2008) this threshold is outdated, since it originates from early 1990’s. 
Similarly, it was stated that if the threshold of USD50,000 per QALY were to be adjusted by 
the health care inflation rate, then the threshold would nowadays be around USD200,000 
(Tannock et al. 2011). 
Altogether, a strict cut-off point has been argued not to be justifiable either in theory or 
in practice. It has been argued that the empirical basis for threshold values is lacking. Using 
ICER and WTP as the only determinants for reimbursement would disregard objective 
measures such as equity and fairness. (Rawlins and Culyer 2004) The threshold value may 
vary depending on the health condition, outcome gained with the treatment, and the risks 
associated with the treatment. While the interpretation of the cost-effectiveness is often 
weighed against a WTP threshold, it has been argued that the strict limits of WTP do not 
apply in real life settings. Different societies set different thresholds, which may be implicit 
or explicit, about what is considered to be cost-effective. (Peppercorn et al. 2011) In 
addition, the same threshold has often been used interchangeably for both life-year and 
QALY, and the concept of WTP is further complicated by different outcome measures. 
Consequently, the utilized and presented thresholds have been criticized as being either too 
low, too high or too vague (Grosse 2008). 
4.2 BUDGET IMPACT ANALYSIS 
The purpose of budget impact analysis (BIA) is to estimate the financial consequences of 
the adoption and diffusion of a new health care intervention within a specific health care 
setting given the inevitable resource constraints. BIA predicts how a change in a mix of 
drugs and other therapies (that are used to treat the health condition of interest) will impact 
on the spending for the treatment of that health condition. (Mauskopf et al. 2007) Thus, the 
interest is focussed on the expected changes that will happen in the entire treatment 
practice when new treatments are introduced, instead of estimating only the cost of a 
certain drug. In contrast to cost-effectiveness analyses, the results obtained from budget 
impact analyses take into consideration the entire population of interest. The basic 
schematic concept of a BIA is depicted in Figure 8. 
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Figure 8. The basic concept and an illustrative flow of budget impact analysis (Mauskopf et al. 
2007) 
 
Budget impact analyses are seldom published in scientific journals. A recent review by 
Orlewska and Gulácsi (2009) found 34 publications, published during 2000–2008, where 
BIA was included. Most (65%) of these publications concentrated specifically on budget 
impact issues, and in 35% of the publications, budget impact was presented as a secondary 
subject matter in a study. The location of the studies was rather evenly distributed between 
Europe (47%) and USA (41%). More than half (58%) of the studies were sponsored by the 
pharmaceutical industry, and 18 studies (53%) were prepared for pharmaceuticals. The 
majority (65%) of the reviewed studies were published during 2007–2008, reflecting the 
increasing importance and the recognition of budget impact issues. (Orlewska and Gulácsi 
2009) 
In 2007, the International Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) published a report concerning the principles of good practice for budget impact 
analysis (Mauskopf et al. 2007). This has been the most obvious attempt to provide an 
international standard for budget impact analysis, though the need for such guidelines has 
been previously acknowledged, and the process in this direction initiated at the beginning 
of the 21st century (Trueman et al. 2001). In addition to the recommendation provided by 
ISPOR (Mauskopf et al. 2007), some countries have their own national recommendations or 
guidelines for performing budget impact analyses. However, these national documents 
have been reported to be variable in terms of defining what constitutes a budget impact 
analysis, and most have provided only limited details of the important factors in the BIA. 
(Mauskopf et al. 2005, Orlewska and Gulácsi 2009). Official Finnish guidelines or 
recommendations on budget impact analyses are lacking. 
According to Mauskopf and colleagues (2005), budget impact estimations for new 
pharmaceuticals have been routinely performed in many countries for years, though 
generally accepted methods have been lacking. Thus, many of the recommendations, based 
on vague definitions, are open to a variety of interpretations, and consequently, these 
analyses have not correctly taken into account the crucial variables present in the budget 
impact estimations. (Mauskopf et al. 2005) This extensive heterogeneity in the budget 
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impact studies, has been observed in the methods utilized, time horizon, population, and 
reporting of the results. As an example, the time horizon in the previously published 
studies has ranged from 100 days to 15 years, although in nearly half (44%) of the studies it 
has been 1 year (Orlewska and Gulácsi 2009). Prolonged follow-up time in budget impact 
analyses inevitably leads to an increase in the level of uncertainty. This is especially true in 
cancer treatment where new treatments are rapidly incorporated into treatment practices, 
and thus, rapid changes have been observed in the field of oncology. In study IV, it was 
observed that already a change from a 1-year perspective to a 4-year perspective increased 
the uncertainty related to the results. Since the uncertainty grows with time, the time 
horizon of budget impact analysis should be relevant to decision makers. It is likely that a 
lifetime perspective in a budget impact analysis will not provide any reliable results. 
Furthermore, in most of the reviewed studies, with time horizons greater than 1 year, the 
cost had been discounted with 3%, 3.5% or 5% discount rates (Orlewska and Gulácsi 2009). 
The current ISPOR guidelines do not recommend discounting, though the possibility is not 
excluded. In addition, the impact of uncertainty has rarely been determined in these 
analyses (Mauskopf et al. 2005). 
There has been a demand for greater consistency in budget impact analyses, especially 
with respect to sensitivity analyses, discounting of costs, general transparency of the 
analyses, and the information sources utilized (Orlewska and Gulácsi 2009). Though the 
aim of evaluating budget impact is not to obtain absolutely exact figures, the scale of the 
results should be reliable. The aim of international recommendations is to promote and 
achieve uniformity and comparability of budget impact analyses both nationally and 
internationally (Mauskopf et al. 2007).  
4.3 GENERAL METHODS USED IN STUDIES I-V 
This section is intended to provide a general view of the pharmacoeconomic methods 
utilized in this thesis. The specific methods used in the studies will be described in detail 
under their own chapters. Markov modeling (Briggs and Sculpher 1998) was used in three 
of the studies (II, III, V). All of these used a model with 3 mutually exclusive health states 
(Figure 9). Markov model stages are characterized as discrete, mutually exclusive, and they 
have no memory (Kuntz and Weinstein 2001). In addition, all patients within a stage are 
assumed to be homogenous. Time in Markov models is applied as cycles, and a 
hypothetical patient population transitions between the predetermined health stages 
following these model cycles (Briggs and Sculpher 1998, Kuntz and Weinstein 2001). The 
health stages and cycle length are determined according to the study perspective and 
disease characteristics. 
The model structure and transition probabilities are intended to illustrate the natural 
flow of the disease concerned. Since all diseases are unique, the same evaluation model can 
rarely be used for different health conditions as such. Thus, the 3-stage model (Figure 9) 
was adjusted to fit the aim and purpose of the individual studies. The technical realization 
of the model varied between the studies, although the basic structure of the model 
remained the same. The structure of the framework model, including health states “No 
progression”, “Progressed disease” and “Dead” is governed by the assumption that these 
health states apply to most types of cancer. This partition is present in clinical trials 
showing end-points such as time to treatment failure, time to disease progression, 
progression-free survival and overall survival. The utilized partition concerning disease 
severity is also present in terms of treatment costs. When treatment is modified from active 
to supportive/palliative, the cost structure changes from drug-intensive to being hospital-
intensive (study III). 
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Figure 9. Basic framework for the utilized cancer model 
 
Probabilistic sensitivity analyses (PSA) were utilized in both of the cost-effectiveness 
analyses (II, V), and in the budget impact analysis of adjuvant trastuzumab (IV). In PSA, 
each of the chosen model inputs is allowed to vary independently according to the 
predetermined probability distributions, in order to incorporate the uncertainty related to 
the model parameters (Briggs 2001). In study II, the model was built with WinBUGS 
software, which directly implements a Bayesian approach (Martikainen 2008). The PSA 
results were depicted as cost-effectiveness planes (V), cost-effectiveness acceptability curves 
(II, V), and affordability curves (IV). The affordability curve in BIA shows the probability of 
staying within a given budget (Sendi and Briggs 2001). 
Value of Information analysis (VOI) was applied to the probabilistic model in study V. 
The value of additional research informs what are the maximum costs that one would be 
willing to pay to reduce uncertainty. This may also be used to quantify parameter 
uncertainty, in order to more effectively allocate research resources. (Barton et al. 2008) 
It is relevant to take population dynamics into consideration in budget impact models 
with chronic diseases, unstable populations, and in studies using a long time horizon. In 
this thesis the population dynamics was handled through state transition models (Kuntz 
and Weinstein 2001). The two cost-effectiveness models (II, V) utilized closed cohort 
modeling, where the hypothetical patients were followed through their lifetime. Both of the 
budget impact models (III, IV) were open cohort stage-transition models, where new 
patients entered the model according to the estimated incidence of new cases. New cases 
entered the patient pool and stayed there until the end of follow-up or death. Treatment 
effectiveness was incorporated into the budget impact models. This enabled accounting for 
differences in costs within different disease stages between the treatments being compared. 
A general illustration of patient dynamics utilized in the open cohort models in this thesis is 
depicted in Figure 10. 
 
 
Figure 10. Illustration of patient dynamics in the utilized budget impact models 
 
Economic evaluations may be performed from several perspectives (Figure 11), which 
determines the included resource use and costs. In cost-effectiveness analyses, the most 
commonly the utilized perspective is that of society or of the health care payer. The payer 
perspective is considered to be most relevant for budget impact analyses (Annemans 2010), 
while the use of societal perspective is rare but cannot be excluded. The study perspective 
derives from the aims of the study, and thus it varies among the studies included in this 
thesis. 
14 
 
 
 
Figure 11. Different perspectives of economic evaluations (Mogyorosy and Smith 2005) 
 
Irrespective of the chosen model structure, a model itself will produce nothing without 
proper inputs. It may be said that a model is only as good as the inputs it contains. Thus, 
the selection of reliable data sources is a crucial step in the modeling process. Figure 12 
illustrates the type of model inputs that are required in cost-effectiveness and budget 
impact models. Decisions on model inputs are based on the requirements of a study and the 
availability of data. Thus, the model inputs presented in Figure 12 may not completely 
apply to all circumstances, as some disease-specific or treatment-specific features may be 
lacking. The choice of data sources and model inputs is often based on individual decisions. 
Nevertheless, guidelines for measuring drug costs have been presented by the International 
Society for Pharmacoeconomics and Outcomes Research (ISPOR). In addition, several 
recommendations for good practice in different modeling techniques are currently under 
preparation by ISPOR.  
 
 
Figure 12. Required model inputs in cost-effectiveness and budget impact analyses. The dotted 
lines represent optional inputs depending on study perspective. 
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5 Specific aspects and methodological challenges of 
pharmacoeconomics in cancer care 
Pharmaceuticals go through a rigorous evaluation process prior to obtaining marketing 
authorization and a possible reimbursement status. Randomised clinical trials are 
considered as the golden standard for demontrating the efficacy of new therapies. The 
regulatory authorities, such as European Medicines Agency, use these data along with 
other additional information to assess the balance between risks and benefits of the 
intervention. The regulatory approval process, however, does not consider issues related to 
costs or funding of the treatment. In the European Union, the costs and reimbursement 
policies are considered within each of the member states. (Tannock et al. 2011) In Finland, 
health economic evaluations are required for medicines with a new active pharmaceutical 
ingredient, when applying for a reasonable wholesale price and reimbursement status (Laki 
sairausvakuutuslain muuttamisesta 802/2008). Nevertheless, economic aspects are only one 
of the issues that are considered when funding decisions are made, since these are also 
affected by clinical issues and equity. Other issues influencing these decisions are the 
degree of uncertainty related to the results, the innovative nature of the technology, certain 
features of the disease, characteristics of the target population, and issues concerning the 
wider societal costs and benefits (Barry 2007).  
Figure 13 presents a schematic illustration of the requirement that a pharmaceutical faces 
when entering the Finnish market. Marketing authorization is rarely sufficient for a 
successful market entry, especially among prescription products that are used in outpatient 
care. If a medication is not considered to be suitable for reimbursement, then its market 
penetration will prove difficult. Successful entry to the market most often requires 
demonstrations of cost-effectiveness and affordability (i.e. ability to pay for the treatment). 
 
 
Figure 13. Pharmaceuticals entry to Finnish market via the European centralized marketing 
approval process 
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5.1 LIMITATIONS RELATED TO CLINICAL TRIALS AS A DATA SOURCE  
Despite the fact that randomized clinical trials are considered the golden standard as a 
source of efficacy data, they also contain various inherent limitations. Firstly, they present 
the results gained under ideal conditions, and in selected institutions, with highly selected 
patients. These aspects are likely not to depict the real-life effectiveness which can be 
attained in daily clinical practice. Secondly, statistical significance between experimental 
and control intervention, may not always reflect true clinical significance. Thirdly, 
randomized trials often use surrogate endpoints as their primary endpoint. This permits 
faster reporting of the results, though another important issue relates to the high costs of 
clinical trials. In cancer studies, disease-free survival (DFS) is often used as a surrogate for 
overall survival (OS) when evaluating adjuvant therapy. Similarly, progression-free 
survival (PFS) is used as a surrogate in studies evaluating therapy for metastatic disease. 
(Carroll 2007, Tannock et al. 2011) Surrogate endpoints are often expected to predict the 
final outcome, though the evidence for this proposition is limited. The exact timing of 
progression remains in many cases unknown, which has led to some questions about the 
value of PFS as a primary end point in clinical trials (Carroll 2007). However, PFS has been 
considered to be an acceptable surrogate for OS, for example in advanced colorectal cancer 
(Buyse et al. 2007). In addition, Delea and colleagues (2009) found that PFS predicted OS in 
patients with metastatic renal cell carcinoma. Based on 21 trials, their results suggested that 
a 1 month difference in disease progression was associated with a 1.4 month difference in 
OS. Nevertheless, it has been stated that better defined criteria are needed in order to 
validate surrogate markers for rare diseases (Drummond et al. 2009).  
In addition to the above mentioned, patient crossover may represent a major issue when 
using clinical trial results in economic evaluations. While this phenomenon is present in 
clinical trials in general, its relevance has been debated particularly in oncology. Crossover 
from one clinical trial arm to another may happen when it has been observed that one arm 
is clinically clearly better than the other. (Chabot et al. 2008, Ishak et al. 2011) In oncology 
trials, this means that patients whose disease progresses under the comparator treatment 
may move into the experimental arm. When patients move from one treatment arm to 
another, this leads to mixing of the effect and obscures the impact of the treatment being 
studied. The contamination of treatment arms may also lead to selection bias in the 
patients. Patients crossing over to the experimental group are likely to have a different 
prognosis than those who do not crossover. Patients who crossover may be initially sicker 
and thus, they do not respond to the standard therapy (i.e. those with early progression are 
the first candidates to crossover). While the crossover cannot be predicted, it represents a 
potential source of bias in the analyses. Several approaches to control for crossover have 
been proposed. These include different restrictions on the data, such as regrouping patients 
or excluding some of the patients, and censoring follow-up at crossover. Nevertheless, the 
bias caused by crossover cannot be adequately corrected with standard statistical methods. 
(Chabot et al. 2008, Ishak et al. 2011) Overall survival as an outcome measure is more likely 
to be confounded by crossover issues and the use subsequent therapies than PFS. Examples 
of ways for controlling this bias have been presented recently; these include the use of 
prediction equations and external information to minimize the impact of crossover in 
economic evaluations (Ishak et al. 2011). 
5.2 EXTRAPOLATION OF SURVIVAL DATA 
The follow-time in clinical trials is usually relatively short. Thus, the obtained survival 
estimates (e.g. Kaplan Meier -survival curves) from clinical trials often need to be 
extrapolated over time if they are to be utilized in cost-effectiveness analyses (Drummond 
et al. 2005). In addition, in trials with rare cancers, it may be difficult to demonstrate 
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statistically different benefits, due to the limited number of available patients (Chabot et al. 
2008). These may lead to different assumptions about the magnitude and length of 
treatment benefit, which will affect the cost-effectiveness results, as illustrated in study V. 
The extrapolation of survival data may be performed in alternative ways, often leading 
to alternative results. The use of modeling to extrapolate survival involves predicting the 
shape of the survival curves beyond what has been observed. (Drummond et al. 2005) 
Already minor changes in the extrapolated survival can have a significant impact on the 
cost-effectiveness estimates (Hoyle and Henley 2011). Figure 14 illustrates how the same 
empirical data may be extrapolated over time using different continuous probability 
distributions. When using an exponential function, the hazard of an event is assumed to 
remain constant over time. Whereas, when using a parametric distribution providing a 
changing hazard (Weibull in this case), the function is based on all data points in the 
empirical data. In the latter case, the hazard is time-dependent and thus may be different at 
different points in time. Varying results in cost-effectiveness may be expected when using 
different approaches for extrapolating the empirical data. 
 
 
Figure 14. Hypothetical example of data which is extrapolated using different continuous 
probability distributions: A) exponential distribution and B) Weibull distribution. The figure is 
drafted and presented for illustrative purposes. 
 
The decision on how survival is applied to the model is often driven by the availability 
of data, and unfortunately, the patient-level data is often unavailable (Drummond et al. 
2005). Thus, the analysis may have to be based on mean or median times to an event, which 
leads to the assumption of constant hazard. Mean and median times both have their place 
in characterizing survival, and the choice between these parameters depends on the 
availability of data and the aims of the study (Davies et al. 2011). Study V demonstrates 
how the lack of available patient-level data may be overcome, to some extent. In this 
technique, the visual image of published survival curves were manually traced back in 
order to obtain numerical values of patients at risk, or those being censored at different 
points in time. If individual patient data is available, these should be used for fitting the 
curve for modeling purposes (Hoyle and Henley 2011). Nevertheless, even if all patient 
level data were available, this may not resolve all of the complications related extrapolation 
of survival data. The chosen parametric function (providing changing hazard of an event) 
may appear differently depending on the outlying assumptions (Thompson Coon et al. 
2010). An example of this is illustrated in Figure 15, where the same patient-level data is 
fitted using two alternative scenarios. The original fitting utilizes all patient data, whereas 
the alternative fitting excludes some of the patients as outliers. In addition to visual 
inspectation of the extrapolated curve, statistical methods can be used to select the best 
fitting curve (Hoyle and Henley 2011). Furthermore, it is meaningful to inspect if the 
distribution-based projections are clinically plausible.  
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Figure 15. An example of possible variability in fitting the same empirical survival data 
(Thompson Coon et al. 2010) 
5.3 CONCEPT OF SOCIAL VALUE IN CANCER 
A treatment may be considered as cost-effective, even if the incremental cost-effectiveness 
ratio is above the normally approved implicit or explicit willingness to pay threshold. This 
is related to factors beyond costs that can modify the views of what is considered as the 
highest acceptable ICER in the society. An example of this is given by National Institute for 
Health and Clinical Excellence, which has issued a guidance, that allows certain treatments 
to exceed the range of normally approved upper end of ICER (£30,000/QALY), in England 
and Wales. The guidance allows higher ICERs for treatments that are indicated for patients 
with a short life expectancy, and that offer an additional survival of at least 3 months 
compared to the current treatment. (NICE 2009) It has been noted that society places more 
weight on a health benefit gained in a severely ill patient than in a health benefit gained in a 
less severely ill individual (McGregor 2003). Thus, the treatments for different health 
conditions may be valued differently by the surroundind society. 
The social value of the disease may affect what is perceived as an acceptable willingness 
to pay threshold value (Drummond et al. 2009). This is illustrated in Figure 16, where circle 
“A” depicts a normal situation, with no great deviation between social value and cost-
effectiveness. In this situation, decisions on the acceptable incremental cost-effectiveness 
ratios are made based on existing explicit or implicit predetermined WTP levels. 
Consequently, an assessment based on cost-effectiveness alone is likely to be acceptable to 
most members of the community. Treatments placed inside circle “B” illustrate those 
treatments that may be considered as relatively cost-effective, but nonetheless society is not 
willing to publicly fund these treatments, due to their low social value. Controversially, in 
certain other diseases (circle “C” in Figure 16) the society is willing to accept relatively low 
cost-effectiveness (i.e. high ICERs). Medications for some cancers or rare diseases may be 
included in this category when the health condition is life-threatening, and there is a lack of 
effective alternative treatment options. Drummond and colleagues (2009) proposed that 
reimbursement agencies should show greater commitment to adopting a fair and 
transparent decision-making process. 
The traditional measures used in economic studies do not incorporate all elements of 
social value, and thus, the need for alternative measures should be recognized to balance 
equity with an efficient use of resources. In some situations, the social value may be 
connected also to the expected budget impact of the treatment. This might be the case in 
rare cancers, where orphan drugs with high ICER are reimbursed and funded by the 
society, because of the limited budget impact of the treatment, unmet medical need and 
high social value of the disease. (Drummond et al. 2009) 
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Figure 16. Relationship between social value of the disease and incremental cost-effectiveness 
ratio (ICER). A=normal situation, B=low social value, C=high social value (Drummond et al. 
2009). 
5.4 QUALITY-ADJUSTED LIFE-YEAR AS AN OUTCOME MEASURE IN 
CANCER 
Cancer therapy includes not only curative treatments, but also supportive care to meet the 
end of life phase of therapy. Thus, in many instances, the focus of the treatment is on 
achieving improvements in quality of life and survival. (Tannock et al. 2011) Nevertheless, 
the extended survival is only as good as the quality of life that it prolongs. Quality-adjusted 
life-year is a measure that combines life years gained from a treatment with the quality of 
life during those years. In principle, by using QALYs it is possible to capture the differences 
in tolerability, side effect profiles and other aspects of a treatment that could affect the 
health-related quality of life, but not the length of life itself. (Arbuckle et al. 2002) Even 
though QALY is a well established measure, it has been debated whether QALY adequately 
captures the health gains achieved by cancer treatments. 
Garau and colleagues (2011) discussed the potential methodological limitations of using 
QALYs in cancer. They noted that a generic index instrument (for measuring health-related 
quality of life) may be relatively insensitive to those changes that appear in health status of 
the cancer patient. Furthermore, when utilities are measured with different instruments, the 
number of QALYs gained may differ according to the methods being used (McGregor 
2003). This phenomenon has been illustrated also in other therapeutic areas, such as critical 
care (Vainiola et al. 2011). In addition, limitations related to techniques used for estimating 
the values of the health states, may also affect the QALY results. It has been argued that the 
time trade-off (TTO) method may not be suitable when valuing health conditions with 
proximity to end of life. In short, in TTO a person makes a trade-off between living a 
shorter time in good health and living longer in poor health (Drummond et al. 2005). 
Moreover, it is problematic to use valuations gained from the general population in the 
context of potentially fatal conditions such as cancer (Garau et al. 2011). The above 
mentioned challenges apply to the overall concept of QALY, and thus they should be 
considered as limitations.  
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Adjusting for health-related quality of life may not lead to a large difference in the cost-
effectiveness analysis of cancer treatments (Tengs 2004). Greenberg and Neumann (2011) 
reviewed CEA and CUA studies, published until the end of 2009, that were related to 
treatment, prevention and screening of cancer. They identified 117 original cancer-related 
studies that reported values for both cost per life-year gained (LYG) and cost per QALY 
gained. Approximately 60% of the cost/QALY values and 70% of the cost/LYG values were 
below the USD50,000 threshold. The corresponding proportions for ICERs between 
USD50,000–100,000 were approximately 17% and 13%. Among the reviewed studies, the 
median cost per QALY was USD28,451, and median cost per life-year gained was 
USD26,568. The mean costs in the same studies were USD112,965 per QALY gained, and 
USD111,172 per life-year gained. According to the review of Tengs (2004), cost-effectiveness 
and cost-utility estimates are highly correlated with each other, and the adjustment should 
not, in practice, lead to any difference in decision making. 
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6 Pharmacoeconomics of metastatic renal cell carcinoma  
6.1 REVIEW OF COST-EFFECTIVENESS OF SUNITINIB IN METASTATIC 
RENAL CELL CARCINOMA (STUDY I1) 
Sunitinib is one of the first targeted treatments for metastatic renal cell carcinoma (mRCC), 
and is currently considered as the standard of care for most of the mRCC patients in the 
first-line setting. The introduction of targeted treatments has, in the past few years, led to 
improvements in disease management and survival of these patients, however, with 
increasing cost. Cost-effectiveness issues have become more important, when limited health 
care resources are stressed by the increasing treatment costs and aging of the population. 
Cost-effectiveness of sunitinib has been assessed on several occasions, and a systematic 
literature search was conducted to find all published research articles as well as all research 
abstracts presented in various congresses. This study presents an overview of the currently 
existing cost-effectiveness analyses of sunitinib in mRCC, along with the main results and 
the utilized methodology. 
6.1.1 Introduction 
Renal cell carcinoma (RCC) is the most common form of kidney cancer, and it account for 2-
3% of all malignant diseases in adult population (Rini et al. 2009). RCC may occur in any 
age, but it is most often diagnosed after 60 years of age. There are approximately 209,000 
new cases and 102,000 deaths per year worldwide due to RCC (Gupta et al. 2008). The 
incidence and mortality rates increase with age (Figure 17). RCC is significantly more 
common in men than in women.  
RCC is characterized by scarcity of early warning signs, and most patients do not have 
identifiable risk factors for the disease (Rini et al. 2009). Patients may present with local or 
systemic symptoms. Local signs include hematuria, flank or abdominal pain, and palpable 
flank or abdominal mass. These symptoms occur as a combination in fewer than 10% of 
patients. Other findings are nonspecific symptoms, such as fever, nausea and weight loss. 
Small local tumours are typically asymptomatic. Most of the cases are currently found 
incidentally during abdominal imaging. (Motzer et al. 1996, Rini et al. 2009). Nevertheless, 
approximately 25–30% of RCC patients present with metastases at diagnosis (Motzer et al. 
1996, Gupta et al. 2008). RCC-related deaths are predominantly due to metastatic disease 
(Rini et al. 2009). 
In the past few years, management of RCC has gone through a transformation. Increased 
understanding of the underlying biological processes in RCC has led to advances in the 
treatment of metastatic disease (Rini et al. 2009). Before the era of targeted treatments, 
cytokine-based treatment (interferon-α, interleukin-2) was considered as the standard of 
care for patients with metastatic RCC (mRCC), despite the modest outcomes. The response 
rates to these agents have been low (5 to 20%), and the effectiveness is still controversial, 
even though these drugs have been used since 1980’s (Motzer et al. 2007a, Rini et al. 2009). 
Radiotherapy or traditional chemotherapy have limited role in the treatment of mRCC, and 
their use is often limited to palliative setting. Recently, several new targeted anticancer 
drugs have been launched for the treatment of advanced or metastatic renal cell carcinoma 
providing substantial improvements in the management of the disease. The introduction of 
                                                          
1 Adapted with permission of Expert Reviews Ltd from: Purmonen T. Cost-effectiveness of sunitinib in metastatic renal 
cell carcinoma. Expert Review of Pharmacoeconomics & Outcomes Research 11(4):383–393, 2011 
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these targeted treatments (such as sunitinib) has thereafter changed the treatment 
recommendations and guidelines.  
Sunitinib is a multitargeted receptor tyrosine kinase inhibitor. Receptor tyrosine kinases 
are associated with tumour growth, neoangiogenesis, and metastatic progression of cancer. 
The recommended dose of sunitinib is 50 mg (per os) once daily for 4 consecutive weeks, 
followed by 2-week rest period, in the treatment of mRCC (Sutent: Summary of product 
characteristics). Sunitinib was first introduced to 2nd line treatment for patients who were 
intolerant to or progressed after cytokine therapy. Before this, active treatment options for 
these patients were practically non-existing, and cytokine-based treatment was followed by 
different local treatment practices; defined later here as best supportive care (BSC). The 
efficacy of sunitinib (schedule 4/2) in cytokine-refractory mRCC was studied in two phase 
II, single-arm trials, where sunitinib demonstrated median progression-free survival of 8.2 
months (n=168), and median overall survival of 23.9 months (n=105) (Motzer et al. 2006a, 
Motzer et al. 2006b, Motzer et al. 2007b). Following this, sunitinib has demonstrated its 
efficacy also in the 1st line treatment of mRCC. In a Phase III trial, sunitinib showed 
improvements in both overall survival (24.4 vs. 21.8 months) and progression-free survival 
(11 vs. 5 months) compared to interferon-alpha (IFN-α) (Motzer et al. 2007a, Motzer et al. 
2009). 
Currently, sunitinib is considered as the new standard of care for the 1st line treatment of 
mRCC, in patients with favorable or intermediate prognostic risk (Escudier and Kataja 
2009, Rini et al. 2009, Escudier 2010). In the treatment of poor risk patients, temsirolimus 
has been recommended as the first-line treatment, sunitinib being an option (Escudier and 
Kataja 2009). For those progressing after 1st line targeted treatment, everolimus has been 
suggested to be the following treatment of choice (Mozer et al. 2008). Other targeted agents, 
such as sorafenib and bevacizumab (given in combination with IFN-α), are also currently 
licensed for treatment of mRCC. In addition, several agents are currently under 
investigation. 
The introduction of new and relatively expensive treatments has pressed the need for 
economic evaluations. The ultimate aim of assessing cost-effectiveness is to optimally 
allocate scarce health care resources. The aim of this study was to recognize all studies 
related to cost-effectiveness of sunitinib in the treatment of advanced or metastatic renal 
cell carcinoma. The present review concentrates on cost-effectiveness issues. A review of 
sunitinib in the management of mRCC may be found elsewhere (Escudier 2010). 
 
 
 
Figure 17. Incidence and mortality per 1 million inhabitants in different age groups among 
Finnish RCC patients. Mean values from the 10-year period 1995-2004. RCC is defined as 
cancer of the kidney, excluding cancer of the renal pelvis (Finnish Cancer Registry 2006). 
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6.1.2 Review of literature 
A systematic literature search was conducted to find all published research articles as well 
as all research abstracts presented in various congresses. The literature search was 
conducted using various databases: PubMed, ISI Web of Science, Cost-effectiveness 
analysis registry, CINAHL (Cumulative Index to Nursing and Allied Health Literature), 
and CRD databases (Centre for Reviews and Dissemination: including Database of 
Abstracts of Reviews of Effects (DARE), NHS Economic Evaluation Database (NHS EED), 
Health Technology Assessment (HTA)). In addition, congress abstracts were also searched 
directly from the websites of two congress organizers: International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) and American Society of Clinical 
Oncology (ASCO). No restrictions were applied to the publication date or language during 
the search. The following search terms were used: sunitinib, sutent, cost, economic, 
evaluation, utility, QALY, cost-effectiveness, cost effectiveness, renal, kidney, RCC, mRCC. 
Evaluation reports from the manufacturer or from different national agencies were not 
searched. Nevertheless, formal HTA reports are covered by the searched HTA database, 
and these were not excluded if found in the database search. Letters, editorials, 
correspondences or comments were excluded.  
The literature search was performed in December 2010, and it resulted with 421 hits 
(Figure 18). After first exclusion, a total of 58 possible titles were identified. When all 
duplicate search results were excluded, altogether 26 congress abstracts, 4 research articles, 
and one HTA-report were identified. The included HTA-report contained information used 
as a source of evidence in technology appraisals from National Institute for Health and 
Clinical Excellence (NICE TA169, NICE TA178). To avoid duplicate reporting of results 
these were not included in the current study. In addition, one review concerning economic 
evaluations of several mRCC treatments, including sunitinib, was found (Norum et al. 
2010). One of the abstracts could not be accessed (Négrier et al. 2007), and thus, was 
excluded. Furthermore, one abstract was excluded since it concerned only cost with no 
actual economic evaluation. The search was done again in February 2011, resulting with 
one new article. Reference list search was done manually for all articles and the HTA-report 
included in the current review. This was also done to the review article before it was 
excluded from the study (Norum et al. 2010). The manual search resulted with no new 
abstracts or articles with matching inclusion criteria. 
 
 
Figure 18. Literature search flow chart 
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Information from the included studies was systematically collected. Incremental costs, 
outcomes, and incremental cost-effectiveness ratios (ICER) were gathered, and missing 
values were calculated for the purpose of this review, when possible. Majority of the 
included studies were related to 1st line treatment. Results from first and second-line 
treatments are presented in their own sections. 
Most of the included congress abstracts (16 out of 24) were presented in different ISPOR 
meetings during 2007–2010. Five abstracts were presented in ASCO meetings 2007–2010, 
and three in ESMO 2008 (European Society for Medical Oncology). The one inaccessible 
abstract was from ECCO 2007 meeting (European Cancer Organization) (Négrier et al. 
2007). From the 16 included ISPOR abstracts, the related congress posters were available in 
11 cases, either from congress web site or from authors own archives. Posters provided 
additional information and assisted in evaluating the type of utilized cost-effectiveness 
models. If posters were available, they were used as the primary source of data, if 
information between abstract and poster was conflicting. 
Industry funding or industry employee among authors was reported in all articles (n=5) 
and in nearly all abstracts (21 out of 24). One of these was sponsored by the manufacturer 
of temsirolimus, and the rest (n=20) by the manufacturer of sunitinib. In addition, one 
abstract did not report any source of funding, but was using the same model presented in 
manufacturer sponsored studies. 
The methodological quality of the included studies was not evaluated. The author is 
solely responsible for the review process, data extraction and assessment of the published 
articles and abstracts/posters. Monetary results are presented in Euros, no other 
adjustments were made. The exchange rates against Euro currency are from European 
Central Bank (18.1.2011) (USD 1.3371; GBP 0.83565; SEK 8.9203; CAD 1.3182; THB 40.768; 
ILS 4.725; COP 2499.31; ARS 5.319). 
6.1.3 Cost-effectiveness of sunitinib in the first-line treatment of mRCC 
6.1.3.1 Methodology and models used in the first-line economic evaluations 
Cost-effectiveness of 1st line sunitinib was assessed in 3 research articles and 20 congress 
abstracts. In addition, a HTA from the Peninsula Technology Assessment Group (PenTAG) 
evaluated sunitinib in 1st line mRCC treatment (Thompson Coon et al. 2010). This report 
contained PenTAG estimates of cost-effectiveness, and results from manufacturer 
submission on cost-effectiveness to the National Institute for Health and Clinical Excellence 
(NICE). The PenTAG estimates were based on their own model as well as based on 
manufacturer’s model, adjusted by the assessment group. 
All of the model-based studies (n=23) used a Markov model (Briggs and Sculpher 1998), 
which simulated disease progression, and determined survival and cost outcomes for a 
hypothetical cohort of mRCC patients. The cost-effectiveness models included 3 or 4 health 
stages among which patients transition during the modeled time horizon. The most used 
model structure included the four following mutually exclusive health stages: First-line 
until progression, Second-line (composite), Best supportive care, and Death (due to cancer 
or other causes). The model structure and stage names were nearly identical in all of the 1st 
line articles. Another utilized structure for the Markov model included 3 stages: 
Progression-free survival, Progressed disease, and Death. This was used for example by 
PenTAG in their estimation (Thompson Coon et al. 2010). Only one study used other than 
model-based approach (Ondrakova and Demlova 2010). 
Out of the 20 congress abstracts concerning 1st line mRCC treatment, 16 were based on a 
same model or similar model structure presented in more details in the full articles (Remák 
et al. 2008, Chabot and Rocchi 2010, Benedict et al. 2011). Despite the observed similarities 
in the utilized models among the studies, the original cost-effectiveness model may have 
been modified by the authors, and localized in accordance with national requirements. The 
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model (built in MS Excel) was reported to be intended for global use, and thus could be 
adapted to various national health systems (Remák et al. 2007a). 
In Markov models, patients can be in one health stage at a time, and in each cycle there is 
a certain probability to transition between the health stages. In the included studies, the 
modeled time horizon was most commonly life-time (10y), however, this varied between 1 
to 10 years. Cycle length was 6 weeks in all studies where it was reported. The utilized 6 
week cycle reflects the dosing schedule of sunitinib (4-week treatment followed by 2-week 
pause). When using a Markov model, the modeled population contributes costs and 
outcomes in each model cycle according to the health stages. The per-cycle costs are driven 
by health care resource use (depicting treatment practice) and the country-specific unit 
costs. Usually both the number of resources used and the unit costs differ across countries 
due to differences in health care systems, treatment practices and patient populations. This 
presents a challenge for the localization of global cost-effectiveness models. In the included 
studies, the source for country-specific resource use was most commonly expert opinion, 
where reported. Data from local patients were collected during some of the studies and a 
few used databases as the primary source of resource use information. 
Published clinical trials were used as the primary source of effectiveness in nearly all the 
studies. Phase III trial comparing sunitinib and IFN-α (Motzer et al. 2007a, Motzer et al. 
2009) was apparent in nearly all the studies. In those studies comparing several substances, 
an indirect comparison was utilized. Using an indirect comparison it may be possible to 
compare the health outcomes between substances when direct comparisons are not 
available (i.e. when substances have not been compared against each other in the same 
clinical trial). Indirect comparison was described in a full text article by Benedict et al. 
(2011), where several treatment options for 1st line mRCC were compared at the same time, 
using IFN-α as the common comparator (Benedict et al. 2011). Similar approach was also 
chosen in 13 abstracts. Remák et al. (2008) as well as Chabot and Rocchi (2010) compared 
the cost-effectiveness of sunitinib against IFN-α, using head-to-head trial to elicit treatment 
efficacy (Remák et al. 2008, Chabot and Rocchi 2010). Also three of the abstracts had similar 
comparators and methods. 
Inclusion of active second-line treatment was done differently in studies based on the 
same model structure, which included the “second-line (composite) health state”. Chabot 
and Rocchi (2010) noted that in order to isolate incremental effect of sunitinib versus IFN-α, 
it was necessary to exclude subsequent use of any tyrosine kinase inhibitor in 2nd line 
treatment (Chabot and Rocchi 2010). On the contrary, Remák et al. (2008) included second-
line composite treatment, which consisted of sunitinib (40%), sorafenib (40%), IL-2 (10%), 
and IFN-α (10%), regardless of the initial treatment assignment (Remák et al. 2008). In this, 
two thirds of the patients were assumed to receive the composite treatment after 1st line 
treatment with sunitinib. Moreover, in the article by Benedict et al. (2011), 80% of the US 
patients were assumed to receive active 2nd line treatment despite of the initial treatment 
assignment (sunitinib, sorafenib or bevacizumab/ IFN-α), whereas in Swedish population, 
30% received 2nd line treatment after sunitinib, and 43% after bevacizumab/IFN-α (Benedict 
et al. 2011). Since several studies have utilized similar model structure (including second-
line composite treatment), it is likely that there have been different approaches among the 
studies, in how second-line treatment is incorporated. In the manufacturer submission to 
NICE, patients receive sunitinib or IFN-α until progression, followed by BSC in both 
groups – 2nd line drugs were not a part of that analysis (Thompson Coon et al. 2010).  
6.1.3.2 Results from the published cost-effectiveness analyses (first line) 
The cost-effectiveness of 1st line sunitinib has been assessed in several published studies 
during 2007-2011. In these studies, the incremental cost-effectiveness ratios (ICER) have 
been estimated in cost per life-years (LY), progression-free life-years (PFLY), progression-
free months (PFM), and quality-adjusted life-years (QALY) gained. ICER informs how 
much additional costs would have to be invested for an additional unit of health benefit 
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(e.g. QALY). The cost-effectiveness of 1st line sunitinib has been compared against 
interferon-alpha (IFN-α), interleukin-2 (IL-2), sorafenib (SFN), temsirolimus (TMS), or 
combination of bevacizumab and IFN-α (BEV/IFN). An overview of the results from the 
cost-effectiveness analyses is presented in Table 3. 
Incremental cost-effectiveness ratios for 1st line sunitinib ranged from €4,786 to 
€109,416/QALY, and €33,807 to €100,212/LYG when compared with IFN-α. Sunitinib 
dominated IFN-α in only one study with 1-year study perspective. From US societal 
perspective (excluding indirect costs) the ICERs for sunitinib were €13,920/PFLY, 
€50,269/LYG and €39,333/QALY, when compared to IFN-α. The probability of sunitinib 
being cost-effective compared to IFN-α was 46% at willingness to pay (WTP) threshold of 
USD50 000/QALY (~€37,400), and 65% at USD100,000/QALY (~€74,800) (Remák et al. 2008). 
These results (Remák et al. 2008) were reported to have been previously presented in part 
in various congresses (Négrier et al. 2007, Remák et al. 2007b). Nevertheless, other 
unreported matching ICERs were found among a few of the studies. In manufacturer’s 
submission to NICE, the ICERs were €25,269/LYG, €54,731/PFLY, and €34,160/QALY, when 
sunitinib was compared with IFN-α from UK National Health Service perspective. The 
probability of sunitinib being cost-effective compared with IFN-α was 54% at WTP of 
£30,000/QALY (~€35,900) (Thompson Coon et al. 2010). When the model (submitted by 
manufacturer) was adjusted by PenTAG, the ICER increased to €57,500 - €67,000/QALY 
(Thompson Coon et al. 2010). In another study, performed from the perspective of 
Canadian public health care system, the ICERs were €100,100/PFLY, €79,525/LYG and 
€109,416/QALY, when sunitinib was compared with IFN-α (Chabot and Rocchi 2010). 
Furthermore, an analysis from the perspective of health care provider in Thailand showed 
an ICER of M3.6 Baht per QALY (€88,305), when sunitinib was compared to IFN-α. This 
was reported to be beyond the ICER threshold for a developing country (Topibulpong et al. 
2010). Treatment with IL-2 was dominated by both sunitinib and IFN-α (Remák et al. 2008). 
Combination therapy with bevacizumab and IFN-α was dominated in all the studies 
where it was compared against sunitinib (n=16). From a Swedish health care payer 
perspective, the probability that sunitinib was cost-effective compared to BEV/IFN was 99% 
at WTP of SEK500,000 (~€56,050) (Benedict et al. 2011). Sunitinib dominated sorafenib (i.e. 
was more effective and less costly) in 7 studies, in terms of cost per LY or QALY gained. 
Furthermore, sunitinib was more costly and more effective compared with sorafenib in 
another 6 studies, where the ICER was ranging from €24,149 to €52,036. From the US health 
care payer perspective the probability of sunitinib providing a cost-effective alternative to 
sorafenib and BEV/IFN was 74% at WTP of USD100,000 (~€74 800) (Benedict et al. 2011). 
Temsirolimus was dominated treatment option when compared with suninitib, in 
standard mRCC population (n=5). In studies with poor prognosis population (n=3) 
sunitinib was either less costly and more effective (Benedict et al. 2009), more costly and 
more effective (ICER €29,712/QALY) (Remák et al. 2009), or less costly and less effective 
compared to temsirolimus (Silverio et al. 2009). The last study was sponsored by 
manufacturer of temsirolimus, and others by manufacturer of sunitinib. In the last study 
the cost for an additional QALY gained with temsirolimus was €21,783, when compared to 
sunitinib in poor risk patients (Silverio et al. 2009). 
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Table 3. Cost-effectiveness studies of first-line sunitinib treatment 
 
Author Year Country Comparator ICER (€/LYG) ICER (€/PFLY) ICER (€/QALY) 
Articles             
Benedict et al. 2011 USA SFN domin. domin. domin. 
   
BEV/IFN domin. domin. domin. 
Benedict et al.  2011 Sweden BEV/IFN domin. domin. domin. 
Chabot and Rocchi 2010 Canada IFN-α € 79,525 € 100,100* € 109,416 
Thompson Coon et al. ** 2010 UK IFN-α € 70,181 N/A € 85,517 
Remák et al. 2008 USA IFN-α € 50,269 € 13,920 € 39,333 
      IL-2 domin. domin. domin. 
Abstracts 
      Benedict et al. 2009 USA SFN N/A domin. domin. 
      BEV/IFN N/A domin. domin. 
      TMS (p.r.) N/A domin. domin. 
Benedict et al. 2008a USA SFN € 43,037 € 20,941 € 44,877 
      TMS domin. domin. domin. 
      BEV/IFN domin. domin. domin. 
Benedict et al. 2008b USA SFN € 40,229 € 27,201 € 49,121 
      TMS domin. domin. domin. 
      BEV/IFN domin. domin. domin. 
Remák et al. 2007b USA IFN-α (model 1) € 50,269 N/A € 39,333 
   
IFN-α (model 2) N/A € 69,841 N/A 
Remák et al. 2007a USA IFN-α € 50,269 € 13,920 € 39,333 
      IL-2 domin. domin. domin. 
Remák et al. 2009 Sweden BEV/IFN domin. domin. domin. 
      TMS (p.r.) € 25,257 € 16,838 € 29,712 
Sandin et al. 2008 Sweden SFN € 19,938 € 13,483 € 24,149 
      TMS domin. domin. domin. 
      BEV/IFN domin. domin. domin. 
Munir et al. 2008 Sweden SFN € 19,938 € 13,483 € 24,149 
      TMS domin. domin. domin. 
      BEV/IFN domin. domin. domin. 
Calvo et al. 2010 Spain SFN domin. domin. domin. 
      BEV/IFN domin. domin. domin. 
Diaz et al. 2008 Spain SFN € 22,577 € 11,398 € 24,272 
      BEV/IFN domin. domin. domin. 
Godoy et al. 2009a Colombia  IFN-α € 40,211 € 29,110* N/A 
      SFN domin. domin. N/A 
      BEV/IFN domin. domin. N/A 
Godoy et al. 2009b Colombia  IFN-α € 40,211 N/A N/A 
      SFN domin. N/A N/A 
      BEV/IFN domin. N/A N/A 
Caceres et al. 2008 Colombia  IFN-α (1y)# domin. domin. domin. 
      IFN-α (10y)# € 5,983 N/A € 4,786 
Salinas-Escuerdo et al. 2009 Mexico  SFN domin. domin. domin. 
      BEV/IFN domin. domin. domin. 
Mould-Quevedo et al. 2009 Mexico  IFN-α € 50,865 € 33,807 N/A 
      SFN domin. domin. N/A 
      BEV/IFN domin. domin. N/A 
Greenberg 2009 Israel SFN N/A N/A € 52,036 
      TMS N/A N/A domin. 
      BEV/IFN N/A N/A domin. 
Teich et al. 2010 Brazil IFN-α ICER positive+ ICER positive+ N/A 
      BEV/IFN domin. domin. N/A 
Topibulpong et al. 2010 Thailand IFN-α € 66,228 € 49,058 € 88,305 
Ondrackova and Demlova 2010 Czech Rep. IFN-α € 100,212 € 88,651 N/A 
Silverio et al. 2009 Portugal TMS (p.r.) N/A N/A €21,783*** 
IFN-α = Interferon-alpha; IL-2=Interleukin-2; SFN=sorafenib; BEV/IFN=bevacizumab and IFN-α combination therapy; TMS=temsirolimus; LYG=life-year 
gained; PFLY=progression-free life-year; QALY=quality-adjusted life-year; N/A=Not Available; (p.r.)=poor prognosis patients; 
*=estimated from published values; **=Health Technology Assessment –report; ***TMS more effective and more costly than sunitinib 
+ = sunitinib more costly and more effective; #=different time horizon; domin. = dominated by sunitinib (i.e. sunitinib more effective and less costly) 
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Results from cost-effectiveness analyses of sunitinib in first-line treatment of mRCC are 
presented in a cost-effectiveness plane (Figure 19), where point estimates of incremental 
costs and incremental effects of sunitinib are plotted. Included in the figure are studies 
presenting incremental costs and incremental QALYs, as well as studies where this 
information could be extracted if it was not presented. The cost-effectiveness plane is 
divided into 4 sections according to costs and outcomes (NE: more costly and more 
effective; SE: less costly and more effective; SW: less costly and less effective; NW more 
costly and less effective). In most cases sunitinib was situated in SE corner of the cost-
effectiveness plane, showing dominance over the comparator. The results in NE corner 
show that incremental health benefits are achieved with sunitinib, but with higher costs 
than the comparator. The results of those in NE corner are presented with incremental cost-
effectiveness ratios (ICER). Sunitinib was less effective and less costly in only one study 
(SW), and was not dominated in any of the studies (NW). The values presented in the 
Figures 19 and 20 are from studies conducted in various countries, and thus the relative 
position of these points has to be interpreted with prudence due to potential differences 
between the studies.  
 
 
 
Figure 19. Results from cost-effectiveness analyses of sunitinib in first-line treatment of mRCC. 
Included are studies presenting incremental costs and incremental QALYs. NE=north-east, 
NW=north-west, SE=south-east, SW=south-west. 
29 
 
 
6.1.4 Cost-effectiveness of sunitinib in the second-line treatment of mRCC 
6.1.4.1 Methodology and models used in second-line studies 
The literature review identified 5 abstracts and 2 full articles considering 2nd line sunitinib 
treatment in mRCC. In addition, the included HTA-report contained results from 2nd line 
cost-effectiveness analysis that the manufacturer had submitted to NICE (Thompson Coon 
et al. 2010). All the 2nd line studies using Markov-model and reporting its structure, utilized 
a structure with three similar health stages (Roughly: No new progressions, New 
progressions, Death) (Garduño-Espinosa et al. 2007, Purmonen et al. 2007, van Nooten et al. 
2007, study II, Paz-Ares et al. 2010). One of the studies reported to have used and localized 
a model developed and tested in the USA (Paz-Ares et al. 2010), and it is likely that a 
closely similar evaluation model was used also at least in 2 of the abstracts (Garduño-
Espinosa et al. 2007, van Nooten et al. 2007). In the Finnish studies (2nd line) the Markov-
model was built in WinBUGS software (Purmonen et al. 2007, study II). All the model-
based studies used life-time horizon (5 or 10 years), and one month model cycles. One of 
the studies was not a model-based evaluation (Ondrakova and Demlova 2010). 
Published clinical trials were used for extracting the treatment efficacy of sunitinib in all 
the studies. Most commonly, the efficacy was based on single arm, Phase II trials assessing 
the efficacy and safety of sunitinib in 2nd line treatment (Motzer et al. 2006a, Motzer et al. 
2006b, Motzer et al. 2007b). Published head-to-head trials of 2nd line sunitinib are lacking. 
Thus, the treatment effectiveness of the comparator (i.e. best supportive care; BSC) was 
based either on local patient data, literature or databases. Three of the studies had collected 
local patient data for obtaining information on current treatment practice. Others had used 
literature sources or various databases as the primary source of comparator data. The 
comparability of the patient populations in clinical trial and in clinical practice was one of 
the main concerns in studies using data from local patients. Four of the studies reported to 
have included resource use information provided by a panel of clinical experts. 
6.1.4.2 Results from the published cost-effectiveness analyses (second line) 
In this section, second-line treatment refers to treatment, which is initiated if patient is 
intolerant to or has failed to respond to 1st line cytokine-based (IFN-α or IL-2) therapy. 
Sunitinib was among the first targeted therapy to be indicated for 2nd line treatment. The 
cost-effectiveness of 2nd line sunitinib treatment was studied in 5 abstracts and in 2 articles, 
published between 2007 and 2010. The comparator was best supportive care (BSC) in nearly 
all cases, reflecting the local treatment practice at the time. However, BSC was formally 
defined only in the full articles, and it was described either as “current clinical practice 
including bio-chemo-therapy” (study II) or ”palliative care without chemotherapy” (Paz-
Ares et al. 2010).  
The full text articles evaluated the cost-effectiveness from health care payer perspective 
in Finland and Spain. In Spanish settings the ICER was €34,196/QALY, with 95% 
probability of being cost-effective at WTP of €45,000 (Paz-Ares et al. 2010). In the Finnish 
study, the ICER was €43,698/QALY with a corresponding probability of 70% (study II). The 
preliminary findings of the Finnish study we reported to have been presented as an abstract 
(Purmonen et al. 2007) prior to the publication of the full text article (study II). In the 
included research abstracts the incremental cost-effectiveness ratio for progression-free life-
year ranged from €20,000 to €92,000 (n=5), when sunitinib was compared to BSC. Similarly, 
the additional cost per QALY gained ranged from €10,000 to €43,000 (n=3). In the 
manufacturer’s submission to NICE, the ICERs were around €34,800/LYG, and 
€44,900/QALY, and the probability of sunitinib being cost-effective compared with BSC was 
36% at WTP of €36,000/QALY (Thompson Coon et al. 2010). In the non-model-based study, 
sorafenib was compared against a combination sunitinib (70%) and BSC (30%). The study 
showed that combination of sunitinib and BSC was more effective and more costly 
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compared to sorafenib in 2nd line treatment, leading to an ICER of €20,000 per progression-
free life-year (Ondrakova and Demlova 2010). The results of the included 2nd line studies 
are presented in Table 4. The incremental costs and QALYs, among studies conducted in 
various jurisdictions, are illustrated in a cost-effectiveness plane (Figure 20). Sunitinib was 
associated with additional benefits and higher costs compared to BSC in all studies, in the 
2nd line treatment of mRCC. 
 
Table 4. Cost-effectiveness studies of second-line sunitinib treatment after cytokine failure 
 
Author Year Country Comparator 
ICER  
(€/LYG) 
ICER 
(€/PFLY) 
ICER 
(€/QALY) 
Articles 
      Paz-Arez et al. 2010 Spain BSC € 25,199 € 72,876 € 34,196 
Purmonen et al.  
(study II) 2008 Finland BSC € 30,831 € 57,624 € 43,698 
Abstracts 
      Ondrackova and Demlova 2010 Czech Rep. SFN** N/A € 19,878 N/A 
Aiello et al. 2007 Argentina BSC € 7,430 € 21,650 € 10,048 
Garduño-Espinosa et al. 2007 Mexico BSC N/A € 54,550* € 26,354 
Purmonen et al. 2007 Finland BSC € 30,014* € 57,719* € 42,877 
van Nooten et al. 2007 Belgium BSC € 35,389 € 91,980 N/A 
BSC=Best supportive care; SFN=sorafenib; N/A=Not Available; LYG=life-year gained; PFLY=progression-free life-year; 
QALY=quality-adjusted life-year; *=estimated from published values; **= sunitinib arm consists of sunitinib (70%) and 
BSC (30%) 
 
 
 
 
Figure 20. Results from cost-effectiveness analyses of sunitinib compared to best supportive 
care (BSC) in second-line treatment of mRCC. Included are articles and abstracts presenting 
incremental costs and incremental QALYs (n=5), as well as results from manufacturer’s 
submission to National Institute for Health and Clinical Excellence (n=1). NE=north-east, 
NW=north-west, SE=south-east, SW=south-west. 
31 
 
 
6.1.5 Discussion 
Sunitinib is among the first targeted anticancer agents for the treatment of metastatic renal 
cell carcinoma. The cost-effectiveness of sunitinib in this indication has been assessed in 
several studies. In the 1st line treatment, the cost-effectiveness of sunitinib was assessed 
against multiple substances. In these analyses, sunitinib was more effective than the 
comparator in nearly all cases, and it was associated with either cost-savings or additional 
costs. Sunitinib was less effective and less costly in only one study, when it was compared 
against temsirolimus in poor risk population. In 2nd line treatment of cytokine-refractory 
mRCC, sunitinib was more costly and more effective compared to best supportive care in 
all the studies. In most studies, the ICER of sunitinib in the treatment of mRCC was on an 
acceptable range, and thus deemed as cost-effective. Although sunitinib seems to be a cost-
effective treatment option in mRCC as a whole, the decisions related to the potential cost-
effectiveness have to be compared against the willingness to pay threshold levels in 
different jurisdictions. The National Institute for Health and Clinical Excellence, health 
authority in England and Wales, has recommended sunitinib as the 1st line treatment option 
for mRCC (NICE TA169, NICE TA178). 
The reviewed studies were published during 2007–2011, including 5 full text articles, 24 
research abstracts and a health technology assessment -report. Previously published 
reviews have identified only minority of the studies found in the present study. The 
included HTA-report contained a thorough review of cost-effectiveness of mRCC 
treatments (Thompson Coon et al. 2010). However, the review was based on literature 
search performed during 2007 and 2008, and thus could identify only 3 of the sunitinib 
abstracts. In another review, 1 abstract, 2 articles, and an evaluation report concerning cost-
effectiveness of sunitinib in mRCC, were identified. In the latter review, the literature 
search was performed in 2008 and 2009 (Norum et al. 2010). A recent review, published 
during the review process of the current article, identified 3 articles covering issues related 
to cost-effectiveness of sunitinib in the treatment of RCC (Shih et al. 2011). This 
demonstrates the difficulty to publish up-to-date reviews in a field that is constantly 
changing. Nevertheless, the present review had potential methodological limitations. The 
quality of the included studies was not formally evaluated, and the review process was not 
performed by two independent reviewers, as recommended for systematic reviews. In 
addition, some of the included articles and abstacts contain same results. Thus, the total 
number of studies found in this review would be smaller if all duplicate results had been 
discarded. (Centre for Reviews and Dissemination 2009, Higgins and Green 2011) 
The present review revealed that several studies were based on the inherently same cost-
effectiveness models. These “global models” are developed by/for pharmaceutical industry 
to be used in several jurisdictions. Often, they are localized to different countries simply by 
redefining the resource use and unit cost information. This produces a new kind of bias, 
when a variety of namely independent studies are using the same cost-effectiveness model, 
and thus produce similar outcomes. When the variation arising from different modeling 
approaches is lacking, the large number of studies does not necessarily increase the power 
of evidence. Thus, a recommendation for good practice would be that articles using global 
models should inform if (and where) results based on the same models have been 
published. In addition, it should always be reported if same results have been previously 
presented. 
Health care resource use information may be obtained with different methods, and from 
various sources (e.g. expert opinion, registers, local patients, literature). When cost-
effectiveness models are localized to different countries, it is a common practice that local 
clinical experts are asked to define the resource use related to the treatments compared. 
This was also the case in most of the included studies. Expert opinion is, despite its 
drawbacks, in many cases the best and only available source of information when the cost-
effectiveness of novel products is estimated. Nevertheless, the estimated resource use 
32 
 
 
during different phases of treatment should be reported to enhance transparency. 
Interestingly, the assumptions related to resource use (and consequently costs) may affect 
the results of cost-effectiveness. This may be studied in sensitivity analyses, which are the 
means to show what specific model inputs affect the results the most. For example, in 
article by Remák et al. (2008), cost of best supportive care was one of the most sensitive 
parameters in the analysis, and a 20% reduction in its cost doubled the incremental costs 
per QALY gained (Remák et al. 2008). Cost of BSC in that study was USD16,011 per 6-week 
cycle, and it included several CT scans per cycle. In Benedict et al. article (2011) the cost for 
BSC in USA was USD19,467 and in Sweden USD2,775 (Benedict et al. 2011). The difference 
in BSC costs between the two countries was mentioned to be due to differences in unit costs 
and hospitalization rates. In the latter article, sunitinib remained dominant when BSC costs 
were decreased with 20%. In Finland, the expected cost of symptomatic care after IFN-α 
treatment has been €1,500 per month, based on health care resource use of 81 mRCC 
patients (study III). 
Health-related quality of life has been more favorable in patients treated with sunitinib 
compared to those treated with IFN-α (Cella et al. 2010). In the reviewed studies, the 
utilized quality of life instrument was EQ-5D. This was explicitly mentioned in all full text 
articles and in eight of the abstracts. However, due to similarities among the analyses, it 
may be assumed that EQ-5D has been used in most of the QALY estimations. Thus, the 
obtained QALYs among different studies should be well comparable. Nevertheless, the 
differences in health care systems, patient characteristics and treatment patterns as well as 
differences in discount rates or other model-related assumptions among the studies may 
still influence the comparability of the results. 
Lack of adequate information on resource use and costs, limited clinical evidence, and 
short follow-up times present major challenges for performing timely economic evaluations 
of novel cancer treatments. Due to different adverse event (AE) profiles among the targeted 
treatment, it has been suggested that more attention should be paid on the cost differences 
of treating AEs (Mickisch et al. 2010). However, a properly conducted cost-effectiveness 
analysis should include information of all relevant cost parameters, such as cost of 
managing adverse events. When new treatment options for mRCC arise, the issues related 
to AE profile are likely to be of increasing importance. Indirect comparison of treatment 
efficacy was utilized among the studies comparing several treatment options against each 
other. Nevertheless, other indirect comparisons of mRCC treatments have been conducted 
using different methodology, which has led to varying or even conflicting results of relative 
treatment efficacy (Mills et al. 2009, Thompson Coon et al. 2010, Benedict et al. 2011, 
Mickisch et al. 2011). Uncertainty is inevitably present in the cost-effectiveness estimations. 
In majority of the included studies, this uncertainty was assessed through probabilistic 
sensitivity analysis. However, more precise estimates on treatment costs as well as disease 
burden are needed to support decision making, and to further enhance the accuracy of the 
cost-effectiveness evaluations. In addition to cost-effectiveness, also the budgetary impact 
of the novel treatment should be assessed, to inform decision makers about the net costs of 
an adoption decision. Nevertheless, budget impact analyses are rarely performed in 
published articles. Rapid development of treatments and sequencing of targeted therapies 
is likely to have an impact on both treatment costs and survival. The costs and benefits of 
the emerging treatments should be carefully assessed prior to adapting those to clinical 
practice. 
Management of mRCC will continue developing when new targeted anticancer agents 
are introduced. Sunitinib is likely to stay among the 1st line treatment options, while others 
will arise. Targeted drugs will be more often included in subsequent treatment lines, 
though knowledge about an optimal treatment strategy is currently lacking. Cost-
effectiveness issues are to become even more important, when both treatment costs and the 
number of patients are expected to rise. As a current standard of treatment, sunitinib will 
present the baseline against with the emerging treatments will be compared. This leads to 
number of new cost-effectiveness analyses of sunitinib beyond this review. 
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6.2 ECONOMIC EVALUATION OF SUNITINIB IN SECOND-LINE 
TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN FINLAND 
(STUDY II2) 
6.2.1 Introduction 
Renal cell carcinoma (RCC) is the most common kidney cancer among the adult population. 
Because there are few, if any, early warning signs or symptoms, the diagnosis may be 
delayed, perhaps until after RCC is at a locally advanced or metastatic stage (mRCC). 
(Motzer et al. 1996) RCC has a poor, if any, response to chemo- or radiotherapy and low 
rates of response to cytokines, interleukin-2 (IL-2), and interferon-alpha (IFN-α). Even in 
first-line treatment, the response rate with these agents is in the range of 10% to 20%. 
(Motzer et al. 1996, Motzer and Russo 2000) The prognosis for mRCC is poor, with 5-year 
survival estimated to be <10% (Motzer et al. 1996). 
At the time of writing this article, there was no generally approved standard treatment of 
mRCC. Cytokine therapy (IFN-α or IL-2) had long been thought to be the most effective 
treatment and was used as first-line therapy, although only a small number of patients 
respond to these agents (Motzer et al. 1996). For second-line therapy, the treatment options 
at the time were even more limited (Motzer et al. 2004). Until recently, there was no 
effective therapy available for patients with mRCC who failed to respond, who were unable 
to tolerate cytokine therapy, or whose disease progressed after an initial response (Motzer 
et al. 2006c). However, a growing understanding of the biological process underlying 
different malignancies, including RCC, has offered possibilities for new treatment 
alternatives. 
Tyrosine kinases play an important role in the regulation of cellular proliferation and 
survival through numerous pathways. In cancer cells, tyrosine kinases are dysregulated in 
several ways, and this disturbance has been associated with cancer progression. (Krause 
and Van Etten 2005) Sunitinib is a multitargeted tyrosine kinase inhibitor that inhibits these 
malignant processes through multiple pathways and has been found to have antitumour 
and antiangiogenetic activity. (Motzer et al. 2006c) At the time of writing this article 
sunitinib was indicated for the treatment of mRCC and Gatrointestinal stromal tumour 
(GIST). A dose of 50 mg is administered orally on 28 consecutive days, followed by a 2-
week rest period (Sutent: Summary of product characteristics). Treatment is continued in 6-
week cycles until disease progression or intolerable adverse events occur. Compared with 
other therapies, sunitinib has been associated with high objective response rates in patients 
with cytokine-refractory mRCC. (Motzer et al. 2006b, Staehler et al. 2006) 
The aim of this study was to compare the costs and outcomes among patients with 
mRCC actively treated with sunitinib to those receiving second-line treatment as practiced 
in the healthcare setting in Finland, at the time of writing the article. The present second-
line treatment is usually best supportive care (BSC), including palliative biochemotherapy 
(subsequently referred to as BSC). The difference in costs and outcomes between these 2 
treatment arms represents the incremental impact of the use of sunitinib for second-line 
treatment of mRCC. The analysis is conducted from the perspective of the health care payer 
in Finland; indirect costs were not assessed. 
6.2.2 Materials and methods 
Disease Model. Economic evaluation was conducted using a probabilistic Markov state-
transition model. A model with 3 disease states was used to describe the natural history of 
patients with mRCC who have experienced failure on prior cytokine-based therapy. The 
                                                          
2 Adapted with permission of Elsevier Ltd from: Purmonen T, Martikainen JA, Soini E, Kataja V, Vuorinen RL, 
Kellokumpu-Lehtinen PL. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell 
carcinoma in Finland. Clinical Therapeutics 30(2):382–392, 2008 
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simplified structure of the model is shown in Figure 21. The transitions through the states 
were assumed to occur in 1-month (i.e. 30-day) cycles, and the model was run until all 
patients in the modeled cohort had transitioned to the death state. In practice, the model 
was run up to 5 years because at that point all patients in the model had deceased. This 
finding is consistent with empirical studies (Motzer et al. 2004, Elson et al. 1988). 
 
 
Figure 21. Structure of the Markov-model of mRCC along with the base-case transition 
probabilities (S=sunitinib; B=BSC) 
 
The Bayesian modeling approach was applied to enable the simultaneous estimation of 
all inputs in the model (including transition probabilities, resource utilization, unit costs, 
and utilities), sensitivity analysis for data and model specifications, and evaluation of the 
model (Cooper et al. 2004). Uncertainty was propagated into the model using prior 
probability distributions, which were specified from the prior evidence identified from 
clinical trials, the literature, and a local sample (N=39) (Table 5). The model was constructed 
and evaluated using a Markov chain Monte Carlo simulation implemented in WinBUGS 
software version 1.4 (MRC Biostatistics Unit, Cambridge, United Kingdom). 
 
Table 5. Characteristics of Finnish mRCC-population from two university hospitals (i.e. local data 
sample) 
 
Characteristics (N=39) 
 
Value 
 
Age, median, years 68 
Sex, no. (%)  
 Men 27 (69) 
 Women 12 (31) 
Prior nephrectomy, no. (%) 33 (85) 
Prior systemic cytokine-based treatment, no. (%)  
 Interferon-alpha 39 (100) 
 Interleukin-2 0 (0) 
 
Transition Probabilities. The efficacy of sunitinib in the treatment of mRCC was gathered 
from published trials (Motzer et al. 2006a, Motzer et al. 2006b). Both studies were Phase II, 
multicenter, open-label, single-arm trials. A pooled analysis (Motzer et al. 2006b) (N=168) of 
these trials was used to determine median progression-free survival (PFS). Because median 
overall survival (OS) was not obtained in both trials, the information from a single trial 
(N=63) was used (Motzer et al. 2006a). Detailed information on survival estimates and 
patient characteristics in sunitinib trials can be found in the original reports (Motzer et al. 
2006a, Motzer et al. 2006b). 
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Because both sunitinib trials (Motzer et al. 2006a, Motzer et al. 2006b) were single-arm 
trials, a comparator arm was needed to perform the incremental cost-effectiveness analysis. 
Therefore, data were gathered from the medical records (June–August 2006) of a local 
sample of 39 patients from two Finnish university hospitals; these data were used to 
represent survival and resource utilization in the BSC arm in the comparison. Information 
about the BSC was collected by 3 clinical experts on a structured form composed for this 
study. The sample was collected cumulatively 1 year at a time from patients who had 
deceased during the years 1996–2006. According to expert panel consisting of 4 Finnish 
oncologist treating patients with mRCC, the treatment practice had not changed during 
these years, and thus the sample was coherent. To ensure better consistency with the 
exclusion criteria of the sunitinib trials, patients with a history of brain metastases, other 
cancers, and/or serious cardiovascular events were not included in the sample. Patients 
with a poor general condition were excluded because their condition would not have 
permitted active treatment. The baseline characteristics of the local sample are shown in 
Table 5. Prior nephrectomy was not an inclusion criterion in one of the sunitinib trials 
(Motzer et al. 2006a), and thus the patients in the local data sample were not excluded, even 
if they had not undergone nephrectomy. 
In the sunitinib trials (Motzer et al. 2006a, Motzer et al. 2006b), progression was defined 
using the Response Evaluation Criteria for Solid Tumors (RECIST) or as death related to 
RCC. However, in routine clinical practice, it is neither possible nor meaningful to use 
imaging (e.g. radiography, computed tomography [CT], or magnetic resonance imaging) to 
define progression in stage IV disease. In the local data sample, progression was assumed 
to have occurred when there had been a major change in treatment (e.g. start of 
radiotherapy, surgical treatment, hospitalization, change in cytostatic treatment). The 
decisions on what constituted a major change were discussed and made by the expert panel 
prior to data collection. The 3 clinical experts who collected the information then traced 
those major changes from the medical records. Death related to RCC was also considered 
disease progression. PFS was defined as the time between cytokine failure and disease 
progression.  
Estimating progression-free (PFS) and overall survival (OS). Survival analysis was used to 
estimate the PFS and OS after cytokine failure by fitting a Weibull model to data from the 
local sample. Kaplan-Meier survival analysis was used to ensure the validity of the 
obtained results. The probability that an individual survived from the time origin to a point 
in time beyond t was estimated by the Weibull survival function S(t): 
 
S(t) = P(T  t) = exp(–λtγ), 
 
where λ (lambda) was the scale of the distribution and γ (gamma) was the shape of the 
distribution. The scale parameter was parameterized as exp(β0), and the shape parameter 
was estimated from the data. Correlation between PFS and OS were also modeled with the 
assumption that PFS may influence OS, but that there was no inverse effect of OS 
influencing PFS. Hence, correlation structure was modeled using a Weibull regression 
model: 
 
 
 
where PFS was used as a covariate. PFS was centered to mean to speed up convergence. To 
obtain a fully Bayesian approach, the model specification was completed by adding prior 
distributions on β, λ, and γ. Noninformative prior distributions for the model parameters 
were assumed without any prior expectations about the magnitude of parameter values. 
This assumption was used to ensure that the data from the local sample dominated the final 
inferences. 
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Goodness-of-Fit of Survival Models. A point estimate of the deviance (i.e. –2log[likelihood]) 
was used to assess the goodness-of-fit of the Weibull models for the data from the local 
sample (Nixon and Thomson 2004). The estimated Weibull survival curves and the 
corresponding Kaplan-Meier survival estimates from the local sample are presented in 
Figure 22. 
 
 
Figure 22. Goodness-of-fit of Weibull survival estimates for the data from the local sample 
(N=39). OS=Overall survival; PFS=progression-free survival 
 
Transition probabilities between health states. Because the mean survival times were not 
attained or available in sunitinib trials, the median values were used to estimate monthly 
transition probabilities in both study arms. In the sunitinib treatment arm, the median 
survival estimates were obtained from the published trials, whereas for BSC treatment the 
corresponding figures were estimated directly from the collected data. In the base-case 
analysis, Weibull estimates were used as the more conservative option for modeling 
purposes because they did not favor sunitinib. The median survival estimates (Table 6) 
were converted to monthly transition probabilities using the following formula: 
Risk for an event (1 month) = [1 – (0.5)(1/median time to event)] 
 
Table 6. Survival with sunitinib versus best supportive care (BSC) in the treatment of metastatic 
renal cell carcinoma 
 
 Median 95% CI SE Source 
Overall survival (OS), months    
   Sunitinib (N=63) 16.4 10.8-NA NA Motzer et al. 2006a 
   BSC (N=39) 
- Kaplan-Meier estimate 
- Weibull estimate* 
 
3.83 
4.98 
 
(2.16-5.51) 
(2.55-9.42) 
 
0.85 
1.79 
Local data sample 
 
Progression-free survival (PFS), months   
 
   Sunitinib (N=168) 8.2 (7.8-10.4) 0.66 Motzer et al. 2006b 
   BSC (N=39) 
- Kaplan-Meier estimate 
- Weibul estimate* 
 
1.43 
1.49 
 
(0.7-2.17) 
(0.97-2.28) 
 
0.37 
0.33 
Local data sample 
NA=Not yet attained *Used in the base-case analysis, SE=Standard error 
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The estimated base-case transition probabilities of disease progression were 0.081 in the 
sunitinib arm and 0.372 in the BSC arm. The monthly risks for death due to mRCC in 
sunitinib and BSC arms were 0.041 and 0.130, respectively, if no further progression in the 
disease had occurred. The corresponding risks in progressive disease were 0.081 and 0.180, 
respectively. In the analysis, these transition probabilities were assumed to remain constant 
over time (i.e. the OS and PFS curves were assumed to follow a declining exponential 
distribution in both groups). The transition probabilities from "history of progression-
related events" to "death" were derived from the difference between OS and PFS. 
Characterizing Uncertainty Related to Transition Probabilities. The uncertainty related to 
transition probabilities in the sunitinib arm was characterized by expressing the parameter 
values in the model as β (beta) distributions. The β distributions were parameterized as 
β(α, β), where α was defined as the number of patients transferring to a new state during 1 
month, and β was defined as the sample size of the sunitinib trials minus α. The values of α 
were approximated based on the estimated monthly probabilities of disease progression 
and death. In the BSC arm, the uncertainty related to transition probabilities was 
propagated directly from the Weibull survival models. Thus, no further distribution 
assumptions were needed. Because there were multiple possibilities to transitions from "no 
new progression-related events" health state in the model, the associated transition 
probabilities were normalized to ensure that they summed to 1 during the simulation 
process. 
Resource Utilization and Unit Costs. To define the monthly costs of BSC in the Finnish 
setting, data on health care resource utilization, including medication use in each patient in 
the local sample, were collected for the entire follow-up period. The recommended unit 
costs for health care services were case-mix adjusted for Finnish regional price differences 
(Hujanen 2003) and real-valued to 2005 with the official health care price index (Statistics 
Finland and Local Finland 2006). 
The consumption and cost of cancer medications, additional IFN-α products, analgesics, 
and bisphosphonates were specified. Medical costs not related to RCC were assumed to 
have been equal in both treatment arms and therefore data on these costs were not 
collected. The 3 clinicians who collected the data made the expert decision about whether a 
particular medicine was related to the treatment of RCC. The consistency of these decisions 
was checked during the data procession. 
The costs of medication were calculated using the most economic generic product prices 
in the official price list when applicable (Pharmaca Fennica 2005). For medications no 
longer on the consumer market, the last existing price was used. Prices from previous years 
were not converted to 2005 currency because medications in Finland do not follow the 
general price index, partly because medicine wholesale prices in Finland were cut by 5% in 
2006 and also due to the launch of generic substitution program in 2003. 
Prices for products with special sales permits (e.g. thalidomide) were gathered directly 
from the distributor and converted to retail prices using the official formula 
(Valtioneuvoston asetus lääketaksasta 2002). To avoid double-counting of costs, 
medications administered in hospital care were assumed to have been included in the cost 
of a treatment day and not in the costs of medication. If the duration or dose of medication 
was not mentioned, the defined daily doses (DDD) from the year 2006 were used (World 
Health Organization 2006), and the duration was assumed to be 1 month. Travel costs were 
allocated to all separate outpatient visits and radiotherapy treatment days using the 
average travel costs in both primary and secondary health care (Hujanen 2003). 
Resource utilization for the follow-up period is shown in Table 7. Resource utilization 
among BSC patients was heterogenic. Thus, an average cost per follow-up day from the 
whole population was used in the analysis and comprised an average treatment cost of 
€1,339/month. The price without value added tax was used in the calculation of all costs. 
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Table 7. Resource utilization in local mRCC-patient sample (N=39) 
 
Number of medications used during the follow-up 
 
 
IFN-α 
n (%) 
Cancer medication 
n (%) 
Bisphosphonates 
n (%) 
Analgesics 
n (%) 
0 33 (85) 14 (36) 32 (82) 9 (23) 
1 6 (15) 12 (33) 5 (13) 12 (31) 
2 0 (0) 7 (18) 2 (5) 6 (15) 
3 or more 0 (0) 5 (13) 0 (0) 12 (31) 
 
Number of imaging examinations used during the follow-up 
 X-ray 
n (%) 
CT 
n (%) 
Ultrasound 
n (%) 
MRI 
n (%) 
0 12 (31) 24 (61) 25 (64) 36 (92) 
1 11 (28) 10 (26) 8 (20) 3 (8) 
2 3 (8) 2 (5) 3 (8) 0 (0) 
3  3 (8) 1 (3) 1 (3) 0 (0) 
4 or more 10 (25) 2 (5) 2 (5) 0 (0) 
 
Number of health care service units utilized during the follow-up 
 Ward care days 
(University hospital) 
n (%) 
Ward care days 
(Health care centre) 
n (%) 
Outpatient visits 
(all levels) 
n (%) 
Radiation therapy 
days 
n (%) 
0 10 (26) 19 (49) 14 (36) 23 (59) 
1-5 6 (15) 2 (5) 15 (38) 2 (5) 
6-10 6 (15) 2 (5) 6 (15) 6 (15) 
11-19 12 (32) 3 (8) 3 (8) 3 (8) 
20 or more 5 (13) 13 (34) 1 (3) 5 (13) 
IFN-α=interferon-alpha, MRI=magnetic resonance imaging, CT=computed tomography 
 
Based on the opinion of the expert panel and on conducted literature search (PubMed; 
Key terms: sunitinib, sutent, Finland and Finnish) little information on the use of sunitinib 
in current Finnish practice was available. Thus, the expert panel was used to define an 
average treatment protocol for the patients with mRCC eligible to use sunitinib. The 
monthly treatment costs in the sunitinib arm were defined according to this protocol. 
Patients were assumed to have been seen by an oncologist and undergone laboratory 
analysis twice in the first cycle and once in all subsequent cycles. Imaging was utilized once 
in the 2 first cycles and then in every other cycle. One third of the use of imaging was 
assumed to be computed tomography; two thirds, sonography or radiography. The cost of 
medication and estimated costs for the treatment of adverse events were added to the 
monthly costs. 
The mean monthly costs are illustrated in Table 8. The more active resource utilization at 
the beginning was due to the follow-up of the treatment tolerability and entry medical 
examinations. After the termination of sunitinib treatment, the monthly costs were assumed 
to be equal to those in the BSC treatment arm. The costs were assumed to be γ (gamma) 
distributed. Because, based on the literature search, no information on the variance of mean 
monthly costs in the sunitinib treatment was available, the variance was assumed to be 
proportionally equal to the variance of the mean monthly costs in the data from the local 
sample. The parameters of gamma distributions were estimated using the method of 
moments (Briggs et al. 2002). In practice, the method of moments can be applied to solve 
the parameters of any unknown statistical distribution when the sample moments (e.g. 
mean, variance) of distribution are known. For example, if a model parameter θ (theta) is 
distributed as   ,~ gamma (alpha, beta), then the corresponding distribution moments are 
   E and   2var   . Assuming that the sample moments (i.e. mean and variance) are 
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known it can simply equate the sample moments to the distribution moments (i.e.    
and 22 s ). After this, these two equations can be solved for the two unknowns 
simultaneously. (Briggs et al. 2002) 
 
Table 8. Mean monthly costs per patient in sunitinib- and BSC-treatments 
 
SUNITINIB-arm  Cost (€) SE Distribution (α, β) 
Health care utilization    Month 1 545* 114‡ Gamma (2600, 4.77) 
 Months 2-3 324 68‡ Gamma (1546, 4.77) 
 Months 3 => 201 42‡ Gamma (959, 4.77) 
Drug costs per month 3,748  Uniform (3748, 4061)  
BSC-arm 1,339† 281 
 
Gamma (6389, 4.77)  
*) Includes treatment of adverse events 
†) Total costs within the follow-up divided by cumulative days alive (x30) 
‡) Proportionally equal to SE of mean monthly costs in the data from the local sample 
#) 1 Euro equals 1.46 USD (14.11.2007), SE=Standard error 
 
Utilities. The utility values were obtained on days 1 and 28 of every 6-week cycle in the 
sunitinib trial using the EQ-5D quality of life instrument (The EuroQol group 2006). The 
mean (SE) utility before new progression was 0.764 (0.026) and decreased to 0.731 (0.061) 
after progression (Huder et al. 2004). The utility of a deceased patient was defined as zero. 
Because utility data were unavailable in the BSC arm, utility values in different health states 
were assumed to be equal in both study arms and to be β (beta) distributed. The parameters 
of β distributions were obtained using the methods of moments (Briggs et al. 2002). 
Sensitivity Analysis. The sensitivities of selected discount rates and time horizon were 
considered using different discount rates and time horizons in the analysis. In the base-case 
analysis for 5 years, both costs and quality-adjusted life-years (QALYs) were discounted 
using a discount rate of 5%. Because the survival data used in the current model were not 
collected in a parallel study setting, it was considered to be a potential source of 
uncertainty. When the observed covariates between sunitinib trials and the local sample 
were compared, the differences in the mean ages were considered to be the most important 
source of uncertainty, and thus the impact of age difference was studied. Also the impact of 
using Kaplan-Meier survival times instead of Weibull estimates was studied. 
Model Evaluation. To evaluate the Markov model, data from a cohort of 1,000 artificial 
mRCC patients with evidence of metastases were entered into the model. Also, it was 
assumed that patients with mRCC had failed to benefit from cytokine therapy because of 
intolerability or disease progression before they entered into the model. This Markov model 
was evaluated simultaneously with the Weibull survival models. Final posterior parameter 
estimates were based on a total of 50,000 Markov chain Monte Carlo (MCMC) samples. The 
first 10,000 samples were discharged to ensure stability of the posterior sampling 
procedure. Furthermore, the model convergence was confirmed by checking the trace plots 
of the samples, autocorrelation samples, and the Monte Carlo standard error statistics in 
WinBUGS. The code for the cost-effectiveness model is available from the authors on 
request.  
Cost-Effectiveness and Cost-Utility Analyses. The parameter uncertainty was converted into 
decision uncertainty using cost-effectiveness acceptability curves (CEACs), which illustrate 
the probability of cost-effectiveness at different willingness to pay threshold values 
(Fenwick et al. 2001). 
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6.2.3 Results 
According to the simulation results, treatment with sunitinib compared with routine 
treatment in Finland (BSC) prolonged overall survival (OS) by ~1 year and progression-free 
survival (PFS) by 6.7 months. It also resulted in 0.74 QALY gained compared with BSC. 
However, in the 5-year time period, it was associated with ~€32,630 incremental costs per 
patient. The base-case results indicated that cost per progression-free month gained was 
€4,802, cost per life-year gained was €30,831, and cost per QALY gained was €43,698. In the 
5-year time period, the expected mean costs of BSC were €5,543. 
The uncertainty related to incremental cost-effectiveness ratio (ICER) is depicted as a 
cost-effectiveness acceptability curve (CEAC), which was established through the 
probabilistic sensitivity analysis (Figure 23). According to the CEAC, it seems that when 
society’s willingness to pay rises to >€40,000/QALY, the probability of cost-effectiveness of 
sunitinib increases rapidly. For example, with a €45,000/QALY willingness to pay 
threshold, sunitinib has an ~70% probability of being cost-effective compared with BSC in a 
5-year period in the Finnish setting.  
 
 
Figure 23. Cost-effectiveness acceptability curve of sunitinib versus best supportive care in the 
treatment of mRCC  
 
Sensitivity Analyses. The discounting of costs and effects was not associated with any 
significant effect on the results. Most of the sunitinib-related costs were incurred in the first 
year because of the relatively short time to disease progression. The incremental cost-
effectiveness ratio for a QALY gained decreased after the first year and rapidly leveled off 
to the base-case level. No statistically significant difference either in PFS or OS was found 
when comparing the patient groups aged <60 and 60 years in the BSC arm. Results from 
analysis using survival data from patients aged <60 years in the BSC arm were in line with 
results obtained from the base-case analysis.The ICER of €42,721/QALY was obtained when 
Kaplan-Meier survival estimates were used in the BSC arm. This estimate is comparable 
with the base-case results and consistent with the assumptions made above because, in 
general, it would be expected that the use of more conservative assumptions led to greater 
ICER estimates. Finally, a one-way sensitivity analysis was performed assuming that 
sunitinib-treatment would be continued for an additional month after the progression had 
occurred. In this analysis, the ICER was increased to around 49,000 €/QALY. This approach 
may, however, underestimate the possible outcomes caused by the prolonged therapy. 
41 
 
 
6.2.4 Discussion 
Based on these simulation results, sunitinib is more costly but also more effective than BSC 
in all situations from the Finnish health care perspective. The incremental cost-effectiveness 
ratio of €43,698/QALY gained suggests that sunitinib treatment is potentially cost-effective 
compared with current treatment practice in Finland. The literature found a limited 
number of studies available concerning the cost-effectiveness of novel cancer treatments in 
the Finnish setting. However, in one study, the cost of temozolomide per QALY gained in 
the treatment of glioblastoma multiforme was €32,471, which is of a similar magnitude as 
the value estimated in this study (Martikainen et al. 2005). These figures are also 
comparable to those stated by National Institute for Health and Clinical Excellence (NICE) 
(Devlin and Parkin 2004). 
Despite the good reliability of the data sources, this study had some limitations. The first 
concerns the comparability of the patient populations. Differences in patient characteristics, 
health status, and severity of disease at baseline may raise doubts about the comparability 
of Finnish data and data from previous clinical trials of sunitinib. Also, the number of 
patients in the local sample was relatively low (N=39). However, to determine the costs and 
effectiveness related to current routine clinical practice in Finland, unselected sampling 
with criteria comparable to those in the sunitinib trials was carried out using data from 2 
university hospitals. Thus, data from routine practice for the treatment of mRCC in Finland 
was obtained, and in this respect the survival difference due to different baseline 
characteristics in the patients in our analyses versus those from previous clinical trials 
would be expected to have little impact on the results of survival and cost analyses. 
Furthermore, the subgroup analysis revealed no significant difference in survival times 
between the different age groups. However, the sample size of patients aged <60 years was 
12; therefore, these results must be considered with caution. 
Another limitation of this study was that the results were dependent on the expected 
survival times. However, the survival estimates from the Finnish data sample are 
comparable to those stated in earlier studies (Elson et al. 1988, Motzer et al. 2004). It has 
been previously reported that median survival in patients with recurrent or metastatic RCC 
ranges from ~2 to 13 months, depending on patient’s risk factors (Elson et al. 1988). A 
review of 29 consecutive clinical trials involving 251 patients undergoing conventional 
second-line mRCC treatment reported the median OS and PFS to be 10.2 and 2.4 months, 
respectively (Motzer et al. 2004). 
Survival times in patients with mRCC have been poor already at the time of first-line 
treatment. There are some studies concerning the first-line treatment of mRCC in Finland. 
In a study in which patient were treated with either vinblastine monotherapy (n=81) or 
with a combination of IFN-alpha-2a + vinblastine (n=79) the median OS values were 9.5 
months and 16.9 months, respectively (p=0.0049), and median PFS values were 2.25 and 
3.25 months (p=0.0001), respectively (Pyrhönen et al. 1999). In a Phase II, single-arm study 
in which IFN-α was given as first-line therapy monotherapy (N=75), the median PFS was 
12.3 and OS 19.3 months (Kankuri et al. 2001). In a similar Finnish study the median PFS 
was 6.9 months and OS 15.5 months, when IFN-α was given on a frequent-dose schedule in 
combination with thalidomide (N=30) (Hernberg et al. 2003). 
In a Phase III trial, sunitinib was compared with IFN-α as first-line treatment (N=750). 
Sunitinib was associated with marked improvement in PFS (11 vs. 5 months corresponding 
to a hazard ratio of 0.42; p<0.001) and a higher objective response. (Motzer et al. 2007a) 
However, according to the clinical experience among the authors, sunitinib was, at the time 
of making this study, more widely used as a second-line rather than first-line treatment in 
routine practice in Finland. Studies that have provided evidence on the efficacy of sunitinib 
in mRCC set high expectations for future first-line treatment of mRCC (Motzer et al. 2006a, 
Motzer et al. 2006b, Motzer et al. 2007a). 
Nonetheless, patients who present in routine clinical practice may be in a weaker initial 
health state than patients participating in clinical trials. There may also be a bias with 
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regard to selection of patients with more slowly progressive disease in clinical trials of 
second-line therapy because patients with poor health status would not be included in the 
population receiving such treatment (Motzer et al. 2004). Thus, the expected survival in 
clinical studies may be longer than that encountered in the general mRCC population. For 
these reasons, a weak general condition was one of the exclusion criteria in our study. 
However, it may be challenging for the investigators to identify those patients using only 
medical records. Nevertheless, the data used in the present study were collected from 
patients with mRCC and thus can be considered reliable. However, the potential gap 
between the evidence collected from clinical trials and from the effectiveness studies 
conducted in clinical practice may be affected by patient compliance and characteristics of 
provider institutions. (i.e. clinical trials are conducted in specialized institutions, which 
might not be the case in clinical practice). In this study, patients’ compliance was not a main 
concern, but potential gaps between efficacy and effectiveness may have been present due 
to difference in provider institutions. Unfortunately, the uncertainty that arises due to these 
potential differences is difficult to capture into a model. 
Another limitation of this study concerns the fact that the treatment protocol in the 
sunitinib arm was based solely on expert opinion and did not necessarily depict clinical 
practice. However, because there is no consensus on what represents routine practice in 
patients treated with sunitinib, this assumption was used as the best available information. 
The assumption that sunitinib treatment would be discontinued immediately after 
observed disease progression may not reflect clinical practice in all settings. No published 
evidence existed to suggest that switching from sunitinib to another tyrosine kinase 
inhibitor after the onset of progression would be effective (Staehler et al. 2006). Finally, the 
results of cost-effectiveness studies based on modeling are not necessarily directly 
transferable between different locations due to for example different healthcare systems 
and cost structures. The limitations of the study settings were noted and carefully assessed 
in the analyses. The assumptions made in this study were confirmed by clinical experts 
treating patients with mRCC and were conservative rather than overoptimistic. 
Based on the available evidence, sunitinib may be considered as a potentially cost-
effective alternative to BSC as second-line therapy for mRCC from the Finnish health care 
perspective. Compared with routine treatment practices in Finland, the ICER obtained in 
this study was less than the generally approved threshold values for novel treatments in 
oncology.  
At the time of writing this article, IFN-α was used as the standard first-line treatment of 
mRCC, and second line treatment consisted of best supportive care. The targeted 
treatments, which are currently commonly used as first- and second-line therapies, were 
not yet used in clinical practise. During the last years, there has been a significant increase 
in the available treatment options, and the survival times have increased substantially 
during the era or targeted treatments (Najjar and Rini 2012). In Finland, sunitinib is 
currently reimbursed for the treatment of mRCC, and it is considerd as the treatment of 
choice in first-line therapy. The annual (2011) wholesales of sunitinib was €6.4M (IMS 
Health 2011). 
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6.3 CURRENT AND PREDICTED COST OF METASTATIC RENAL CELL 
CARCINOMA IN FINLAND (STUDY III3) 
6.3.1 Introduction 
Renal cell carcinoma (RCC) accounts for 3% of all cancer deaths in Finland (Statistics 
Finland 2008). However, information on its burden on Finnish society and health care is 
scarce. The total annual cancer-related costs in Finland were €530 million in 2004, and the 
costs are estimated to double by 2015. The increase in costs is expected to be especially 
steep with respect to cancer medications, which are estimated to be more than fourfold by 
2015 compared with 2004 (Mäklin and Rissanen 2006). 
Most RCC cases are diagnosed in age groups over 50 years, but RCC may occur at any 
age (Figure 24) (Finnish Cancer registry 2006). In many cases RCC is diagnosed incidentally 
during abdominal imaging, and it currently is often detected at an early stage (Rini et al. 
2009). However, diagnosis may be delayed due to a lack of early warning signs, and 25–
30% of patients have metastases at diagnosis (Motzer et al. 1996, Gupta et al. 2008). The 
average annual incidence of RCC in Finland has been 10.2/100,000 in men and 5.6/100,000 in 
women in 1995–2004. In 2004, 363 Finns died of RCC. The majority of new cases (57%) and 
deaths (56%) were in men (Figure 24) (Finnish Cancer registry 2006). The incidence of RCC 
has been rising for several years (Pantuck et al. 2001, Gupta et al. 2008, Rini et al. 2009), and 
there are approximately 209,000 new RCC cases and 102,000 deaths due to RCC per year 
worldwide (Gupta et al. 2008). 
Cytokines (interferon-α, Interleukin-2) have been widely used in first-line treatment of 
metastatic RCC (mRCC), and until recently they have been the standard of care for mRCC 
patients. Chemotherapy has a limited, if any, role in the treatment of mRCC. In addition, 
the response rates to cytokines have also been low, and the effectiveness of these drugs is 
still controversial (Motzer 2007a, Rini et al. 2009). In Finland, interferon-alpha (IFN-α) has 
long been the standard first-line treatment of mRCC, and it still has its place in treatment of 
metastatic cases. Nevertheless, information on treatment modalities and the cost of 
treatment in different hospitals is scarce. In addition, despite its growing importance, data 
on the economic burden of RCC is sparse even globally (Gupta et al. 2008, Mantovani et al. 
2008). 
The median overall survival period of patients treated with first-line cytokine-based 
therapy has been approximately one year (Motzer et al. 2007a). Novel targeted treatments, 
such as tyrosine kinase inhibitors, have shown their effectiveness and offer new treatment 
options for patients with mRCC. A median overall survival time of 26.4 months has already 
been reported (Motzer et al. 2009). Nevertheless, the economic consequences of these 
treatments have not been widely estimated. The introduction of new treatments has 
pressed the need for health economic evaluations, such as cost-effectiveness analyses. These 
will provide information on the costs of additional health benefits achieved with new 
medication compared with current care. In order to estimate the impact of new treatments, 
there has to be information on the current situation, which forms the basis for any analysis. 
The current study shows the costs and outcomes among patients with mRCC actively 
treated with first-line cytokine treatment. It also provides estimates of the future burden of 
renal cell cancer from the perspective of Finnish health care. We believe the results from the 
current study can be used as a baseline against which the impact of emerging treatments 
may be evaluated. 
 
                                                          
3
 Adapted with permission of Informa Healthcare from: Purmonen T, Nuttunen P, Vuorinen RL, Pyrhönen S, Kataja V, 
Kellokumpu-Lehtinen PL. Current and predicted cost of metastatic renal cell carcinoma in Finland. Acta Oncologica 
49(6):837-843, 2010 
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Figure 24. Number of new cases (A) and number of deaths (B) related to RCC in Finland in year 
2004 (Finnish Cancer Registry 2006) 
 
6.3.2 Materials and methods 
The current study includes resource use and survival data from local patients, estimations 
based on available statistics, and model-based estimations (Table 9). The empirical data are 
presented first, and they provide a background and basis for the modeling estimations. The 
study was conducted from a societal perspective. 
 
Table 9. Study outcomes and the utilized information sources 
 
Study outcome Source of information 
IFN treatment costs and treatment times Local patient data 
Estimation on future RCC incidence Expected population growth (1), New RCC-diagnoses (2)  
Life-years lost due to RCC Life expectancies (1), New RCC deaths (2) 
Productivity loss due to mRCC Expected population growth (1), New RCC diagnoses (2) 
Future cost predictions of mRCC 
treatment 
State-transition model (parameters from local data and 
literature (3, 4) 
  (1)Statistics Finland 2008, (2)Finnish Cancer registry 2006, (3)Motzer et al. 2007a, (4)Study II 
 
Treatment cost and treatment times. Data from 83 mRCC patients who had received first-
line cytokine-based therapy were gathered from the patient records of three Finnish 
university hospitals. The data were collected with a structured form in two phases (June-
August 2006 and June-July 2007). The data were collected in each hospital from consecutive 
patients with mRCC. Consistent with the clinical practice at the time, all eligible patients 
who were diagnosed with metastatic disease, received first-line IFN treatment. Those with 
a very poor general condition and/or with contraindications to IFN treatment were treated 
in primary health care units and thus were not included in the study. The data collection 
process is described in more detail in a previous publication that included information 
about second-line mRCC treatment after active IFN treatment (study II). This data set from 
2006 was extended in 2007 with 47 patients, from whom all data relating to health care 
resource use were extensively collected from initiation of active treatment until death. 
Thus, the detailed information on health care resource use during first-line IFN therapy is 
available only in the latter case (2007). The patient characteristics are presented in Table 10. 
The patients died during 1996–2007; 86% of them in the 21st century. The treatment had 
remained similar during these years. One patient was alive at the end of the data collection. 
This case was included in the cost per follow-up day analysis but not in the survival 
estimates. 
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Table 10. Characteristics of the study population 
 
 
Pooled data 
N=83 
2007 data 
N=47 
2006 data 
N=36 
Sex, no. (%) 
   Male 55 (66) 29 (62) 26 (72) 
Female 28 (34) 18 (38) 10 (28) 
 
Age at time of diagnosis (years) 
  mean 63.6 63.1 64.4 
median 65 64.5 65.6 
range 38-83 38-80 44-83 
    Nephrectomy (%) 
  Yes 66 (81) 36 (78) 30 (83) 
No 16 (19) 10 (22)   6 (17) 
Study site, No. patients (%) 
Hospital A 31 (37.5) 16 (34) 15 (42) 
Hospital B 31 (37.5) 31 (66)   0 (0) 
Hospital C 21 (25)   0 (0) 21 (58) 
ALL 83 (100) 47 (57) 36 (43) 
 
 
The collected resource use data included information on medication use, hospital stays, 
outpatient visits, radiotherapy, surgical procedures, nursing home stays, and diagnostics. 
Recommended Finnish unit costs, adjusted for regional price differences, were applied to 
all health care resource use (Hujanen et al. 2008). Unit costs were real-valued to the year 
2008 using the official health care price index (Statistics Finland and Local Finland 2009). 
The cost of medication was taken from the Finnish drug compendium (Pharmaca Fennica 
2008). Travel costs were not included. A statistical package (SPSS 14.0) and a spreadsheet 
(MS Excel) were used for data management and analyses. Kaplan Meier analysis was used 
in the survival estimates, and linear regression in defining the determinants of treatment 
costs. 
Estimation of future RCC incidence and life-years lost due to RCC. Estimations concerning the 
current and future burden of RCC were performed using available statistics. 
Epidemiological data were obtained from the Finnish Cancer Registry, which provided 
data on all RCC cases in Finland in 1994–2004. RCC was defined as cancer of the kidney, 
excluding cancer of the renal pelvis. Future estimations of RCC incidence were made using 
official population change projections up to 2020 (Statistics Finland 2008). At the same time, 
the relative age distribution of new RCC cases was assumed to remain constant. 
Furthermore, the number of potentially lost life-years due to RCC were estimated using 
gender-specific expected lifetimes in every age group (Statistics Finland 2008) and annual 
RCC deaths (Finnish cancer registry 2006). 
Estimation of productivity loss due to mRCC. Potential productivity loss due to metastatic 
RCC (mRCC) was estimated using the time from diagnosis to retirement, which in Finland 
begins at the age of 65 years. As a base-case, we assumed that 30% of new RCC cases are 
metastatic, and that working-age patients (15–65 years) would not return to work at any 
point after the devastating diagnosis. The impact of a greater proportion of metastatic cases 
was tested in sensitivity analyses. 
Future cost predictions of mRCC treatment. Modeling techniques were used to estimate the 
future cost of mRCC treatment and the budget impact of sunitinib in first-line treatment of 
mRCC. Sunitinib, one of the tyrosine kinase inhibitors, was the only targeted drug 
indicated for first-line treatment in Finland, and it was therefore chosen for our analysis. In 
budget impact analyses the treatment protocols, not only drug prices, are compared against 
each other in order to find out the net difference in treatment cost. An open cohort stage 
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transition model was built to reproduce the natural history of mRCC. With this approach 
we were able to take into account the natural patient flow and to predict the prevalence of 
patients in different disease stages at a certain point in time. This method was chosen 
because mRCC is a rapidly progressing disease, and there are substantial differences in 
costs between active and symptomatic treatment. A similar approach has been previously 
utilized in budget impact analysis of cancer treatments (study IV). The included disease 
stages in the model were “Diagnosed mRCC; active treatment”, “Progressed disease; 
symptomatic treatment”, and “Dead”. Death was assumed to follow only after disease 
progression. The model assumes that there are no seasonal changes in the diagnosis of new 
cases, and that patients enter the model steadily during every monthly cycle. We assumed 
that 30% of RCC patients would demonstrate with metastases at diagnosis, and that 50% of 
these patients would be eligible to receive sunitinib. As a sensitivity analysis, the 
proportion of metastatic cases was assumed to be 50%, which reflects the situation where 
additional patients eventually develop a metastatic disease. Transition probabilities 
between the model stages were derived from the local data (Table 11) using the formula [1-
(0.5)^(1/median)]. The length of IFN-α treatment was assumed to reflect the disease-free 
time among patients receiving interferon. In one scenario, sunitinib was assumed to 
prolong the median disease-free time by six months when compared with IFN-based 
treatment (Motzer et al. 2007a). Possible effects on overall survival were not included. 
The treatment costs are different between the modeled health stages. The collected, 
population-level, costs (Table 12) were used as the cost of active IFN-based treatment (€870 
per month). These were also used as the cost of symptomatic care (€1,500 per month), and 
this was applied similarly in both groups after disease progression. The cost of active 
sunitinib-based treatment in the model was €4,000 per month, which included both the 
drug costs and other health care costs. This is parallel to that previously estimated in 
second-line sunitinib treatment in Finland (study II). It was assumed that the cost of 
sunitinib-based treatment is likely to be of similar magnitude also in first-line mRCC 
treatment. The model was built in MS Excel, which was also used in all the calculations. 
6.3.3 Results 
Survival and treatment times. The treatment paths of the hospitals were similar. The median 
time from diagnosis to nephrectomy was one month, and three months from diagnosis to 
the beginning of IFN treatment. The mRCC patients survived 11.9 months (median; 95% CI 
9.2-14.7) after initiation of active IFN treatment (Table 11). The median duration of IFN 
treatment was 5.6 months (95% CI 4.3-6.9); mean 7 months (95% CI 5.6-8.4). Most patients 
had died soon after active treatment was finished. The median survival time after IFN 
treatment failure was 4 months (95% CI 1.2-6.7); mean 8.7 months (95% CI 6.8-10.6). The 
differences between hospitals were not statistically significant. There was a strong 
correlation between the length of IFN treatment and total survival time (Spearman 
correlation 0.689; p<0.01). 
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Table 11. Survival times among the local mRCC patients 
 
From IFN-start to death (months) n mean median 
Pooled 81 15.2 11.9 
Hospital A 30 12.5 7 
Hospital B 30 16.0 11.2 
Hospital C 21 17.9 15.0 
From IFN-end to death (months) n mean median 
Pooled 78 8.7 4.0 
Hospital A 28 6.1 3.6 
Hospital B 29 9.4 8.1 
Hospital C 21 11.3 6.7 
 
 
Treatment costs among patients. Costs were divided into medication costs and other 
treatment costs (Table 12). Other treatment includes hospital stays, outpatient visits, 
radiotherapy, surgical procedures, nursing home stays, and diagnostics (laboratory tests 
and imaging). Medication costs include IFN-α, other cancer medication, bisphosphonates, 
and analgesics. The average total treatment cost from initiation of IFN treatment until death 
was €32,951 (median €27,938; n=46). 
Treatment costs and their composition differed during and after active IFN treatment. 
Medication comprised 60% of total treatment costs during IFN treatment, whereas after 
disease progression it caused only 6% of all costs. Treatment after disease progression may 
be characterized as mainly symptomatic. Hospital in-patient treatment caused most (79%) 
of the total non-medication costs. However, during active IFN treatment it was responsible 
for 70% of non-medication costs, and after disease progression the proportion increased to 
80%. Other non-medication costs were due to outpatient visits (7%), radiotherapy (7%), and 
diagnostics (5%). A minority of the costs was caused by surgical procedures and nursing 
home stays. Only one patient had received treatment also outside public health care.  
All the patients had received IFN-α as the cytokine of choice; both interferon-α2a and 
α2b were used. IFN treatment caused 89% (median per-patient-cost €7,130) of all 
medication costs during the entire follow-up. Other cancer treatment consisted of various 
agents (e.g. vinblastine, capesitabine, epirubicin, carmofur, vinorelbine, interleukin-2, and 
progestines), which were responsible for 6% of total drug costs. Approximately 20% of the 
patients had received bisphosphonates, which comprised 3% of all drug costs. Analgesics 
caused 2% of total medication costs. Medications administered during hospitalization were 
not included in medication costs, since their costs were allocated to hospital care costs.  
The cost of medication, and specifically IFN-α, comprised most of the total costs during 
active treatment. However, due to the growing need for hospital treatment, the total cost 
per treatment day was more expensive after disease progression. Variation in treatment 
costs was great among patients. In an age- and sex-adjusted regression analysis (adjusted 
R2=0,254), one additional survival month increased treatment costs by €783 (se 187; 
p<0.0001). The Spearman correlation between costs and survival was 0.569 (p<0,01). 
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Table 12. Treatment cost per day among patients with metastatic renal cell carcinoma 
 
 
Population 
mean (€)** 
Patient-level results proportion  
of costs median (€) mean (€) range (€) SE 
During IFN treatment 
      medication* (n=47) 18 23 24.5 1.5-65 2.23 60% 
other treatment (n=47) 12 14 30.5 0.5-212 5.9 40% 
total (n=47) 29 46.5 55 3.5-230 6.46 100% 
After IFN treatment 
      medication* (n=81) 3 2 4.5 0-40 0.81 6% 
other treatment (n=81) 47 58 146 0-981 23.63 94% 
total (n=81) 50 66 150 0-981 23.54 100% 
During entire follow-up 
      medication* (n=47) 12 15 15.5 1.5-45 1.63 27% 
other treatment (n=47) 24 31.5 54 1.5-402 10.32 73% 
total (n=47) 36 48.5 69.5 7-414 10.69 100% 
*Medications administered during hospitalization are not included in medication costs 
** sum of costs divided by sum of follow-up days, SE=Standard error 
 
Estimations of Future Disease Burden. The aging of the population is likely to increase the 
future cancer burden. With respect to RCC, there would be nearly 960 new cases annually 
in Finland by 2020. This equals nearly a 2% increase in the absolute number of cancer cases 
each year, leading to an unadjusted incidence of 17.2 per 100,000 inhabitants in 2020. 
RCC results in premature death. During 2004, renal cell cancer caused approximately 
5,300 prematurely lost life-years in Finland. This equals an average of 14.7 years of life lost 
per-person-dying. Morbidity also leads to productivity losses. According to our 
estimations, in 2008 mRCC caused approximately 890 lost potential working years, and by 
2020 the corresponding number will be 820. However, when 50% of the RCC cases are 
assumed to be metastatic, the results are 1,485 and 1,365 years, respectively. Due to the 
increasing number of retired people, productivity loss will start to decrease over time. 
Nevertheless, the results concerning productivity losses hold only when it is assumed that 
without mRCC, the patients would remain working until the age of 65 years, and that the 
patients would otherwise live a normal, healthy life. These measures reflect a possible 
productivity loss of €23.6M in 2008, given that the average labor productivity cost in 
Finland is approximately €26,500 per year (Hujanen et al. 2008). 
Predicted cost of IFN-based mRCC treatment and the budget impact of sunitinib. The future 
costs of mRCC treatment were estimated through modeling. With 227 annual patients, 
mRCC will cause €15.6M in treatment costs, among patients entering the model during five 
years, when treated with IFN-α. When half of this population receives sunitinib instead of 
IFN-α, the additional cost will be, on average, €2.7M per year. Inclusion of a population 
forecast increases these costs by 3-4%. If the additional health benefit obtained from 
sunitinib is included (Motzer et al. 2007a), the five-year budget impact of sunitinib is 
€24.4M compared with IFN-based treatment (€40M vs. €15.6M). If, in addition, population 
changes are included, the estimated five-year budget impact rises to €25.2M (€41.3M vs. 
€16.1M). In a scenario where 50% of annual RCC cases are metastatic, the five-year budget 
impact of sunitinib is €40.8M (€66.8M vs. €26M) when neither population forecast nor 
increasing treatment effectiveness is included. In these estimations, only first-line mRCC 
treatment is taken into account.  
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6.3.4 Discussion 
We estimated the economic consequences of mRCC for Finnish society, both currently and 
with future projections. Most of the treatment costs are caused by hospitalization and active 
drug therapy. New targeted treatments will inevitably lead to increasing costs in mRCC 
treatment, because previously available treatment options have been scant. In addition, the 
overall burden of renal cell cancer is likely to increase along with the aging population.  
In order to effectively allocate finite health care resources, health care providers require 
estimates of the future cancer burden as well as treatment costs (Bray and Møller 2006). 
Currently, there are only a limited number of studies on the cost of treatment and the 
burden of renal cell cancer. Nevertheless, there is an increasing information demand for 
more detailed patient-level costs related to specific diseases (Mantovani et al. 2008). In the 
present study we have illustrated the costs per treatment day during different phases of 
treatment. We used official population forecasts and reliable incidence data from the 
Finnish Cancer Registry, which covers the vast majority of all cancer cases in the country 
(Teppo et al. 1994). Reliable population forecast and high-quality population-based data are 
considered to be the prerequisites for sensible predictions of cancer incidence (Bray and 
Møller 2006).  
However, there are a number of limitations in the current study. The first limitation 
relates to the size of the study population (N=83). However, due to the small number of 
inhabitants in Finland (5.3M), this equals approximately 25% to 40% of annual mRCC cases 
in the country. The limited number of patients did not allow sufficient subgroup analyses. 
The treatment day costs were derived from natural variation of RCC patients, which 
reflects true clinical treatment practice at the time. Secondly, we did not have complete 
information on resource use during active IFN treatment from all the patients. 
Nevertheless, it was clear that IFN-α was the cost driver during that time period. The third 
limitation relates to the assumptions made during the study. The estimation of future 
burden was based on patient statistics from 2004. These were then projected to the future 
using population forecasts, which are predictions by nature, and thus include a source of 
error. Furthermore, a decrease in the incidence rates would balance the impact of aging, 
and thus there is a possibility of overestimation in the current study. Estimations 
concerning mRCC were based on the assumption that 30% or 50% of new cases would be 
metastatic, regardless of age at diagnosis. Furthermore, the proportion of new cases at each 
age was fixed to the 2004 level. However, it has been stated that age is the most important 
time-related variable that quantitatively influences the risk of cancer (Bray and Møller 
2006). Finally, there was no information on patient status at the baseline. In addition, some 
of the differences in the observed survival times may be due to possible differences in the 
continuation of IFN treatment between hospitals. 
Studies addressing the burden of mRCC are relatively sparse in the literature (Gupta et 
al. 2008). Gupta and colleagues (2008) have, in their review, presented a range of studies 
illustrating costs related to RCC and mRCC. Depending on the stage of the disease, 
included costs, and the perspective of the study, the per-patient cost ranged from 
USD12,500 to USD64,900 (Gupta et al. 2008). The annual cost of distant RCC, prior to the 
launch of new treatments, has been estimated at USD28,271 per patient (Lang et al. 2007). 
The monthly treatment cost for a patient with advanced renal cell cancer treated with 
bevacizumab, sorafenib, or sunitinib has been estimated to be USD13,351, USD6,998, and 
USD8,213, respectively. Intravenous bevacizumab was concluded to have similar 
therapeutic value as oral agents (sorafenib and sunitinib) but to be more costly (Duh et al. 
2009). In addition, in the treatment of mRCC bevacizumab is combined with IFN, which 
increases the total costs. In an Italian register-based study, the average mRCC treatment 
costs were €17,656 per patient for the total follow-up, and €13,692 for the first year. 
Hospitalization was responsible for 81% of total treatment costs during the total follow-up 
and 85% during the first year. The corresponding proportions for drug costs were 8% and 
6%. The average monthly cost per patient was €1,400 (Mantovani et al. 2008). These results 
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differ from those obtained in our study. However, in the study by Mantovani and 
colleagues (2008), the cost of hospitalization was based on diagnostic-related groups, and 
drug costs were based on prescriptions dispensed to outpatients by community 
pharmacies. Nevertheless, the results from different studies are not fully comparable due to 
differences in health care systems, cost structures, and study designs. Country-specific data 
on costs and effectiveness of treatments are needed. In order to provide up-to-date 
information concerning first-line sunitinib treatment in Finland a prospective follow-up 
study has been initiated (Kellokumpu 2009). 
As to cancer treatment in Finland, the cost of medication and outpatient treatment has 
been estimated to increase the most in the near future. Due to the aging population, 
productivity losses are expected to increase less than other cancer-related costs (Mäklin and 
Rissanen 2006). Our estimates concerning prematurely lost life-years in the current study 
are close to those previously presented. Life-years lost due to cancer of the kidney and renal 
pelvis have been presented to be 15.7 years per-person-dying (Gupta et al. 2008). This 
parallels our estimate of 14.7 years for RCC only. The incidence of mRCC in Finland has 
earlier been estimated to be 8.0/100,000, with the assumption that 27.5% of RCC cases are 
metastatic at diagnosis. It was stated that these values may be underestimations, since 
patients with subclinical metastatic disease were not included. However, in the review 
Finland was inaccurately placed together with Australia and Asia instead of Europe (Gupta 
et al. 2008). Quality-of-life issues were not within the scope of the current study. 
Nevertheless, the mRCC burden related to the patient’s quality of life has been studied 
using various measurement scales, and a review of this subject may be found elsewhere 
(Gupta et al. 2008).  
Sunitinib is currently seen as the new standard of care for first-line treatment of mRCC in 
good or intermediate risk clear cell renal carcinoma (Escudier and Kataja 2009, Rini et al. 
2009). At the time of writing this article, it was the only targeted treatment indicated for 
first-line treatment of mRCC in Finland. In poor risk clear cell renal carcinoma temsirolimus 
is recommended as the first-line treatment, sunitinib being an option (Escudier and Kataja 
2009). The National Institute for Health and Clinical Excellence, the health authority in 
England and Wales, revised (August 2009) its recommendations for the use of targeted 
drugs, concluding that sunitinib is their recommended first-line treatment option for mRCC 
(NICE technology appraisal guidances 169 and 178). Additional information on the costs 
and effectiveness of existing treatment options are still needed, while at the same time new 
treatments emerge. Targeted drugs are likely to be included more often in subsequent 
treatment lines, though knowledge about an optimal treatment strategy is lacking (Escudier 
and Kataja 2009). Lately, it has been stated that for patients whose disease progresses after 
treatment with targeted therapies, everolimus should be regarded as the following 
treatment of choice (Motzer et al. 2008). Inevitably, progress in disease management will 
come with considerable costs. The issues related to the impact of novel treatments on the 
epidemiological and economic burden of mRCC are not yet adequately evaluated. The need 
for more research on the overall burden of mRCC has previously been recognized. (Gupta 
et al. 2008, Rini et al. 2009) 
In conclusion, despite the limited number of patients, metastatic renal cell carcinoma 
places a considerable economic burden on Finnish society. Medication costs in the 
treatment of mRCC are likely to increase in the future due to more expensive medications, 
the aging population, and enhancement in survival times. Growing possibilities of offering 
subsequent treatment lines are also likely to have an impact on both treatment costs and 
survival. In order to enable more efficient health care planning, more attention should be 
paid to estimations of both costs and the epidemiological burden of specific indications. 
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7 Pharmacoeconomics of HER2-positive early breast 
cancer 
7.1 BUDGET IMPACT ANALYSIS OF TRASTUZUMAB IN EARLY BREAST 
CANCER – A HOSPITAL DISTRICT PERSPECTIVE (STUDY IV4) 
7.1.1 Introduction 
Breast cancer is the most common cancer among women, and there are over a million new 
breast cancer cases in the world each year. In Finland it is the leading cause of cancer deaths 
in women, and accounts for 16% of all female cancer deaths (Statistics Finland 2007). 
Approximately 12-30% of breast cancer cases overexpress Human Epidermal Growth 
Factor Receptor 2 (HER2) (Slamon et al. 1989, Joensuu et al. 2003, Owens et al. 2004). These 
HER2-positive (HER2+) cases are associated with an aggressive disease, and the prognosis 
is poorer compared with HER2-negative cases (Drucker et al. 2008, Herceptin: Summary of 
product characteristics). Recently, new targeted therapies have offered new alternatives in 
the treatment of HER2-positive patients, however, with increasing costs. 
Trastuzumab is a monoclonal antibody used for the treatment of HER2-positive breast 
cancer patients (Herceptin: Summary of product characteristics). At first, trastuzumab was 
used only in the metastatic disease and, until recently, it has been the only targeted therapy 
for HER2-positive breast cancer. There are several studies concerning trastuzumab in 
adjuvant treatment of early breast cancer (Piccart-Gebhart et al. 2005, Romond et al. 2005, 
Slamon et al. 2005, Joensuu et al. 2006, Slamon et al. 2006, Perez et al. 2007, Smith et al. 
2007). Today it is widely used in this indication. Together with the indication extension, the 
number of eligible patients grew substantially. This, in turn, increased concern about the 
affordability of trastuzumab, since the health care budget and resources are limited. 
Trastuzumab is used in addition to existing therapies and does not replace them. Since it 
is an expensive drug, it causes a substantial impact on the health care budget. Recent 
reviews show that in most analyses, trastuzumab is considered to be cost-effective, despite 
the diversity of the results (McKeage and Lyseng-Williamson 2008, Younis and Skedgel 
2008). However, cost-effectiveness analyses alone do not provide information on the drug’s 
impact on the total health care budget, since this is dependent on the number of treated 
patients. Thus, the expected budget impact of a new treatment should be explicitly 
estimated, in addition to the traditional cost-effectiveness. A few of the cost-effectiveness 
studies of adjuvant trastuzumab have included evaluation of its budgetary impact (Liberato 
et al. 2007, Neyt et al. 2008, Shiroiwa et al. 2008). Furthermore, the cost burden of 
monoclonal antibodies has been evaluated from the Canadian health care perspective 
(Drucker et al. 2008). However, a comprehensive budget impact analysis of trastuzumab 
that includes the estimated effectiveness of the treatment and probabilistic analysis, has not, 
to our knowledge, been previously published. 
In this study we created an evaluation tool for estimating the budget impact of new 
cancer treatments. This was done on the request of the consortium of the Finnish Office for 
Health Technology Assessment (Finohta) and local hospital districts. In Finland, the health 
care system is publicly funded, and hospital districts are allowed to operate rather 
independently. Thus, there are concerns regarding the cost burden of trastuzumab, both at 
                                                          
4
 Adapted with permission of Cambridge University Press from: Purmonen T, Auvinen P, Martikainen JA. Budget 
impact analysis of trastuzumab in early breast cancer - a hospital district perspective. International Journal of 
Technology Assessment in Health Care 26(2):163–169, 2010 
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the national level and in hospital districts. In this study the new tool was used to explore 
the budget impact of trastuzumab in early breast cancer in a single Finnish hospital district. 
Furthermore, we analyzed how different treatment protocols and changes in the number of 
patients affect the estimated budget impact.  
7.1.2 Materials and methods 
Perspective and Time Horizon. This study was conducted from the perspective of a single 
hospital district with ca. 250,000 inhabitants (payer’s perspective). In the target organization 
(Hospital district of Northern Savo), all trastuzumab treatments are given in one hospital 
(Kuopio University Hospital). Only direct costs allocated to the hospital district were 
included in the study. The maximum follow-up time was set to be 4 years, since a longer 
perspective was not considered relevant for the budget holder. All results are depicted 
cumulatively from 1 to 4 years.  
Population. Population-based epidemiological data were obtained from the Finnish 
Cancer Registry, which covers the vast majority of cancer cases in the country. The 5-year 
average yearly number of new breast cancer cases (ICD-10 C50) in the hospital district was 
176. The age-adjusted incidence of breast cancer in the whole country in 2006 was 
86.6/100,000, which is slightly higher than in the target hospital district (Finnish cancer 
registry 2008). The prevalence of HER2+ was 18%, which reflects the 3-year average HER2+ 
incidence rate in the local district (Department of Pathology, Kuopio University Hospital 
2008). Thus, there are approximately 32 new HER2-positive breast cancer cases in this 
district yearly. Previously diagnosed breast cancer cases were not included in the analysis. 
Ten percent of the HER2-positive patients were assumed not to receive trastuzumab 
because of other diseases and poor general condition, or because of a very small tumour 
size. 
Model. A spreadsheet model was created to assess the budget impact of trastuzumab. A 
simplified structure of the model is presented in Figure 25. The model took into account the 
number of patients, HER2+ prevalence, the length and cost of treatment, and its 
effectiveness. Estimates concerning distant disease free survival (DDFS) were derived from 
the published data of a Finnish trial (Joensuu et al. 2006). These estimates were applied to 
the model in order to include the effectiveness of the treatment. Mortality was not included 
due to the short time horizon. The effectiveness of trastuzumab was assumed not to depend 
on the length of the treatment. The model utilized is a simple stage transition model 
typically used in cost-effectiveness analyses. The mutually exclusive health stages in the 
model are “free of distant recurrence” and “distant recurrence”. The number of new cases 
was used as the population entering the model each year. Yearly new cases were followed 
throughout the model, depending on the chosen time span. Each additional follow-up year 
increased the number of eligible patients and prolonged the time spent in the model. The 
results of the model apply to periods from 1 to 4 years. Consistent with the current 
recommendations for budget impact analyses, discounting was not incorporated in the 
model (Mauskopf et al. 2007). 
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Figure 25. Structure of the budget impact model of trastuzumab in early breast cancer 
 
Treatment mix and costs. The treatment mix and costs of breast cancer therapy are based 
on current clinical practice in the treating hospital. Activity-based costing was used as the 
costing method (in 2008 Euros, value added tax (VAT) excluded). Patient copayments 
attributable to hormonal cancer therapy and oral cytostatics were not included, since in 
Finland they are reimbursed by the Social Insurance Institute (SII). In the target hospital 
district, chromogenic in situ hybridization (CISH) is used to test the patient’s HER2 status. 
Since all new cases are tested similarly, the cost of testing was not included in the analysis. 
Treatment cost of HER2+ early breast cancer. The first year after diagnosis is more 
treatment-intensive than the following years. Average first-year adjuvant treatment 
without trastuzumab constituted a total cost of €9,540 per patient for the hospital district 
(Table 13). The treatment includes hormonal treatment (tamoxifen or aromatase inhibitor), 
but their cost is not allocated to the hospital district. Trastuzumab is given in addition to 
standard breast cancer treatment. In local clinical practice, adjuvant trastuzumab treatment 
in early breast cancer includes two treatment lengths – 9 weeks and 1 year. All patients 
initially receive 9 weekly doses of trastuzumab (1st dose 4 mg/kg, then 2 mg/kg) together 
with chemotherapy. Subsequently, 40% of the patients receive an infusion every 3rd week 
(1st dose 8 mg/kg, then 4 mg/kg) for up to 1 year. The cost of a subsequent month with 
trastuzumab was €2,800, which adds up to €35,000 a year. All trastuzumab costs include the 
administration and preparation costs covered by the treating organization. Trastuzumab 
drug wasteage in the hospital is marginal due to the concentrated preparation practices, 
and is therefore not included. Since stable use of trastuzumab does not reflect real clinical 
practice, the developed model was adjusted to take into account variability in treatment 
lengths. Every 10th patient was assumed to discontinue the trastuzumab treatment at 6 
months due to adverse events or other reasons. All adverse events were assumed to be fully 
reversible, and thus not to cause any additional costs to the hospital district. 
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Table 13. Annual average cost of adjuvant treatment of HER2+ early breast cancer in the 
hospital district 
 
 
Resource use and treatment* 
1st year  
standard 
treatment 
1st year 
adjuvant 
trastuzumab 
Annual  
follow-up 
(no progression) 
Treatment without trastuzumab  
 
 
Initial medical assessment €275 
 
 
Docetaxel treatment €3,750 
 
 
FEC combination treatment# €1,440 
 
 
Radiotherapy 2Gy (25 times) €3,900 
 
 
Treatment control visits €175 
 
€350 
Mammography follow-up  
 
€60 
9-week trastuzumab treatment (60%)  €7,000  
1-year trastuzumab treatment (40%)  €35,000  
    
Average cost (€/patient/year)* €9,540 €18,200 €410 
*Drug costs other than those of the hospital district are excluded. 
#FEC = fluorouracil+epirubicin+cyclophosphamide.  
 
Treatment cost of HER2+ metastatic breast cancer. The use of trastuzumab in metastatic 
disease was included in the model according to local clinical practice. All HER2-positive 
patients with metastatic breast cancer were assumed to receive trastuzumab, even if they 
had received it earlier in the adjuvant setting. In the treatment of metastatic breast cancer, 
trastuzumab is given in 3-week cycles for one year, which constitutes an average cost of 
€33,600 per patient per year. The average treatment mix and cost are described in Table 14. 
 
 
Table 14. Average treatment mix and cost of metastatic HER2+ breast cancer by year from 
progression 
 
 
Treatment* 
 
Cost per  
year 
Proportion 
Year 1 
Proportion 
Year 2-4 
    
Hormonal (tamoxifen) €1,500†  5 % 
Hormonal (aromatase inhibitor) €1,500†  10 % 
Cytostatic (FEC)# €10,000  10 % 
Cytostatic (vinorelbine) + trastuzumab €38,400† 50 % 20 % 
Cytostatic (capesitabine) €2,500  20 % 
Cytostatic (docetaxel) + trastuzumab €54,725 50 % 20 % 
Other €10,000  15 % 
    
Weighted average cost (€/patient/year)†  €46,563 €21,850 
    
* All treatment costs include follow-up visits and imaging (ultrasound and radiography).  
† Drug costs other than those of the hospital district are excluded.  
# FEC = fluorouracil+epirubicin+cyclophosphamide 
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Sensitivity analyses. Sensitivity analyses were performed in order to evaluate uncertainty 
attributable to the applied assumptions and model parameters. Uncertainty related to the 
assumptions was explored by performing a series of “what-if” scenarios, which consisted of 
the following one-way sensitivity analyses. In scenario A, all patients were assumed to 
receive trastuzumab according to the 1-year treatment schedule. In scenario B, a short, 9-
week treatment schedule was applied to all patients. The prevalence of HER2+ was 
assumed to be 12% in scenario C and 25% in scenario D. In scenario E, the cost of the 
trastuzumab treatment decreased by 40%. Finally, in scenario F, the effectiveness of the 
treatment was discarded from the model. These extreme scenarios were assumed to reflect 
the range of circumstances that the budget holders may face. 
In addition to the traditional deterministic sensitivity analyses, a probabilistic sensitivity 
analysis was also performed. It takes into account the degree of variability and uncertainty 
related to these parameters simultaneously. In the model, probability distributions were 
assigned to all key parameters (i.e. number of patients, HER2+ prevalence, transition 
probabilities and treatment costs).  
7.1.3 Results 
Base-case results. The introduction of trastuzumab in the treatment of HER2-positive early 
breast cancer caused substantial costs to a rather small hospital district with 250,000 
inhabitants and around 29 patients receiving adjuvant trastuzumab each year. In a 4-year 
follow-up period the net budget impact was €1,302,000, and in one year the figure was 
approximately €474,000. The additional cost per treated patient was around €16,000 in the 
first year. The total net costs included adjuvant treatment, the cost of the follow-up period, 
and treatment of metastatic disease. Most of the additional costs were accrued from the 
acquisition costs of adjuvant trastuzumab. However, there were also savings related to 
adjuvant trastuzumab treatment due to improved cancer recurrence rates. Thus, the 
acquisition costs were partially offset by the reduction in costs associated with the 
treatment of cancer recurrence and metastatic disease. However, the majority of these 
savings were due to the reduction in late-stage trastuzumab use. Figure 26 shows the 
contribution of each cost type to the total net budget impact when trastuzumab is added to 
the treatment of early breast cancer. 
 
 
Figure 26. Cumulative changes in different cost types by time, along with the net budget impact 
of trastuzumab in early breast cancer 
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Sensitivity analyses. The sensitivity of the results was studied through alternative case 
scenarios (Figure 27). The short treatment schedule (scenario B) gave a smaller budget 
impact than the other scenarios. The budget impact of this 9-week treatment decreased over 
time when effectiveness, in terms of disease progression, was included in the model. The 
difference between short (B) and prolonged (A) therapy was around €750,000 in one year, 
and €3M in 4 years. In scenario E, the treatment cost of trastuzumab was reduced by 40%. 
This constituted a 46% reduction in the 4-year budget impact compared with the base-case. 
When the prevalence of HER2+ was altered from 12% to 25%, the 4-year budget impact 
varied between €868,000 and €1,808,000. As assumed, the results of the study were fairly 
sensitive to the length of the trastuzumab treatment and the number of patients. Also, when 
the effectiveness of the treatment was excluded from the model (scenario F) the budget 
impact was notably higher than in the base-case. 
 
 
Scenario A: All patients receive trastuzumab according to a 1-year schedule  
Scenario B: All patients receive trastuzumab according to a short 9-week schedule 
Scenario C: Prevalence of HER2+ is 12% 
Scenario D: Prevalence of HER2+ is 25% 
Scenario E: Cost of the trastuzumab treatment is reduced by 40%  
Scenario F: Efficacy is not included in the analysis 
 
Figure 27. Cumulative net budget impact of trastuzumab in the selected what-if scenarios and 
base-case analysis (in a population with 176 annual breast cancer cases) 
 
 
The results of probabilistic sensitivity analysis are presented as affordability curves 
(Figure 28), which depict the probability of staying within a certain budget (Sendi and 
Briggs 2001). The information provided by these curves can be expected to be useful for the 
budget holders who make decisions under uncertainty. For example, if the annual budget 
constraint is €500,000, there is around a 70% probability that the budget will not be 
exceeded in the first year. In four years the same level of confidence is reached when the 
budget constraint is €1,350,000. However, these particular results hold only with the base-
case assumptions. Uncertainty related to the results grows along with the longer time 
horizon. 
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Figure 28. Affordability curves showing the probabilities that trastuzumab is affordable as a 
function of the budget constraint 
7.1.4 Discussion 
Evaluation of both cost-effectiveness and budget impact of new treatments is necessary due 
to limited health care resources. Economic evaluations are needed, not only to ascertain the 
best possible value for money, but also to assess to what extent the treatments are 
affordable. Nevertheless, the means for performing timely economic evaluations are 
currently limited. In this study, an evaluation model was developed to assess the budget 
impact of new cancer treatments. We found that adjuvant trastuzumab causes substantial 
costs even for a rather small hospital district. The net budget impact was greatly influenced 
by the number of treated patients, and the length and cost of the treatment.  
Trastuzumab has proven its clinical efficacy in HER2-positive breast cancer. The aim of 
adjuvant treatment is to destroy micrometastases, and thus to prevent recurrences and 
improve the survival of the patients. Most clinical evidence regarding adjuvant therapy is 
from a 1-year treatment (Piccart-Gebhart et al. 2005, Romond et al. 2005, Slamon et al. 2005, 
Slamon et al. 2006, Perez et al. 2007), but a shorter 9-week treatment has also been studied 
(Joensuu et al. 2006). However, the optimal duration or dosing frequency of trastuzumab is 
still not known. In the future, longer follow-up data of adjuvant trastuzumab treatment will 
be available from ongoing trials. Survival estimates are also dependent on patient 
characteristics, including age and disease stage. However, currently available information 
did not enable us to do a patient subgroup analysis. In this budget impact analysis the 
effectiveness of the trastuzumab treatment was estimated according to the published data 
of the FinHer (Finland Herceptin) trial (Joensuu et al. 2006). The health benefit gained from 
the treatment was assumed to be the same despite the length of the treatment. However, if 
the 1-year treatment would be clinically better than the 9-week treatment, it would also 
lead to bigger savings during the follow-up than evaluated in this analysis. Furthermore, 
treatments given together with trastuzumab, and possible synergism with certain 
chemotherapy regimens, can be of significance to the treatment outcomes. Nevertheless, the 
most reliable data concerning the best way to give the trastuzumab treatment in early 
breast cancer will be acquired from randomised studies comparing short and long 
trastuzumab treatment. 
Effectiveness of treatment is seldom included in budget impact models, though it has 
been considered to be important (Skedgel et al. 2008). In devastating and progressing 
diseases such as cancer, improved outcomes should be accounted for in order to depict real 
treatment practice. In local clinical practice the trastuzumab treatment was continued 
beyond disease progression. This was also included in the analysis. The financial impact of 
late-stage trastuzumab may, however, be easily discarded from the total net budget impact. 
A budget impact analysis that is solely based on acquisition costs ignores the effects of the 
treatment. It simply describes how much money is spent on the drug within a certain time 
horizon, but, at the same time it fails to include other possible costs or savings related to the 
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treatment. After adjuvant treatment, patients without relapsed disease will be able to 
continue their everyday life and return to work. However, productivity losses or time costs 
were not included in the study. The complex nature of reality can not be completely 
captured in economic evaluations. However, using the best available information and 
modeling techniques, this complexity may, to some extent, be taken into account. 
Hospitals are not always able to manage in the pressure of increasing costs of new 
pharmaceuticals if costs grow faster than the budget assigned for the drug. Unrestricted 
reimbursement of expensive and relatively widely used pharmaceuticals, such as 
trastuzumab, may lead to inequality in treatment access. In the Netherlands, it has been 
already demonstrated that trastuzumab was unevenly distributed among patients in 
different hospitals, largely due to limited drug budgets. Nevertheless, budget impact 
estimations may play a role in preserving patient equality (Niezen et al. 2006, Niezen et al. 
2009). 
Budget impact analyses are usually performed from the perspective of a target 
organization (e.g. a hospital district in this study). However, it is important to note that cost 
shifting between a hospital and other financing bodies, such as municipalities and SII in 
Finland, may lead to suboptimal decisions from the social perspective or the perspective of 
overall health care planning (Häkkinen 2005). This budget impact model was created to 
depict the current situation in one Finnish hospital district. Thus, the results are not 
necessarily applicable to other jurisdictions due to possible differences in treatment 
practices and related costs. Furthermore, treatment practices may change over time, and 
thus affect the applicability of the results of economic evaluations. In addition, the results 
may need to be updated if new products are introduced for the same indication, since they 
may affect both the proportion of patients receiving the treatment and the actual price of 
the treatment. By using a relatively short time horizon, the number of assumptions does not 
grow to be excessive. The markets are volatile and may change when new products are 
introduced. Long-term budget impact analyses do not necessary depict the true future 
situation, which leads to instability in long-term results. In our analysis the market 
diffusion rate was considered to be stable, although the possibility to vary the annual 
diffusion rate was enabled in the model. Possible market changes should be recognised 
when budget impact estimations are performed. 
When new products are introduced they usually slowly replace older treatments. This 
releases resources to fund the new treatment to some extent. However, in respect of add-on 
medicines, all costs will have to be compensated with additional funding or sacrifices made 
elsewhere. Due to the large potential financial impact of trastuzumab, there was an 
increased need for more comprehensive budget impact analysis. Despite the favorable 
incremental cost-effectiveness rations concerning trastuzumab, the eventual economic 
consequences of the treatment are substantial.  
Practical evaluation tools offer a great help for decision-makers and budget holders - 
especially with respect to new and expensive targeted therapies that add significant costs to 
the health care system. Alternative scenarios are an essential part of results in budget 
impact analyses. The model developed in this study was used in only one hospital district. 
However, when local epidemiological and treatment data are obtained, the model may be 
used similarly in other jurisdictions. The treatment costs of different stages of breast cancer 
were those of a single hospital, and were derived from an average treatment protocol 
practiced in the target organization. In order to provide real-time estimates of the economic 
impact of novel treatments and to allow fluent data collection, more attention should be 
paid to improving the usability and coverage of electronic databases. 
The present analysis found that the budget impact of trastuzumab is considerable, from 
the perspective of a Finnish hospital district. However, when the effectiveness of the 
treatment is taken into account, there are also savings related to adjuvant trastuzumab 
treatment. The length of the treatment has a strong effect on the eventual budget impact. 
Future trials will show to what extent the duration of trastuzumab treatment affects its 
effectiveness and the cost-effectiveness of the therapy. 
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7.2 SHORT-COURSE ADJUVANT TRASTUZUMAB THERAPY IN EARLY 
STAGE BREAST CANCER IN FINLAND: COST-EFFECTIVENESS AND VALUE 
OF INFORMATION ANALYSIS BASED ON THE 5-YEAR FOLLOW UP 
RESULTS OF THE FINHER TRIAL (STUDY V5) 
7.2.1 Introduction 
Breast cancer is currently the most common cancer in Finland. There were 4,318 newly 
diagnosed cases in 2008 and the number is expected to rise to 5,247 by 2015 (Mäklin and 
Rissanen 2006, Finnish Cancer Registry 2010). According to the predictions of the Finnish 
Cancer Registry, in 2015 breast cancer will account for 42% of all female cancer incidence. In 
2004, breast cancer alone caused costs of €65M, and the costs are assumed to double by 
2015. It is currently responsible for 12% of all cancer-related costs in Finland. 
Approximately 12–30% of breast cancers over-express human epidermal growth factor 
receptor 2 (HER2) (Slamon et al. 1989, Joensuu et al. 2003, Owens et al. 2004). These HER2-
positive cases are associated with a more aggressive form of disease, and in adjuvant 
setting they are currently treated with trastuzumab, together with conventional breast 
cancer treatment.  
Trastuzumab, a humanised monoclonal antibody, has proven its clinical efficacy as an 
adjuvant therapy in several trials (Piccart-Gebhart et al. 2005, Romond et al. 2005, Joensuu 
et al. 2006, Smith et al. 2007, Joensuu et al. 2009, Slamon et al. 2009). However, there is no 
consensus about the optimal treatment schedule or the length of adjuvant treatment. Also 
the duration of treatment benefit has remained unclear. Most of the randomised controlled 
trials have focused on 12-month treatment (Piccart-Gebhart et al. 2005, Romond et al. 2005, 
Smith et al. 2007, Slamon et al. 2009), but also a shorter 9-week treatment regimen has been 
studied in Finland Herceptin trial (FinHer) (Joensuu et al. 2006, Joensuu et al. 2009). In 
addition, a trial comparing the 9-week and 12-month trastuzumab treatment regimens is 
currently ongoing (SOLD 2008). 
Trastuzumab is a relatively expensive drug. It was first introduced for the treatment of 
HER2-positive metastatic breast cancer, but later the indication was extended to adjuvant 
treatment in early stage of the disease. The increasing number of eligible patients, after the 
indication extension, has led to concerns about the cost-effectiveness and affordability of 
the treatment. Cost-effectiveness of adjuvant trastuzumab has been assessed in several 
studies, and in most cases it has been deemed as a cost-effective treatment (Chan et al. 2009, 
Reed and Schulman 2009). However, most of these economic evaluations have been based 
on published interim results of clinical trials, having a relatively short follow-up. 
Evaluations using data from FinHer trial are few (Dedes et al. 2007, Millar and Millward 
2007, Neyt et al. 2008), and there are no studies assessing the cost-effectiveness of short 
course trastuzumab in the light of the updated results.  
The aim of this study was to assess the potential cost-effectiveness of adjuvant 9-week 
trastuzumab treatment, compared to treatment without trastuzumab, applying the final 5-
year follow-up results of the FinHer trial (Joensuu et al. 2009). In addition, due to 
uncertainty related to the effect size of the 9-week treatment regimen and other model 
parameters, value of information (VOI) methods were used to combine the probability and 
consequences of a wrong adoption decision. Expected value of perfect information (EVPI) 
and expected value of perfect partial information (EVPPI) analyses were performed in 
order to address the question whether and what additional evidence is required to support 
an adoption decision. (Barton et al. 2008) 
                                                          
5
 Adapted with permission of Informa Healthcare from: Purmonen T, Pänkäläinen E, Asseburg C, Turunen J, 
Martikainen JA. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness 
and value of information analysis based on the 5-year follow up results of the FinHer trial. Acta Oncologica 50(3):344–
352, 2011 
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7.2.2 Materials and methods 
A health-economic modeling approach was utilized in the study. The model was used to 
simulate a hypothetical cohort of 1,000 HER2-positive patients of an average age of 50 years 
matching the inclusion criteria and baseline population characteristics of the FinHer trial 
(Joensuu et al. 2009), the primary source of effectiveness data for this study. In the 
published results of the FinHer trial, the hazard ratio for distant disease progression was 
0.65 (95% CI 0.38–1.12) and for death 0.55 (95% CI 0.27–1.11) after a follow-up of 5 years 
(Joensuu et al. 2009). Clinical parameters were extracted from published clinical trials. The 
analysis was performed from a societal perspective that included all direct, but no indirect 
costs (such as productivity losses). Costs and health outcomes were discounted by 3% as 
recommended in the Finnish guidelines. The evaluation model was built in Microsoft Excel 
2007. 
Model structure and clinical parameters. The applied model consists of two parts. The first 
part concerns the first 5 years from the initiation of treatment, and the second part 
continues onwards from year 5 to lifetime. This partition is driven by the available data on 
effectiveness, i.e. the actual survival curves, obtained from the final results of the FinHer 
trial (Joensuu et al. 2009), which were used to inform the clinical outcomes of the first part 
of the model. The second part of the model is a traditional Markov stage-transition model 
(Briggs and Sculpher 1998), which was used to extrapolate the costs and health outcomes 
over the lifetime of the patients.  The initial Markov-stages (at the end of year 5) were 
populated using the information from model part 1. A scheme of the evaluation model is 
presented in Figure 29. 
 
 
Figure 29. Scheme of the cost-effectiveness model 
 
Since the published Kaplan-Meier curves of overall survival (OS) and distant disease-
free survival (DDFS) in the FinHer trial (Joensuu et al. 2009) were not presented in a format 
suitable to health-economic analysis, a parametric (log-logistic) survival model was fitted to 
a manual trace of the curves, using statistical package R. The log-logistic model was chosen 
above other survival models (Weibull, exponential) because it provided the best fit to data 
(Figure 30). Probabilities of being in one of the three health states at a certain point in time 
were derived from this model, together with the associated measures of uncertainty. The 
treatment effect of trastuzumab was estimated as a regression coefficient. Because neither 
the summaries of OS conditional on DDFS nor patient histories have been published, the 
conditional nature of the sequence of events (time from DDFS to OS) was imposed through 
a constraint in the simulation model.  
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Figure 30. Kaplan-Meier survival curves (continuous lines) and the fitted log-logistic model 
(dashed lines) for overall survival and distant disease-free survival for 9-week adjuvant 
trastuzumab. Vertical lines represent drop-outs. Original survival curves obtained from the 
FinHer trial (Joensuu et al. 2009). 
 
Reliable follow-up data from clinical trials was lacking from 5 years onwards, and thus a 
Markov model was populated with data on disease progression. Patients enter the Markov 
model (part 2 of the model) at the beginning of year 6 according to the proportions in each 
of the health states estimated in model part 1. The Markov model utilizes monthly 
transition probabilities between health stages to represent the natural flow of the disease. 
The mutually exclusive health states are “No disease progression”, “Progressed disease”, 
and “Dead”. Only distant progressions are included in the definition of “disease 
progression”. The risk of disease progression is assumed to gradually decrease over time, 
and no new distant progressions are assumed to occur after 20 years of disease-free 
survival. Distant disease progression is assumed to be treated with trastuzumab, regardless 
of initial treatment assignment. Transition probabilities utilized in the Markov-model are 
presented in Table 15. The transition probability from progressed disease to death was 
based on median overall survival (25.1 months) among patients with HER2+ metastatic 
breast cancer treated with trastuzumab (Slamon et al. 2001). Disease progression and its 
treatment are modeled as tunnel states in order to allow variations in treatment length. 
Official Finnish life-tables, adjusted for breast cancer, were used to capture background 
mortality due to other causes than breast cancer (Statistics Finland 2008). In the base-case 
analysis, the treatment effectiveness of adjuvant trastuzumab was limited to 5 years, and 
beyond this point there were not assumed to be any differences in the treatment 
effectiveness between the compared groups (i.e. risk of disease progression was assumed to 
be same after 5 years in both groups). The modeled population contributes costs and 
outcomes each month according to the modeled health stages during the entire model 
presented in earlier Figure 29. 
Quality of life parameters. Since appropriate Finnish quality of life data was not available, 
the applied utility weights were based on a study with 361 Swedish breast cancer patients 
(Lidgren et al. 2007). The utility weights (Table 15) were measured with the EQ-5D quality 
of life instrument. The model calculates quality-adjusted life-years (QALY), which is a 
common outcome measure used in economic evaluations. 
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Cost parameters. Treatments of localised and disseminated cancer can be distinguished. 
Breast cancer-specific treatment costs (in 2008 Euros) were previously obtained from a 
Finnish university hospital (study IV). In addition, patient co-payments were added to the 
present analyses in order to be consistent with the study perspective. The aggregated per-
cycle costs, used in the analysis, are presented in Table 15. Adjuvant trastuzumab is used in 
addition to standard breast cancer treatment, and it is given as an infusion. The short, 9-
week, treatment protocol begins with a loading dose of 4mg/kg and continues with a 
weekly 2mg/kg. Upon disease progression, patients receive trastuzumab in 3-week cycles 
for a maximum of 52 weeks similarly in both groups. The costing includes acquisition, 
administration and preparation costs. 
 
Table 15. Model parameters and their probability distributions 
 
Transition probability per cycle  Probability Distribution Source 
Disease progression 
    
  cycles 1–60 base-case survival model (part 1) Log-logistic regression (1) 
  cycles 1–60 (w/ trastuzumab)^ 0.0031^ 
  
(1) 
  cycles 1–60 (w/o trastuzumab)^ 0.0048^ 
  
(1) 
  cycles 61–120 0.0038 beta α(0.441) β(115.56) (1, 5) 
  cycles 121–180 0.0030 beta α(0.348) β(115.65) (1, 5) 
  cycles 181–240 0.0027 beta α(0.313) β(115.69) (1, 5) 
  cycles 241-> 0.0000 
  
assumption 
     
Progressed disease to death 0.0272 beta α(6.39) β(228.6) (2) 
 
0.0336† beta α(7.89) β(227.1) (2) 
Treatment cost per cycle (1 month) Cost       
Early breast cancer 
    
  trastuzumab(a)* €3,500 normal SE ±10% (3) 
  trastuzumab(b)* €2,800 normal SE ±10% (3) 
  other cancer-related treatment 
    
    cycles 1–12 €817 gamma α(25) β(32.68) (3) 
    cycles 13–60 €57 gamma α(25) β(2.28) (3) 
    cycles 60-> €5 gamma α(2) β(0.2) (3) 
     
Advancer breast cancer 
    
  trastuzumab(c) €2,800 normal SE ±10% (3) 
  other cancer-related treatment €1,122 gamma α(25) β(44.88) (3) 
Quality of life (EQ-5D) Utility weight       
Primary breast cancer, 1st year 0.696 beta α(177.5) β(77.1) (4) 
Primary breast cancer, subsequent years 0.779 beta α(472.3) β(134.0) (4) 
Metastatic breast cancer 0.685 beta α(171.1) β(78.7) (4) 
Dead 0.000 
   
^ Used in a sensitivity scenario to depict treatment effect from 1 to 10 years.  
†Used only in a sensitivity scenario. 
* Only in trastuzumab group. 
    (a) During cycles 1-2 (9 week treatment) 
    (b) During cycles 1-12 (Only in sensitivity analysis for 12 month treatment) 
 (c) At maximum 12 months from disease progression 
   SE=Standard error; SE ±10% = [(Mean±10%)/(1.96*2)] 
References: (1)Joensuu et al. 2009, (2)Slamon et al. 2001, (3)Study IV, (4)Lidgren et al. 2007, (5)Clarke et al. 2005 
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Sensitivity analyses. The model was made probabilistic in order to take into account the 
uncertainty related to all individual model parameters, and to convert this parameter 
uncertainty into decision uncertainty. In a probabilistic sensitivity analysis all model 
variables are allowed to vary simultaneously according to their probability distributions. 
Probability distributions were applied for all model inputs (probabilities, quality of life, 
costs). Beta distributions, whose benefit is the unit interval (0 to 1), are applied for each of 
the probabilities and quality weights. The cost of trastuzumab was assumed to follow 
normal distribution because the dosing of trastuzumab is weight-related, and weight can be 
assumed to be normally distributed. Gamma distributions were used for all other treatment 
costs. The fitted survival curves (Figure 30) were varied by drawing the correlated 
regression coefficients using Cholesky decomposition. With this method, the uncertainty in 
the clinical data can be explored without breaking the correlation structures imposed by the 
chosen parametric survival model (log-logistic in this case). 
The model was calculated repeatedly for 1,000 times in order to elicit the real variation of 
the results, rather than a single point estimate.  The results of the simulation are presented 
in a cost-effectiveness plane.  The uncertainty surrounding the cost-effectiveness of 
trastuzumab is depicted in a cost-effectiveness acceptability curve (CEAC), which plots the 
probability that trastuzumab is cost-effective for a range of cost-effectiveness thresholds. 
In addition to the probabilistic sensitivity analysis, a variety of other sensitivity analyses 
were performed. In conventional one-way sensitivity analyses individual model 
parameters were altered one at a time. In one scenario, the assumption of trastuzumab 
being used after disease progression was tested by excluding the cost of trastuzumab 
treatment in advanced disease from the model. At the same time, the observed treatment 
benefit in advanced disease was also excluded, and the transition probability was based on 
median survival of 20.3 months (Slamon et al. 2001). In another scenario, adjuvant 
trastuzumab was given for 12 months (€2,800/month), while the treatment effect remained 
at the base-case level. In the final sensitivity scenario the first part of the model was 
removed, and the 3-stage Markov model (part 2) was used for the entire comparison. Here, 
the transitions based on fitted survival curves were replaced with constant transition 
probabilities (Table 15). With this modified model, we aimed to illustrate the uncertainty 
related to different assumptions of the effect of treatment benefit persisting beyond 
treatment duration. 
Value of information analysis. The applied probabilistic model characterises the uncertainty 
related to the decision problem, and it was also used to establish the value of additional 
research aimed at obtaining more precise model parameters. Increased precision of the 
model parameters would reduce the decision uncertainty, i.e. minimise opportunity losses. 
In addition, value of additional research for a set of model parameters (i.e. clinical, quality 
of life, and cost parameters) was estimated to determine what type of additional research 
would be most valuable. Additional research may be considered worthwhile if the value of 
additional research in monetary units exceeds the cost of conducting such research. 
7.2.3 Results 
In the probabilistic base-case analysis, 9-week adjuvant trastuzumab treatment led to 0.66 
incremental QALYs or 0.85 life-years gained (LYG) with an additional lifetime cost of 
€7,900, compared to treatment without adjuvant trastuzumab. Thus, the incremental cost-
effectiveness ratio (ICER) of the 9-week treatment was €12,000 per QALY, and €9,300 per 
LYG. The total QALYs gained with and without adjuvant trastuzumab were 8.37 and 7.71, 
and the costs were €61,600 and €53,700, respectively. The probability that the 9-week course 
provides additional benefits at additional costs is high, but the hypothesis of minimal or 
even negative treatment effect cannot be excluded entirely (Figure 31). Most (70%) of the 
1,000 iterations for incremental effectiveness lie between 0.3 and 1.0 QALY. Similarly, 70% 
of the estimates for incremental costs lie between €2,900 and €12,300.  
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Figure 31. Incremental cost-effectiveness plane of adjuvant 9-week trastuzumab in early stage 
breast cancer in Finnish settings. QALY=Quality-adjusted life year. 
 
According to these results, the short 9-week trastuzumab treatment is likely to be cost-
effective already in relatively low willingness to pay (WTP) threshold levels. There is, for 
example, 87% probability of being a cost-effective option at WTP of €30,000 per QALY 
(Figure 32). This figure also shows the observed variation of cost-effectiveness with chosen 
discount rate. The impact of the discount rate reflects the nature of the treatment, in a sense 
that health benefits in terms of survival will be received in distant future. 
The value of information (VOI) analysis indicates that the patient-level expected value of 
perfect information (EVPI) is, for example, €870 at WTP of €30,000 per QALY (Figure 32). 
The EVPI informs the consequences of making a wrong decision in monetary units, 
combined with the probability of that decision. With the WTP threshold of €30,000 and a 
population of 10,000 HER2-positive breast cancer patients, the population EVPI would be 
€8.7M. The EVPI is at its maximum at the point of ICER, where the decision uncertainty is 
greatest. The expected value of perfect partial information (EVPPI) showed that more than 
90% of this can be attributed to the effectiveness parameters. 
 
 
Figure 32. A) Cost-effectiveness acceptability curves (CEACs) and B) expected value of perfect 
information (EVPI) of adjuvant 9-week trastuzumab in early stage breast cancer in Finnish 
settings. Presented with discount rates 0%, 3% and 6% for future costs and outcomes. 
 
A B 
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Sensitivity analyses. In the deterministic one-way sensitivity analyses the model 
parameters were altered one at a time. The results were relatively sensitive to the alteration 
of discount rate and trastuzumab treatment costs. Most parameter uncertainty, however, 
was related to the treatment effectiveness of adjuvant trastuzumab. When the bounds of 
95% confidence interval of treatment co-efficient during years 0–5 were used, the ICER 
varied from €2,500/QALY to being dominated. The inclusion of costs of cardiac monitoring 
or additional travel costs did not have any significant impact on the results. 
Assumptions related to trastuzumab use in advanced disease were tested in a scenario, 
where trastuzumab was discarded from treatment of advanced disease in both groups. This 
had only a marginal effect on the cost-effectiveness results, largely due to the fact that both 
groups were assumed to be treated similarly after disease progression. The impact of 
treatment length was studied in another scenario. When trastuzumab was used according 
to the 12-month treatment schedule, the ICER was €49,600 per QALY, assuming that the 
treatment benefit was the same as in the base-case.  
Another important aspect related to the treatment effect is the assumption of the length 
of clinical benefit received beyond the duration of treatment. Our cost-effectiveness model 
utilized fitted survival data, and thus no further assumptions of the carry-over time of 
treatment effect were needed. However, to demonstrate how assumptions related to the 
length of treatment effect could affect the cost-effectiveness results, model part 1 was 
replaced with constant transition probabilities for disease progression (0.0031/0.0048 per 
cycle). These probabilities were applied for different durations, as illustrated in Figure 33. 
There is a strong dependence with the assumed length of treatment effect and cost-
effectiveness of the treatment. Thus, it is clear that a conclusion on a treatment’s cost-
effectiveness may depend on the assumptions related to carry-over time of treatment 
benefit. 
 
 
Figure 33. The impact of the assumptions related to length of treatment effectiveness in respect 
of incremental cost-effectiveness of 9-week adjuvant trastuzumab 
7.2.4 Discussion  
The aim of the current study was to assess the potential cost-effectiveness of adjuvant 9-
week trastuzumab treatment in Finnish settings using the final results of FinHer trial, 
which have not, to our knowledge, been previously utilized in economic evaluations. We 
found that 9-week adjuvant trastuzumab is likely to be a cost-effective treatment option in 
early breast cancer compared to treatment without trastuzumab, despite the uncertainty 
related to the treatment effect. The value of information analyses show that more 
investment should be directed especially to research related to treatment effect in order to 
reduce the uncertainty related to adoption decision. The maximum acceptable cost 
(population EVPI) for a trial that would eliminate all uncertainty depends on the number of 
patients and society’s willingness to pay threshold level. 
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The first published results from the clinical trials concerning adjuvant trastuzumab 
treatment were with relatively short follow-up (from 1 to 3 years) (Piccart-Gebhart et al. 
2005, Romond et al. 2005, Joensuu et al. 2006, Slamon et al. 2009). The more recently 
updated results show that the treatment effect of trastuzumab may be less favourable as 
previously expected. In the Herceptin Adjuvant (HERA) trial, using 12-month regimen, the 
hazard ratio (HR) for the risk of an event increased from 0.54 to 0.64 as the follow-up period 
changed from 1 year to 2 years (Piccart-Gebhart et al. 2005, Smith et al. 2007). The updated 
results of FinHer trial show similar change with the 9-week treatment. After 3-year follow-
up, the women treated with 9-week trastuzumab+chemotherapy had more favourable 
overall survival (OS) compared to those treated with chemotherapy alone (Hazard Ratio 
[HR] = 0.41; 95% CI 0.16 to 1.08) (Joensuu et al. 2006). However, after a 5-year follow up, the 
corresponding HR was 0.55 (95% CI 0.27 to 1.11) (Joensuu et al. 2009). In the FinHer trial, 
the patient subgroup with HER2 over-expression was small (n=232) compared to the other 
studies. Despite of the size of the patient population, the short course adjuvant treatment 
has shown positive signs about its efficacy, compared to chemotherapy only. Nevertheless, 
the level of statistical significance, related to survival estimates, needs to be considered. In 
the current study, adjuvant trastuzumab led to 0.66 additional QALYs or 0.85 life-years. If 
our analysis would have been based on subgroup that received docetaxel+FEC+ 
trastuzumab, instead of any chemotherapy+trastuzumab, the cost-effectiveness results 
would have been more favourable to trastuzumab. In this subgroup both the distant 
disease-free survival and the overall survival were greater than in the pooled analysis 
(Joensuu et al. 2009). However, this was not used since it does not reflect the current 
treatment practice, and also the population would have been considerably smaller. In 
addition, no patient subgroup analyses were performed due to lack of adequate 
information and sample size. The potential impact of patient cross-over from control group 
to receiving active treatment has not been addressed in the current study. 
Economic evaluations are being used increasingly often in attempt to meet the challenges 
of optimally allocating the scarce health care resources. Cancer presents a challenge to 
health care funding both due to more expensive treatments and rising incidence rates.  
Furthermore, due to ageing of the population the annual number of new cases is increasing 
more rapidly than the age adjusted incidence. When expensive drugs are used in a number 
of patients, the economic issues become even more important. Trastuzumab has been 
available for metastatic breast cancer from year 2000, and in 2006 the indication was 
extended for the adjuvant treatment of HER2-positive early breast cancer. This indication 
extension multiplied the number of potential patients. Since then, the cost-effectiveness of 
adjuvant trastuzumab has been investigated in several publications, and it has been 
estimated to be cost-effective in most of the analyses. However, a large part of these 
analyses are based on interim results of efficacy, and thus may need to be updated. Results 
from cost-effectiveness analyses based on the 1-year HERA results (Piccart-Gebhart et al. 
2005) have varied from €6,000 per QALY to £18,000 (€22,000) per QALY (Reed and 
Schulman 2009). Analyses based on the 2-year HERA results (Smith et al. 2007) have 
presented results from €17,000 per LYG to 127,900 Canadian dollars (€96,000) per QALY 
(Reed and Schulman 2009). From UK perspective, an ICER of £25,803 (€31,600) per QALY 
has been recently reported when 2-year follow-up was included in the analysis (Hall et al. 
2010). Based on the above mentioned results, it seems these cost-effectiveness results are 
strongly associated with the follow-up time in the original study. However, the analyses 
based on shorter follow-up currently outnumber those using longer follow-up. A similar 
phenomenon may now be detected from economic evaluations based on 9-week treatment. 
In an Australian study, 9-week treatment had an ICER of A$1,700 (€1,300) per QALY 
(Millar and Millward 2007), and in a Swiss study it was found to be cost-saving (Dedes et 
al. 2007). A Belgian study showed that 9-week adjuvant treatment is most of the times cost-
saving (in 11 out of 15 subgroups), and has ICER above €30,000/LYG in only one of the 
patient subgroups (age 80+, stage I disease) (Neyt et al. 2008). In the present analysis, we 
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found a very low probability of 9-week trastuzumab being cost-saving, though the ICER 
was still on an acceptable level.  
Trastuzumab use and its economic consequences have been studies in Nordic countries 
in recent years. In Norway, the incremental cost per life-year saved ranged between €8,148 
and €35,947 for a 1-year adjuvant treatment. The study assumed 10% or 20% improvement 
in absolute overall survival with trastuzumab treatment (Norum et al. 2007). The actual use 
of trastuzumab has been studied in Swedish Health Care Regions (Wilking et al. 2010), and 
from Swedish societal perspective the ICER for 1-year adjuvant trastuzumab was estimated 
to be €36,000 or €41,500 per QALY, in base-case analysis, depending on the HER2-testing 
strategy (Lidgren et al. 2008).  
The current study was based on modeling, which inherently leads to simplification of 
real life circumstances. The model structure was driven by the available information in the 
primary data source.  In the utilized Markov model (part 2), three mutually exclusive health 
stages were used, following the partition in model part 1. Since the analysis was based on 
published results of the FinHer trial, the inclusion of additional health stages would have 
led to number of assumptions leading to unnecessary uncertainty.  For example, the local 
recurrences could not have been reliably included in the model, since little information has 
been published on this in the original data source (Joensuu et al. 2009). Moreover, distant 
recurrences are more closely associated with mortality than local ones (Joensuu et al. 2009). 
Nevertheless, the modeled health outcomes in the present study were of a same magnitude 
with those reported in previous studied assessing adjuvant trastuzumab. In studies based 
on 12-month treatment, the incremental life-years gained with trastuzumab ranged from 
0.12 (Dedes et al. 2007) to 4.1 (Millar and Millward 2007) years depending on the timeline 
and discount rate. Similarly, in studies using the interim results of FinHer trial (Joensuu et 
al. 2006) the incremental life-years ranged from 0.27 (Dedes et al. 2007) to 5.9 years (Millar 
and Millward 2007). If subgroup analyses were taken into account (e.g. age and disease 
stage) the variation in additional health benefit would be larger than the above mentioned 
(Neyt et al. 2008). The utilized cost data was based on a previous Finnish study (study IV). 
When compared with other economic evaluations of adjuvant trastuzumab, the stage 
specific costs were of similar magnitude to those used by others. Cost of HER2-testing was 
not included in the analysis since all new patients are equally tested. Similarly, cardiac 
toxicity was not taken into account in the analysis, because in the FinHer trial no significant 
differences existed between patients treated with or without trastuzumab (Joensuu et al. 
2009). In addition, relatively fewer cases with cardiac toxicity were observed during the 
short course treatment in FinHer (Joensuu et al. 2009), compared to trials using 12-month 
treatment (Telli et al. 2007). 
Quality of life was based on Swedish breast cancer patients (Lidgren et al. 2007), because 
suitable information was not available from local patients. However, due to close 
geographical and cultural proximity of Finland and Sweden, we believe that the utilized 
values were adequate to be used in the analyses. 
In a sensitivity scenario we illustrated how different assumptions may affect the result of 
cost-effectiveness analyses. This is a key tool to determine the impact of various 
assumptions on the results, and is essential in complicated models, where the individual 
impact of each assumption on the observed results is difficult to infer analytically. Similar 
observations regarding the impact of assumed length of treatment benefit have been 
reported by others (Hall et al. 2010). In previously published cost-effectiveness analyses, 5 
years has been the most used duration of benefit (Reed and Schulman 2009). In the current 
study we applied information directly from the published survival curves for OS and 
DDFS, which were used to estimate the natural flow of the disease for the first 5 years. 
Thus, we demonstrated that, despite their drawbacks, published Kaplan-Meier curves can 
be an appropriate source for fitted survival data in economic evaluations. Because of the 
statistical non-significance of the difference in treatment effects, our model included the 
possibility that adjuvant trastuzumab would lead to worse outcomes than the comparator. 
However, eventually only a small minority of the modeled cases showed negative effect.  
68 
 
 
Economic issues related to cancer treatments are multifaceted and even politically 
sensitive due to equity issues and the social value of the disease (Drummond et al. 2009). 
The Pharmaceutical Management Agency of New Zealand restricted trastuzumab funding 
to cover only 9-week of treatment, in July 2007 (Metcalfe et al. 2007). However, this turned 
into a juridical and political issue, and eventually the funding was extended to include 12-
month treatment. (PHARMAC 2010, Herceptin 2010). There is currently no evidence 
comparing the efficacy of the 9-week and 12-month treatment regimens, and thus the 
relative efficacy of these treatments cannot be evaluated directly. With the currently 
available data, economic evaluations based on an indirect comparison of these treatments 
would support the 9-week treatment. However, with the current level of information and 
uncertainty, such evaluations would not be sufficiently credible to aid decision-making. 
The 9-week treatment may be a promising option in economic terms, compared with the 
12-month treatment, if the treatment effect observed in existing studies is confirmed in 
additional studies. The ongoing SOLD-trial will eventually provide an important answer to 
this question.  Since the duration of the treatment benefit is one of the driving forces of cost-
effectiveness, such studies with longer follow-up are needed for more precise evaluations. 
Economic analyses on adjuvant trastuzumab should be updated when new data is 
available. 
In conclusion, the current study shows that 9-week adjuvant trastuzumab is likely to be 
cost-effective in Finnish setting at relatively low willingness to pay threshold levels. The 
sensitivity analyses and the value of information analysis show that more research should 
be focused on the long-term effectiveness of treatments.  
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8 General discussion 
New cancer treatments are expensive but they may also be valuable. The aim of cost-
effectiveness evaluations is to assess which of the available treatments provides the greatest 
health benefit for the money invested. Pharmacoeconomic evaluations of cancer treatments 
have been performed widely, and there seems to be a global interest in the economic issues 
related to cancer. The pharmaceutical industry has been active in providing cost-
effectiveness information, though certain national agencies, such as NICE, are also actively 
involved in evaluating new treatments. 
Cancer is responsible for major economic expenditures in all developed countries, and 
the burden of cancer is constantly growing. The rising cost of cancer is related both to the 
increase in the absolute number of patients and to the rate of increase in the cost of cancer 
treatments. Another factor that has affected the cost of cancer treatment has been the 
addition of systemic therapies in early cancers after or before surgery or radiation (adjuvant 
and neo-adjuvant treatment). In addition, many cancers are now assessed clinically as 
chronic diseases. (McVie et al. 2011) From a societal perspective, the cost of cancer care is 
driven by the cost of care per patient and the number of patients needing the treatment. 
This is a concern in the developed countries - how to provide high quality and equitable 
cancer care that is affordable to both individuals and society. (Sullivan et al. 2011) 
Economic aspects play an increasing role in the decision making related to funding 
medical treatments, or adapting these new treatments into clinical routines. When a 
treatment is considered to be cost-effective, it usually refers to the treatment being worth 
the added cost, because of the benefit it adds to the compared treatment. Nevertheless, 
while cost-effectiveness analyses are used to support the decision making process, they do 
not address concerns related to equity, social, political, or legal issues. Cost-effectiveness 
analyses do not decide which decision will be the right one. More effective and more 
tolerable medications are needed, but at the same time, these innovations can contribute 
greatly to the cost of care. (Peppercorn et al. 2011)  
The methods utilized in this thesis were chosen individually in each of the studies (I-V). 
Relevant parameters were synthesized through a modeling process, in order to obtain 
reasonable estimates of the expected cost-effectiveness or budget impact of the treatment of 
interest. The studies showed that the model framework with three distinct health stages 
was suitable for modeling the natural disease progression with respect to mRCC and breast 
cancer, despite the fact that the prognosis in these diseases is very different. The common 
endpoints in oncology, progression-free survival and overall survival, support this model 
partition. Nevertheless, all diseases have their unique characteristics - even within a certain 
area of specialty, such as oncology. Thus, the evaluation models need to be modified 
according to the characteristics of the health condition of interest – not vice versa. While 
simplicity in the model structure may come at the price of accuracy, it has to be 
remembered that complexity, per se, is not a means to achieve accuracy (Eddy 2006). In 
addition, complexity in the model structure may require more assumptions, which on the 
other hand, will contribute to the uncertainty present in the results.  
One of the reasons for utilizing modeling methods is the ability to combine information 
from several sources, and to compress this information into a meaningful value. 
Nevertheless, scarcity of data is a major concern when pharmacoeconomic evaluations are 
performed. These evaluations are most often done when there is a lack of data from real-life 
circumstances. Even though everyday clinical practice most often differs from health care 
settings in clinical trials, these published results are used as the best available evidence. 
Commonly, the treatment under evaluation has not been used in clinical practice prior to 
the evaluation. While cost-effectiveness models are usually based on results from clinical 
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trials, the question related to the level of comparability between modeling and reality, 
remains unanswered. However, new data will become available throughout the product 
lifecycle. These data, potentially affecting the health care decisions, can be utilized to 
reassess the value of the treatment. (Fenwick et al. 2006) In addition, real-life data should be 
collected after the product launch, since this information can be used, for example, in 
assessing real-life effectiveness as well as in updating and validating the existing economic 
evaluations. 
This thesis utilized several methods for data extraction. Patient-level data were collected 
in order to obtain information about current clinical practice in two of the studies (II, III). 
Expert opinion from clinical practitioners was used in order to estimate how the new 
treatment would affect the current care, and how this new treatment would be used in 
clinical practice. A panel of experts was used as a source of this information in one of the 
studies (II). Clinical experts have participated in all the studies where there has been a need 
for clinical judgment (II-V). A review of literature has been performed in all the studies in 
this thesis, and much of the required information is based on the published literature and 
published statistics. As a consequence, it was illustrated that available Kaplan-Meier -
survival curves may be sufficient, though not ideal, for obtaining parametric survival 
estimates for modeling purposes (V). Thus, by using these alternative approaches, the lack 
of data may be overcome. One typical methodological feature for the studies included in 
this thesis is the wide use of different data sources, which are combined in the analysis. 
While this is a source of possible uncertainty in the results, it is rarely possible to obtain all 
relevant information from the same data source. Similar methodological choices in data 
extraction have been made by others (I). In this respect, the data extraction methods utilized 
in this thesis may be concerned as valid. Norum and colleagues (2010) reviewed and 
evaluated the health economic evaluations of mRCC – including study II. The study II 
achieved good quality and transferability scores (20/26), which were comparable to those 
achieved by an appraisal by NICE (21.5/26) (Trowman et al. 2007), and a study by Remák 
and colleagues (2008) (19/26). 
The current thesis has attempted to contribute to future recommendations of budget 
impact analysis, while presenting some of the issues that may be considered relevant from 
a national perspective. As a summary of the findings related to budget impact analysis, a 
proposal for national guidelines is presented in Appendix, and it is aimed to be a starting 
point for discussion about the need and content of national guidelines. An attempt to utilize 
this guideline proposal has been made in study IV, where the budget impact of 
trastuzumab has been assessed from the perspective of the Northern Savo hospital district, 
as well as in study III where the budget impact of sunitinib was assessed. In study IV, 
special emphasis was placed on the sensitivity analysis and on accounting for uncertainty. 
This was, to our knowledge, the first published budget impact analysis that has applied an 
approach using probabilistic sensitivity analysis, though similar ideas have been presented 
earlier (Sendi and Briggs 2001). Recently, probabilistic sensitivity analysis has been 
recommended as a form for reporting results of budget impact analyses (Annemans 2010). 
The issues concerned in this thesis affect mostly the developed world. Nevertheless, the 
gap between poor and rich countries also results in growing inequalities in the delivery of 
cancer care. The health gap in respect of cancer care may become greater due to the 
increasing complexity and cost of the treatments. Similar gaps may appear even among 
health districts within the developed countries. (Mano 2006) Is it reasonable to invest in an 
expensive therapy that benefits only a small number of patients, or should the same sum of 
money be invested somewhere else in health care? Are the sometimes modest additional 
health benefits worth the costs to society? There can be no clear answer to these questions, 
and the answers vary according to culture, medical context and budget constraints 
(Peppercorn et al. 2011). 
Increases in the health care costs are driven by innovation. In the field of cancer care, 
these innovations are reflected as new drugs, new indications, new surgical methods, new 
methods to deliver radiation therapy, and ability to diagnose patients in the early phase of 
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disease. The total cost of treatment is increasing because more can be done to treat the same 
patients. This development has been evident in the treatment of metastatic renal cell 
carcinoma. In mRCC, targeted therapies are currently used in subsequent treatment lines, 
among patients whose treatment options a few years ago were scanty. The increased 
number of available treatment options has led to improved disease management but, at the 
same time, it has caused an increased cost of treatment. 
Often new treatments are expensive but they may offer reductions in health care 
resource use elsewhere. In the case of a curative treatment, the treatment cost may be offset 
by reductions in the treatment of recurrent disease. However, many of the new treatments 
are not curative, especially those for advanced cancer. These drugs will delay the time to 
progression, and enhance the overall survival and quality of life. The cost offset might be of 
consequence from reduced costs of symptom management. Nevertheless, in the case of 
incurable disease, these costs are often deferred to later in the course of the illness. 
(Peppercorn et al. 2011, Sullivan et al. 2011) In most cases, new treatments are more 
effective and more expensive compared to their predecessors. Nevertheless, a targeted 
treatment is not always curative, and even the most expensive treatment may not always be 
the best treatment. Patient reported outcomes are becoming increasingly important in 
determining the overall benefit of targeted treatments, for example in patients with renal 
cell carcinoma (Cella 2011). In order to achieve a sustainable development in cancer care, 
the cost-limiting requirements from health care systems and the need for the 
pharmaceutical industry to make a profit do need to be balanced (Tannock et al. 2011, 
Taylor and Catchpole 2011). 
To quote Taylor and Catchpole (2011): “It is difficult even for senior clinicians and 
managers to understand that although a drug or intervention might have an ICER of 
USD50,000 per QALY, its actual cost might be less than USD5,000 or as much as 
USD100,000.” In this respect, there is a need to further educate clinicians and decision 
makers on these issues, in order that they can more efficiently make use of the information 
provided by economic evaluations. While the evaluations are often complex, the evidence 
emerging from these assessments, should be made easier to communicate to those who will 
utilize this valuable information. 
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9 Conclusions and implications 
 The utilized cancer model with three mutually exclusive health stages was suitable 
for modeling the disease progression of metastatic renal cell carcinoma, and early 
stage breast cancer. Additional research will be needed in applying the model to 
other types of cancer. If future cancer treatment moves towards increasing number 
of multiple subsequent treament lines, this will lead to difficulties in detecting an 
individual treatment’s effect on the long-term end-points, such as overall survival. 
 Renal cell carcinoma represents a considerable economic burden on society, and it 
leads to premature deaths and productivity losses. The overall burden of cancer is 
likely to increase due to ageing of the population, intensive care with targeted 
treatments, and increasing treatment costs. 
 Sunitinib has been considered as a cost-effective treatment option in most of the 
pharmacoeconomic evaluations, globally. In Finland, sunitinib was shown to be 
potentially cost-effective in the second line treatment of mRCC, compared to best 
supportive care. Thus, the clinical benefits of sunitinib were considered to outweigh 
its relative cost. The development of new treatments in mRCC has changed rapidly 
the treatment practice. Currently, sunitinib is considered as the treatment of choice 
in the first line treatment of mRCC. 
 The length of the treatment has a strong effect on the eventual budget impact of 
trastuzumab. The short 9-week treatment with trastuzumab has a reasonable cost-
effectiveness profile compared to treatment without trastuzumab. Future trials will 
reveal to what extent the duration of trastuzumab treatment affects its effectiveness 
and the cost-effectiveness of the therapy. According to current clinical trials, the 
short 9-week treatment is a promising option compared to the 12-month treatment in 
the adjuvant treatment of HER2-positive early breast cancer.  
 A budget impact model using local data can be an effective tool to allow hospital 
districts to estimate the future cost burden of expensive medications. Budget impact 
estimations can help planning budgets within the hospital district, or within 
individual clinics. 
 The probabilistic approach in budget impact analysis offers better recognition of 
uncertainty, and is a step forwards in the methodology used in budget impact 
analyses.  
 Further research on the cost-effectiveness, budget impact, as well as the cost and 
burden of different types of cancers are needed globally, but especially nationally. 
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Appendix 
 
  
Appendix. A proposal for national guidelines for budget 
impact analysis 
The following proposal is based on ISPOR guidance (Mauskopf et al. 2007), and national 
guidelines from Poland and Canada (Orlewska and Mierzejewski 2004, Marshall et al. 
2008), which have been synthesized according to the author’s own views considering the 
observed inconsistencies in previously published studies (Orlewska and Gulácsi 2009). 
The proposal is aimed to be a starting point for discussion about the need and content of 
national guidelines. The purpose is to enable uniformity and comparability of budget 
impact analyses both nationally and internationally. This proposal will also propose what 
could be the minimum requirement to be considered in estimating the budget impact of 
pharmaceuticals in Finland. 
 
General structure 
The reporting of the methods, results, and assumptions used, should be transparent, and 
the analytical method should be properly presented. 
 
Definition of study perspective 
Defining the study perspective is possibly the most important factor in a budget impact 
analysis. This will affect all the subsequent decisions. Budget impact analyses should most 
preferably be performed from the payer’s perspective (e.g. hospital, hospital district, 
municipality, Social Insurance Institute). However, a societal perspective may also be 
utilized depending on the aim of the study.  
 
Definition of treatment comparators 
In budget impact analysis, the introduced treatment is always compared to some other 
treatment. It is not sufficient to calculate the cost of the new treatment, since the 
introduction of the treatment will have consequences on the current treatment practice. 
Thus, a calculation of the cost of “drug A”, cannot be considered as a budget impact 
analysis. Budget impact analysis is rather a comparison of two alternative treatment mixes 
– the treatment mix without new treatment and the treatment mix including the new 
treatment. For this reason the current care has to be defined, as this forms the basis on 
which the changes happen, and it also acts as the comparator in the indication of interest. 
The treatment of interest is the new introduced treatment, along with the changes it is 
expected to evoke in the current treatment practice over time. The expected market 
penetration of the new product should be included as illustrations of future treatment 
practice. 
 
Definition of target population 
All decisions related to target population should be made in accordance with the study 
perspective. The target population is defined by the aim and perspective of the study, but 
in general it should be those patients who potentially may benefit from the treatment. The 
target population should include all potential patients who are eligible to receive the new 
treatment, during the time period of the performed analysis. Subgroup analyses may be 
performed when sufficient data is available. Nevertheless, the potential consequences of 
an adoption decision should always be presented at a level of the entire population of 
interest. The target population may be based on incidence, prevalence, or the combination 
of these depending on the treatment and disease characteristics and the study aim. 
Hypothetical population sizes should be avoided. 
 
 
  
 
Time horizon 
The time horizon should be relevant to the budget holder, for whom the analysis is 
performed. A suitable time horizon could be 5 years or less. With a longer time 
perspective, the uncertainty increases substantially.  
 
Selection of data sources 
Official data from national registers and statistics should be emphasized in the selection of 
data sources. Data should be country-specific, identifiable and clearly stated. Local 
registers from the target organization, published peer-reviewed literature, and clinical 
trials are preferred over unscientific data. Protocol-driven resource use should be excluded 
if data from clinical trials are used. Expert opinion as well as data from e.g. manufacturer’s 
market predictions may have to be utilized due to the predictive nature of these analyses. 
Irrespective of the utilized data source, all data should be consistent with the study 
perspective. 
 
Use of modeling 
A model-based approach may be required in estimations performed over time. The design 
of the model may vary among studies, as it should be constructed according to the needs 
of each individual study. In principle, the budget impact model should be an open cohort 
model, but the use of closed cohort models cannot be ruled out. 
 
Resource use and unit costs 
Resource use should ideally be based on the actual resource use observed in the target 
organization. The unit costs from the target organization should be used if possible. 
Alternatively, in Finland, Finnish health care unit costs, which depict the average costs in 
the whole country, may be used (Hujanen et al. 2008). Aggregate level costs may be used if 
necessary. 
 
Discounting 
Discounting is not recommended. Budget impact analysis deals with financial streams 
over time, and thus it is not necessary to use discounting (Annemans 2010). Furthermore, 
discounted costs would not reflect the actual amount that could be expected to be caused 
by the introduction of a new treatment (Marshall et al. 2008). Discounting is also not 
recommended in the ISPOR guidelines, though it does not exclude the possibility to utilize 
discounting (Mauskopf et al. 2007). 
 
Incorporation of treatment effect 
The minimum requirement in all budget impact analyses is to describe the differences in 
the treatment effect, adverse events, and usability. The incorporation of the treatment 
effect in budget impact models is controversial. In studies involving an acute health 
condition, this may be unnecessary. However, in chronic diseases, treatment effect may be 
relevant to consider, as well as in cases where there is large variations in treatment costs 
depending on the stage of the disease. 
 
Reporting results in budget impact analysis  
All studies should present results from a reference case, which includes the parameter 
values and assumptions that the authors consider to be most relevant and correct. 
Nevertheless, the intention of budget impact analysis is not to give one absolutely correct 
value, but by definition, to “provide a range of predictions specific to that decision-
maker’s information needs” (Mauskopf et al. 2007). This may be implemented by using a 
selection of sensitivity analyses. Scenario analyses and one-way sensitivity analyses depict 
the range within where the true value would most likely lie. The reporting of the results 
should enable the availability of results on a yearly basis, as well as over the entire study 
  
period. Decomposition of results by cost types may be performed. In addition, the results 
may be presented for distinct subpopulations. However, the results should always include 
estimates related to the entire target population. In budget impact analysis, the results of 
these sensitivity analyses should be reported side by side along with the base-case results. 
 
Probabilistic sensitivity analysis 
In order to confer natural variation into the results, the use of a probabilistic sensitivity 
analysis (PSA) is recommended. In PSA, all pre-defined model parameters are allowed to 
vary simultaneously according to their probability distributions. The PSA results should 
then be depicted as affordability curves showing the probabilities that a treatment is 
affordable as a function of the budget constraint. 
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